|Drug, bio-affecting and body treating compositions patents - Monitor Patents|
USPTO Class 424 | Browse by Industry: Previous - Next | All
05/2008 | Recent | 08: Dec | Nov | Oct | Sp | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | | 07: D | N | O | S | A | J | J | M | A | M | F | J | | 06: 12 | 11 | 10 | 09 | 8 | 7 | 6 | 5 | 4 | Dec | Nov | | 2010 | 2009 |
Drug, bio-affecting and body treating compositions May archived by USPTO category 05/08Below are recently published patent applications awaiting approval from the USPTO. Recent week's RSS XML file available below.
Listing for abstract view: USPTO application #, Title, Abstract excerpt,Patent Agent. Listing format for list view: USPTO National Class full category number, title of the patent application. 05/29/2008 > patent applications in patent subcategories. archived by USPTO category
20080124270 - Compounds useful as metal chelators: New compounds are provided that may be used to chelute a metal. The compound comprise polyazamacrocyclic compound with at least one phosphonic group substituted on at least one of the aza groups of the polyazamacrocyclic compound. Methods for preparing the compounds are also provided. Methods for preparing a diagnostic imaging... Agent: Kramer Levin Naftalis & Frankel LLP
20080124271 - Method for preventing nasolacrimal duct obstruction: The invention is directed to a method for preventing nasolacrimal duct obstruction (NLDO) in a patient receiving high dose radioactive iodine for treatment of cancer which comprises administering to the eyes of said patient an effective amount of perchlorate anion.... Agent: Patricia A. Coburn P.A. Coburn Consulting
20080124272 - Influenza antibodies, compositions, and related methods: The present invention relates to the intersection of the fields of immunology and protein engineering, and particularly to antigens and vaccines useful in prevention of infection by influenza virus. Provided are recombinant protein antigens, compositions, and methods for the production and use of such antigens and vaccine compositions.... Agent: Choate, Hall & Stewart LLP
20080124273 - Novel cationic metal complex radiopharmaceuticals: This invention relates to novel cationic crown-ether containing metal complexes, methods of preparing the cationic crown-ether containing metal complexes, and radiopharmaceutical compositions comprising the cationic crown-ether containing metal complexes. This invention relates particularly to cationic crown-ether containing 99mTc complex radiopharmaceuticals for diagnosis of cardiovascular disorders and cancer. This invention further... Agent: Brinks Hofer Gilson & Lione
20080124274 - Compositions and methods for detecting and treating tumors containing acidic areas: Compositions have been developed which are selectively sequestered in acidic areas of tumors. When the compositions contain a radioisotope effective to report the presence of the composition, the compositions are useful for detecting tumors. When the compositions contain radioisotopes effective to kill cells, the compositions are useful for treating tumors.... Agent: Teri G. Andrews Attorney At Law
20080124278 - Aglycosyl anti-cd154 (cd40 ligand) antibodies and uses thereof: The invention relates to aglycosyl anti-CD154 antibodies or antibody derivatives, characterized by a modification at the conserved N-linked site in the CH2 domains of the Fc portion of said antibody. The invention also relates to the treatment of immune response related diseases and inhibition of unwanted immune responses with such... Agent: Ropes & Gray LLP
20080124279 - Colonic delivery using zn/pectin beads with a eudragit coating: Drug delivery systems that can deliver therapeutic and/or diagnostic agents to the colon are disclosed. The systems include pectin beads crosslinked with zinc or any divalent cation of interest, which beads are then coated with Eudragit®-type polymers. The drug delivery systems are orally administrable, but can deliver the active agents... Agent: Intellectual Property / Technology Law
20080124275 - Crystalline form of fatty acid amide hydrolase (faah): The present invention is directed to FAAH crystals in complex with the inhibitor methoxyarachidonyl fluorophosphonate (MAFP) and to the use of these crystals to determine the three-dimensional structure of FAAH. This invention id further directed to the use of this structure for the modeling or determination of the structures of... Agent: Olson & Cepuritis, Ltd.
20080124277 - Human and mouse targeting peptides identified by phage display: The present invention concerns methods and compositions for in vivo and in vitro targeting. A large number of targeting peptides directed towards human organs, tissues or cell types are disclosed. The peptides are of use for targeted delivery of therapeutic agents, including but not limited to gene therapy vectors. A... Agent: Fulbright & Jaworski L.L.P.
20080124276 - Synthetic cornea from retinal stem cells: Methods of producing synthetic corneas are disclosed which are differentiated from retinal stem cells (rSC) derived from parthenogenetically activated human oocytes, including that such synthetic corneas are produced in the absence of a 3-D scaffold. Isolated synthetic corneas, produced by the disclosed methods, are also described.... Agent: Dla Piper US LLP
20080124280 - Thyroid hormone analogs and methods of use: Disclosed are methods of treating subjects having conditions related to angiogenesis including administering an effective amount of a polymeric form of thyroid hormone, or an antagonist thereof, to promote or inhibit angiogenesis in the subject. Compositions of the polymeric forms of thyroid hormone, or thyroid hormone analogs, are also disclosed.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.C.
20080124281 - Nanotubular probes as ultrasensitive mr contrast agent: The present invention includes compositions, methods and methods for using MRI contrast agent that include a generally nanotubular carrier and an MRI contrast agent disposed within the carrier.... Agent: Chalker Flores, LLP
20080124282 - Oil-containing deodorizing aerosol compositions having skin-cooling active substances: Essentially alcohol-free deodorizing aerosol compositions which contain selected oils, a skin-cooling active substance, a deodorizing active substance and a propellant gas.... Agent: Paul & Paul
20080124283 - Method of providing fast relief to a user of a nicotine chewing gum: The invention relates to a method of relieving nicotine craving comprising the steps of providing at least one chewing gum comprising tobacco alkaloid to a user, providing relief of nicotine craving to said user by transferring of tobacco alkaloid from the chewing gum to the human body of said user... Agent: Cantor Colburn, LLP
20080124284 - Synthetic peptide constructs for the diagnosis and treatment of periodontitis associated with porphyromonas gingivalis: The present invention relates to an oral composition and an immunogenic composition for the suppression of the pathogenic effects of the intra-oral bacterium Porphyromonas gingivalis associated with periodontal disease.... Agent: Morrison & Foerster LLP
20080124285 - Merocyanine derivatives for cosmetic use: Described are merocyanine derivatives of formula (1a) or (1b) wherein n and o are integers from 2 to 4 and aminocyclohexenone intermediates. They are used in protecting human and animal hair and skin from UV radiation.... Agent: Joann Villamizar Ciba Corporation/patent Department
20080124286 - Algae supplement and treatment method: This invention relates to a method and composition for enhancing epidermal and/or hair follicle stem cell production, cell renewal, and/or growth of the skin, hair and nails, by topical administration of a therapeutic dosage of cyanobacteria and green algae and/or both simultaneous enteral and topical administration of a therapeutic dosage... Agent: Law Office Of Tracy P. Jong
20080124287 - Cosmetic composition having whitening effect comprising extract of pulsatilla radix as main ingredient: Disclosed is whitening cosmetic composition comprising extract of Pulsatillae Radix as main ingredient if necessary, additionally comprising ingredient(s) selected from the group consisting of ranunculin, deoxypodophyllotoxin and 3-O-α-L-ramnopyranosyl(1→2)-[β-D-glucopyranosyl(1-4)]-α-L-arabinopyranoside(SB365) obtained from the extract of Pulsatillae Radix and auxiliary ingredient(s) selected from the group consisting extract of Ulmaceae Cortex and extract of... Agent: Birch Stewart Kolasch & Birch
20080124288 - Method of applying makeup by means of a magnetic composition incorporating at least one coloring agent having optical properties that are sensitive to an external stimulus: exposing at least part of the composition to a magnetic field to modify the orientation and/or to displace at least some of the magnetic bodies.... Agent: Oliff & Berridge, PLC
20080124289 - Use of an alkyloxazolidinone as a moisturizing cosmetic agent and method of moisturizing the skin: A 4-alkyloxazolidin-2-one, particularly 4-decyloxazolidin-2-one, is used as a moisturizing cosmetic agent or as a cosmetic active in a method of cosmetic care for moisturizing skin without significant stickiness.... Agent: Hamre, Schumann, Mueller & Larson, P.C.
20080124294 - Novel amphoteric polysaccharide compounds containing sulfonate function(s), composition comprising them and cosmetic use thereof: The invention relates to novel amphoteric polysaccharide compounds containing sulfonate function(s) corresponding to the formula (I) in which P represents a polysaccharide chain; X, Y and Z each represent a linear or branched, saturated or unsaturated, optionally hydroxylated C1-C12 divalent hydrocarbon-based group optionally comprising at least one ether and/or amine... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP
20080124295 - Process for elimination of the odor retained by keratinic materials in contact with water treated with a halogenated disinfectant: The present disclosure relates to a cosmetic process to reduce or eliminate the odor retained by keratinic materials placed in contact with water treated with a halogenated disinfectant, such as a chlorinated disinfectant and/or a brominated disinfectant, comprising applying onto the keratinic materials at least one composition comprising at least... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP
20080124296 - Compositions containing microspheres: The invention relates to compositions containing a microsphere, a phospholipid, an amphoteric surfactant and a nonionic surfactant, as well as to methods of applying such compositions to keratin materials and to methods of preparing such compositions.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.
20080124291 - Composition containing a lactic acid compound and/or one of its salts or a citric acid compound and/or one of its salts: Composition preferably useful for coating the eyelashes containing an aqueous phase and an emulsifying system having at least one lactic acid compound and/or one of its salts or at least one citric acid compound and/or one of its salts as the main surfactant system of the composition. Methods of use.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.
20080124292 - Composition containing an amino acid compound: m
20080124290 - Cosmetic preparation for eyelashes: It is an object of the present invention to provide a cosmetic preparation for eyelashes used as mascara and the like, which is excellent in long lash effect by improving adhesivity to eyelashes and adhesivity of pigment or fiber. The cosmetic preparation for eyelashes includes: an alkyl acrylate-vinyl acetate copolymer... Agent: Westerman, Hattori, Daniels & Adrian, LLP
20080124293 - Composition for keratin fibres: Conditioning and shine enhancing compositions dramatically and condition hair excellently in terms of combability, elasticity, smoothness and softness for keratin fibres especially human hair are disclosed. Particularly, the compositions disclosed comprise synthetic mica coated with metal oxide or oxides and having a volume particle size distribution of 1 to 750... Agent: Norris, Mclaughlin & Marcus, P.A.
20080124297 - Method for reducing allergencity in indoor spaces: According to this invention, allergenicity in an indoor space is reduced by denaturing allergens in allergen reservoirs that are capable of producing respiratory or skin reactions and physically removing the allergens from the allergen reservoirs in the indoor space. The allergen reservoirs may also be treated with pesticides and fungicides/fungistats... Agent: Hunton & Williams LLP Intellectual Property Department
20080124298 - Antifouling coating composition and its use on man made structures: c
20080124299 - Methods for treating viral infection using il-28 and il-29: IL-28A, IL-28B, IL-29, and certain mutants thereof have been shown to have antiviral activity on a spectrum of viral species. Of particular interest is the antiviral activity demonstrated on viruses that infect liver, such as hepatitis B virus and hepatitis C virus. In addition, IL-28A, IL-28B, IL-29, and mutants thereof... Agent: Zymogenetics, Inc. Intellectual Property Department
20080124300 - Stabilized brood pheromone for manipulating the behavior and physiology of honey bees: This invention relates to a stabilized honey bee pheromone and methods of stabilizing the honey bee brood pheromone, thereby enabling the production and sustained use of commercial products based on that pheromone. The stabilized pheromone can be used to manipulate the behavior and improve the performance of worker honey bees,... Agent: Oyen, Wiggs, Green & Mutala LLP 480 - The Station
20080124301 - Method for stimulating the immune system: i
20080124302 - Uses of recombinant super-compound interferons: This invention provides different uses of recombinant super-compound interferons (rSIFN-cos) and its equivalent with changed spatial configuration, high efficacy and low side effects. Therefore, high dose of rSIFN-co may be used. One characteristic of rSIFN-co is its ability to inhibit the HBV DNA duplication and secretion of HBsAg and HBeAg... Agent: Law Offices Of Albert Wai-kit Chan, LLC
20080124303 - Methods and compositions for treatment of viral infections: A novel method of treating and preventing viral diseases is provided. In particular, the present invention relates to compositions and methods for inhibition of viral infections and the diseases associated with such viral infections. More particularly, the present invention relates to the inhibitory compounds comprising naturally occurring and man-made compositions... Agent: Law Offices Of Khalilian Sira, LLC
20080124309 - Cell surface glycoprotein: This invention relates to a novel protein, termed INSP201, herein identified as a cell surface glycoprotein, and to the use of this protein and nucleic acid sequences from the encoding gene in the diagnosis, prevention and treatment of disease.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association
20080124308 - Gene therapy of solid tumours by means of retroviral vectors pseudotyped with arenavirus glycoproteins: The present invention concerns the use of packaging cells which produce retroviral virions pseudotyped with arenavirus glycoprotein, for the manufacture of a pharmaceutical composition for the gene therapy of solid tumors. The invention further concerns the use of the virions which are produced by these packaging cells, for the manufacture... Agent: Arnold & Porter LLP Attn:IPDocketing Dept.
20080124304 - Method for the generation of virus producing cell lines and cell lines: The present invention relates to a method for generating virus producing cell lines and master producer cell lines. In particular, the present invention relates to methods allowing the production of virus producing cell lines without conducting laborious selection work. Moreover, the present invention pertains to virus producing cell lines obtained... Agent: Greenblum & Bernstein, P.L.C
20080124305 - Methods for isolating phage and for controlling microorganism populations with the phage: A lytic virus specific for a target strain of a microorganism and substantially free of undesirable genes may be utilized in processes including control of populations of microorganisms. The virus may include a host-range mutant, or “h-mutant.” A method for generating virus includes growing virus-resistant variants of a target strain... Agent: Trask Britt
20080124307 - Method for promoting immunotherapy: Although the fields of therapeutic applications of dendritic cells are now expanding, dendritic cell precursors exist only in a small amount in the peripheral blood and, therefore, it is still difficult to obtain them in a therapeutically useful amount even though they are proliferated in vitro. Therefore, it is a... Agent: Birch Stewart Kolasch & Birch
20080124306 - Vigor enhancement via administration of pyrimidine derivatives: Disclosed herein are methods for increasing the overall vigor of a subject, and/or vigor of target tissues of a subject. Exemplified herein is the utilization of pyrimidine derivatives which act to stimulate stem cell proliferation. In addition to increasing vigor, such stem cell proliferation agents (SCPA) may be used to... Agent: Timothy H. Van Dyke Beusse Wolter Sanks Mora & Maire, P.A.
20080124310 - Bead based receptor biology: A method for capturing activated receptor signaling complexes from live cells, utilizing bead based biology wherein live cells are contacted with ligand coated beads to form bead binding sites and thereby initiating formation of a ligand-receptor complex at said bead binding site; and a process for distinguishing and confirming non-specifically... Agent: Mchale & Slavin, P.A.
20080124311 - Novel pharmaceutical compositions for the treatment of virus infection and cancer: The invention describes novel pharmaceutical compositions for the treatment of virus infections and cancer. The pharmaceutical compositions include mutant oligoadenylate synthetases (OAS) that have either enhanced cell permeability, reduced oxidative potential, improved antiviral activity, improved enzymatic activity, or absent enzymatic activity. The pharmaceutical compositions have improved drug properties and retain... Agent: Davis Wright Tremaine, LLP/seattle
20080124313 - Novel trna synthetase: The invention provides tRNA synthetase polypeptides and DNA (RNA) encoding tRNA synthetase polypetides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing tRNA synthetase polypeptide for the protection against infection, particularly bacterial infections.... Agent: Swanson & Bratschun, L.L.C.
20080124312 - Polyamine compositions: The present invention provides a method of inhibiting formation of solid hydrates in a conduit used to contain a flowing, water-containing hydrocarbon, which method comprises introducing into said hydrocarbon in said conduit a gas which raises the pressure threshold for hydrate formation for said water-containing hydrocarbon, said gas being introduced... Agent: Needle & Rosenberg, P.C.
20080124314 - Peptide inhibitors of cyclin-dependent kinase activity and uses thereof: Novel polypeptides or derivatives comprising cdk2 binding site are disclosed. The novel polypeptides or derivatives have growth suppressive activity. Nucleic acids encoding those polypeptides are also disclosed. The polypeptides identified herein are also useful in methods for treating or preventing cancer. The treatment methods comprise administration of the polypeptide to... Agent: Reed Smith LLP
20080124315 - Method of reducing crf receptor mrna: A method of treating a patient is disclosed. In one embodiment, the method comprises the step of reducing the amount of mRNA encoding corticotropin-releasing factor receptor, wherein a portion of the mRNA encoding corticotropin-releasing factor receptor is destroyed and wherein the amount of corticotrophin releasing factor receptor is reduced.... Agent: Quarles & Brady LLP
20080124316 - Use of hyaluronidase for prevention and treatment of cardiovascular diseases: The invention relates to use of the enzyme hyaluronidase in a dosage of at least 6,000 units per day for prevention and/or treatment of cardiovascular diseases whereby the hyaluronidase is administered intra venam over a period of at least four weeks. Hyaluronidase is particularly suited to treating coronary heart diseases... Agent: Leydig Voit & Mayer, Ltd
20080124322 - Activation and inhibition of the immune system: Activation of the immune response by NF-kB inducers, induction of an anergic response by NF-kB inhibitors and the inhibition and activation of immune response by the administration of an activator or inhibitor of NF-kB is disclosed. Examples of NF-kB inhibitors include IkBα, PSI, a nucleotide sequence encoding IkBα anti-sense nucleic... Agent: Nixon & Vanderhye, PC
20080124318 - Algae supplement and treatment method: This invention relates to a method and composition for enhancing pluripotent cell production, longevity and homing to injured or diseased sites, and more specifically, by administration of a therapeutic dosage of cyanobacteria and green algae. The increased concentration of pluripotent cells within the circulatory system of animals is effected by... Agent: Law Office Of Tracy P. Jong
20080124317 - Diagnos and treatment of fibrosis related pathology: This application is directed to a method for the treatment of fibrosis, preferably liver fibrosis, pulmonary fibrosis and cardiac fibrosis, in a subject in need of such treatment comprising administering to said subject an amount of an inhibitor of HNOEL-iso polypeptide sufficient to effect a substantial inhibition of the HNOEL-iso... Agent: Cooper & Dunham, LLP
20080124321 - Isolated bovine igg heavy chain protein and its use as an antimicrobial: A new protein derived from acid hydrolyzed IgG concentrate which has a molecular weight of about 55,000, and is activated by heat within the defined narrow temperature range provides resulting product that has a protective mechanism for bacterial and viral invasion of living cells.... Agent: Schwegman, Lundberg & Woessner, P.A.
20080124319 - Methods for treating inflammation by disrupting mch-mediated signaling: Disclosed herein are methods for treating an inflammatory condition in a patient comprising administering an agent that inhibits the signaling activity of MCH, thereby inhibiting the inflammatory response in the tissue, and in a mammal comprising administering to the mammal an effective amount of an agent that inhibits MCH activity,... Agent: Hamilton, Brook, Smith & Reynolds, P.C.
20080124320 - Use of hmgb fragments as anti-inflammatory agents: Compositions and methods are disclosed for inhibiting the release of a proinflammatory cytokine from a cell, and for inhibiting an inflammatory cytokine cascade in a patient. The compositions comprise an HMGB A box, and an antibody preparation that specifically binds to an HMGB B box. The methods comprise treating a... Agent: Hamilton, Brook, Smith & Reynolds, P.C.
20080124323 - Nutritional composition comprising indigestible oligosaccharides: The present invention provides a method and composition for the treatment and/or prevention of respiratory tract infection and/or respiratory tract infection disease, said method comprising orally administering a composition to a mammal, said composition comprising a galactose containing indigestible oligosaccharide and at least 5 wt. % digestible galactose saccharide.... Agent: Foley And Lardner LLP Suite 500
20080124327 - Cytotoxicity mediation of cells evidencing surface expression of cd44: This invention relates to the staging, diagnosis and treatment of cancerous diseases (both primary tumors and tumor metastases), particularly to the mediation of cytotoxicity of tumor cells; and most particularly to the use of cancerous disease modifying antibodies (CDMAB), optionally in combination with one or more CDMAB/chemotherapeutic agents, as a... Agent: Mchale & Slavin, P.A.
20080124325 - Preventive or therapeutic agent for psoriasis comprising il-6 antagonist as active ingredient: A method for treating psoriasis comprising an interleukin-6 (IL-6) antagonist such as, for example, an antibody against IL-6 receptor.... Agent: Foley And Lardner LLP Suite 500
20080124326 - Stable polypeptide formulations: The invention provides a formulation including a buffer having a pH less than 6.0, a divalent cation between about 5-200 mM, an excipient comprising a sugar or polyol and an effective amount of a therapeutic polypeptide. Also provided is a method of stabilizing a polypeptide. The method includes contacting a... Agent: Amgen Inc.
20080124324 - Single-domain antigen-binding antibody fragments derived from llama antibodies: A phage display library of variable heavy domain (VHH or VH) fragments (sdAb fragments) derived from the antibody repertoire of a non-immunized llama is disclosed. The sdAb fragments of the library are characterized by the absence of cysteine residues in complementarity determining regions (CDRs) and a very low presence of... Agent: Wolf Greenfield & Sacks, P.C.
20080124329 - Conditioned cell immunization: The present invention provides methods and compositions for generating modulators capable of binding to antigens presented by a cell that has been exposed to cellular conditioning. The present invention also includes methods and compositions for the prevention, treatment and diagnosis of disorders using the antigen modulators. The present invention further... Agent: Cooley Godward Kronish LLP Attn: Patent Group
20080124328 - Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins: This invention provides antibodies that specifically bind to and neutralize botulinum neurotoxin type A (BoNT/A) and the epitopes bound by those antibodies. The antibodies and derivatives thereof and/or other antibodies that specifically bind to the neutralizing epitopes provided herein can be used to neutralize botulinum neurotoxin and are therefore also... Agent: Beyer Weaver LLP
20080124330 - Anti-glypican 3 antibody having modified sugar chain: An anti-glypican 3 antibody with modified sugar chains, more specifically, an anti-glypican 3 antibody lacking fucose is provided. The anti-glypican 3 antibody with modified sugar chains of the present invention may be produced by a process comprising introducing a nucleic acid encoding an anti-glypican 3 antibody into host cells with... Agent: Fish & Richardson PC
20080124332 - Compositions and methods using anti-cs1 antibodies to treat multiple myeloma: Compositions and methods for treating MM are provided herein.... Agent: Pdl Biopharma, Inc. Attn: Legal Department
20080124334 - Isolated nucleic acids, vectors and host cells encoding erbb3 antibodies: Antibodies are disclosed which bind to ErbB3 protein and further possess any one or more of the following properties: an ability to reduce heregulin-induced formation of an ErbB2-ErbB3 protein complex in a cell which expresses ErbB2 and ErbB3; the ability to increase the binding affinity of heregulin for ErbB3 protein;... Agent: Heller Ehrman LLP
20080124333 - Methods and compositions for treating melanoma: A method for inhibiting melanoma cell growth in a patient by administering to the patient a therapeutically effective amount of a glutamate release inhibitor, a GRM 1 antagonist, or a combination thereof... Agent: Synnestvedt Lechner & Woodbridge LLP
20080124331 - Compositions and methods for the diagnosis and treatment of tumor: The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.... Agent: Genentech, Inc.
20080124336 - Molecules and methods for inhibiting shedding of kim-1: Disclosed are antibodies that inhibit proteolytic release of a soluble KIM-1 polypeptide from KIM-1 expressing cells. Also disclosed are methods of using the antibodies to inhibit shedding of the KIM-1 polypeptide.... Agent: Fish & Richardson
20080124335 - Novel polypeptide and the use thereof: The present invention provides a variety of useful polypeptides. In particular, a polypeptide comprising the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3, its amide, or a salt thereof can... Agent: Wenderoth, Lind & Ponack, L.L.P.
20080124337 - Proteinase k resistant surface protein of neisseria meningitidis: The identification of a highly conserved, immunologically accessible antigen at the surface of Neisseria facilitates treatment, prophylaxis, and diagnosis of Neisseria diseases. This antigen is highly resistant to Proteinase K and has an apparent molecular weight of 22 kDa on SDS-PAGE. Specific polynucleotides encoding proteins of this class have been... Agent: Seed Intellectual Property Law Group PLLC
20080124338 - Methods for treatment of inflammatory disease and chlamydia infectious disease: Methods are provided for treatment of inflammation or inflammatory disease. Methods are further provided for treatment of Chlamydia infection or persistent Chlamydia infection.... Agent: Woodcock Washburn LLP
20080124339 - Antibodies to madcam: The present invention relates to antibodies including human antibodies and antigen-binding portions thereof that specifically bind to MAdCAM, preferably human MAdCAM and that function to inhibit MAdCAM. The invention also relates to human anti-MAdCAM antibodies and antigen-binding portions thereof. The invention also relates to antibodies that are chimeric, bispecific, derivatized,... Agent: Ropes & Gray LLP
20080124340 - Erythropoietin receptor agonists: Antibodies that bind erythropoietin receptor are provided. Methods of making and using such antibodies are also provided. Kits containing such antibodies are also provided.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP
20080124341 - Therapeutic targeting of escort proteins: The invention provides for inhibition of viral disease by the provision to a mammalian host of antibodies directed against an escort protein likeTsg 101. These proteins appear on the surface of a cell, and thus can be bound by circulating antibodies thereto. By binding escort proteins on the cell surface,... Agent: Jagtiani + Guttag
20080124342 - Anti-tnf alpha antibodies which selectively inhibit tnf alpha signalling through the p55r: The present invention provides anti-TNFα antibodies which selectively inhibit TNFα signalling through the p55R. In particular the present invention provides anti-TNFα antibodies which selectively inhibit TNFα signalling through the p55R relative to the p75R.... Agent: Woodcock Washburn LLP
20080124344 - Novel gene disruptions, compositions and methods relating thereto: The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising disruptions in PRO226, PRO257, PRO268, PRO290, PRO36006, PRO363, PRO365, PRO382, PRO444, PRO705, PRO1071, PRO1125, PRO1134, PRO1155, PRO1281, PRO1343, PRO1379, PRO1380, PRO1387, PRO1419,... Agent: Genentech, Inc.
20080124343 - Treatment of inappropriate immune responses: The invention relates to compositions containing antibodies that can bind activated lymphocytes and/or activated monocytes. The invention also provides methods for making these antibodies and methods for using these antibodies to treat or prevent undesirable immune responses.... Agent: Schwegman, Lundberg & Woessner/nih
20080124345 - Antibodies directed to her-3 and uses thereof: The present invention relates to binding proteins that bind to HER-3 and polynucleotides encoding the same. Expression vectors and host cells comprising the same for the production of the binding protein of the invention are also provided. In addition, the invention provides compositions and methods for diagnosing and treating diseases... Agent: Nixon Peabody, LLP
20080124346 - Metal-binding therapeutic peptides: The present invention is related methods of delivering MBD peptide-linked agents into live cells. The methods described herein comprise contacting MBD peptide-linked agents to live cells under a condition of cellular stress. The methods of the invention may be used for therapeutic or diagnostic purposes.... Agent: Morrison & Foerster LLP
20080124347 - Insulinotropic peptide conjugate using carrier substance: The present invention relates to an insulinotropic peptide conjugate having improved in-vivo duration of efficacy and stability, comprising an insulinotropic peptide, a non-peptide polymer and a carrier substance, which are covalently linked to each other, and a use of the same. The insulinotropic peptide conjugate of the present invention has... Agent: Seed Intellectual Property Law Group PLLC
20080124348 - Immune regulation: A method of regulating the immune system of a subject that involves removing antigen presenting cells from subject and loading preselected class II peptide fragments onto the subjects APC's outside the body of the subject.... Agent: Fish & Richardson PC
20080124349 - Method or use of a solubilized glucan product to increase immunostimulation in animals: β-(1-6)-Glucanase treatment of glucan from yeast cells, pure or feed grade especially yeast from the family Saccharomyces and particularly Saccharomyces cerevisiae, provides a novel glucan product suitable for use in enhancing the stimulation of host animal immune systems. Solubilization of such yeast cell glucan is further disclosed to extend the... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.
20080124350 - Nanoparticle-based vaccine delivery system containing adjuvant: A vaccine delivery system comprising adjuvant and nanoparticles comprising an immunogenic agent is provided. A method of immunizing an animal comprising administering a nanoparticle-based vaccine delivery system is also provided.... Agent: Mcdermott Will & Emery LLP
20080124351 - Proteinase k resistant surface protein of neisseria meningitidis: The identification of a highly conserved, immunologically accessible antigen at the surface of Neisseria facilitates treatment, prophylaxis, and diagnosis of Neisseria diseases. This antigen is highly resistant to Proteinase K and has an apparent molecular weight of 22 kDa on SDS-PAGE. Specific polynucleotides encoding proteins of this class have been... Agent: Seed Intellectual Property Law Group PLLC
20080124352 - Proteinase k resistant surface protein of neisseria meningitidis: Embodiments of the invention disclosed herein relate to methods and compositions for bypassing the involvement of CD4+ cells when generating antibody and MHC class I-restricted immune responses, controlling the nature and magnitude of the response, and promoting effective immunologic intervention in viral pathogenesis. More specifically, embodiments relate to immunogenic compositions... Agent: Sonnenschein Nath & Rosenthal LLP
20080124353 - Proteinase k resistant surface protein of neisseria meningitidis: The identification of a highly conserved, immunologically accessible antigen at the surface of Neisseria facilitates treatment, prophylaxis, and diagnosis of Neisseria diseases. This antigen is highly resistant to Proteinase K and has an apparent molecular weight of 22 kDa on SDS-PAGE. Specific polynucleotides encoding proteins of this class have been... Agent: Seed Intellectual Property Law Group PLLC
20080124354 - Methods for administering tumor vaccines: The present invention provides methods of inducing an immune response in a subject against a protein of interest and treating and suppressing a formation of a tumor comprising a tumor-associated protein, comprising sequential administration of fragments of the protein. The present invention also provides Her-2 protein fragments, recombinant peptides comprising... Agent: Pearl Cohen Zedek Latzer, LLP
20080124355 - Live bacterial vaccines for viral infection prophylaxis or treatment: The present invention provides a vaccine, method of use, and kit employing genetically isolated and stabilized, live attenuated bacterial strains including Salmonella that express one or more avian influenza antigens for use in live vaccine compositions that can be orally administered to an individual to protect against avian influenza. Genetic... Agent: Milde & Hoffberg, LLP
20080124356 - Keratinocyte culturing method and the use thereof: The invention relates to keratinocyte culture, a keratinocyte culturing method and the use thereof for spreading living attenuated viruses. The inventive method makes it possible to obtain living attenuated viruses and vaccines containing said viruses.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.
20080124358 - Modified plant viruses and methods of use thereof: The present invention relates to modulating the nature and/or level of an immune response to a molecule. In particular, the invention relates to effecting an increase in the TH1 immune response to molecules such as, but not limited to, antigens or immunogens. The invention also relates to reducing a TH2... Agent: Trask Britt
20080124357 - Vaccines against vesicular stomatitis: The present invention relates to an immunogenic or vaccine composition to induce an immune response or protective immune response against vesicular stomatitis virus (VSV) in an animal susceptible to VSV. The composition may include a pharmaceutically or veterinarily acceptable vehicle or excipient, and a vector. The vector may contain at... Agent: Judy Jarecki-black, Ph.d, J.d
20080124359 - Hemorrhagic feline calicivirus, calicivirus vaccine and method for preventing calicivirus infection or disease: The present invention relates to a novel, isolated and purified hemorrhagic feline calicivirus FCV-DD1. The invention further embraces monovalent and multivalent vaccines containing the new FCV-DD1 strain. In addition, the invention encompasses methods of protecting felines against infection or preventing disease caused by feline calicivirus alone or in addition to... Agent: Wyeth Patent Law Group
20080124360 - Adenovirus particles with enhanced infectivity of dendritic cells and particles with decreased infectivity of hepatocytes: Provided are adenovirus vectors and the production of such vectors. In particular, adenoviruses with modified or heterologous fiber proteins for targeting to dendritic cells are provided.... Agent: Dla Piper US LLP
20080124361 - Use of flagellin in the immunotherapy of yersinia pestis: The invention provides a fusion protein comprising a flagellin adjuvant and a Yersinia pestis antigen. Also provided are compositions comprising a flagellin adjuvant and a Yersinia pestis antigen. The invention also discloses methods of making a fusion protein comprising a flagellin adjuvant and a Yersinia pestis antigen. The invention further... Agent: Myers Bigel Sibley & Sajovec
20080124362 - Domain ii mutants of anthrax lethal factor: A series of mutants of Anthrax lethal factor (LF) are disclosed which define a conformational epitope or region of the molecule that interacts with the LF target, the MEK enzyme. Such mutants or variants, and nucleic acids encoding them are disclosed. The knowledge of such binding, separate from recognition of... Agent: Price Heneveld Cooper Dewitt & Litton, LLP
20080124363 - Attenuated uracil auxotroph of an apicomplexan and use thereof: Uracil auxotroph mutants of apicomplexans are provided which lack a functional carbamoyl phosphate synthase II (CPSII) enzyme. Also provided are T. gondii autoxtroph mutants which express exogenous antigens, and methods of protecting an animal against a T. gondii and non-T. gondii disease.... Agent: Licata & Tyrrell P.C.
20080124364 - Recombinant plasmid and method for expressing hepatitis b viral antigens and virions in vivo: Disclosed is a recombinant plasmid for expressing hepatitis B viral antigens in vivo, comprising an adeno-associated virus (AVV) vector and a replication-competent hepatitis B virus genome fragment. Mice hydrodynamically injected with the recombinant plasmid of the present invention show persistent expression of hepatitis B viral antigens for more than 6... Agent: Wpat, PC Intellectual Property Attorneys
20080124365 - Innate immune response inducer: The present application describes a method of making concatenated RNA comprising, mixing a single stranded DNA template with a RNA transcription reagent and allowing transcription reaction to occur, and use of the RNA for anti-viral and anti-cancer purposes.... Agent: Jhk Law
20080124366 - Methods and compositions for treating tumors: The present invention is based on the finding that toll-like receptor (TLR) agonists affect immune responses in a subject. The compositions and methods of the present invention include administering to the subject a therapeutically effective amount of a tumor lysate or tumor lysis agent in conjunction with a therapeutically effective... Agent: Viksnins Harris & Padys Pllp
20080124367 - Oil based composition for external use on skin for enhancing percutaneous absorption: A method of enhancing percutaneous absorption of a water-soluble agent comprises the steps of: applying a preparation for external use on skin, which preparation contains a water-soluble agent, onto skin, and applying an oil based composition for external use on skin onto the preparation for external use on skin, which... Agent: Snider & Associates
20080124368 - Composition: An antimicrobial composition is formed from about 5 to about 25 wt % of an antimicrobial formulation and about 75 to about 95 wt % of a polyurethane resin or polyurethane hybrids, copolymers, or mixtures with other polymers such as polyesters, nitrites, PVC, and synthetic rubber latexes. The antimicrobial formulation... Agent: Richard D. Fuerle
20080124369 - Antimicrobial coating for erosive environments: This invention provides for a curable antimicrobial coating system comprising a base coating composition and a top coat coating composition wherein each contains and antimicrobial agent. The base coat forms a non-hydrophilic polymer layer and the top coat preferably forms a hydrophilic polymer layer or a non-hydrophilic polymer layer which... Agent: Edward K. Welch Ii Ip&l Solution
20080124371 - Biocomposite for artificial tissue design: The present invention concerns a biocomposite useful in artificial tissue replacement, methods for its production, and methods of use. The biocomposite can be implanted into humans or animals as an artificial tissue for treatment of a tissue defect. The biocomposite can be formed or manipulated into a desired shape for... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association
20080124370 - Reagents, methods and systems to suppress pro-inflammatory cytokines: The present invention relates to reagents, methods and systems to treat inflammation and pain in a subject using small interfering RNA (siRNA) molecules targeted to either TNFα, IL1, IL6 and other pro-inflammatory cytokines.... Agent: Fox Rothschild, LLP
20080124374 - Decellularized bone marrow extracellular matrix: The invention is directed to compositions comprising decellularized bone marrow extracellular matrix and uses thereof. Methods for repairing or regenerating defective, diseased, damaged or ischemic tissues or organs in a subject, preferably a human, using the decellularized bone marrow extracellular matrix of the invention are also provided. The invention is... Agent: Jones Day
20080124373 - Lumen - supporting devices and methods of making and using: Disclosed herein are medical devices, particularly lumen-supporting devices, which include a biocompatible nanostructured ceramic material configured to be disposed adjacent to a luminal surface and having an average grain size dimension of about 1 nanometer to about 1000 nanometers, a strain to failure of at least about 1 percent, and... Agent: Cantor Colburn, LLP
20080124372 - Morphology profiles for control of agent release rates from polymer matrices: The present disclosure teaches methods of controlling the release rate of agents from a polymeric matrix that include designing and creating a predetermined initial morphology (IM) profile in a polymeric matrix. The teachings indicate, inter alia, that control over the release rate of agents can provide for an improved control... Agent: Squire, Sanders & Dempsey LLP
20080124375 - Device and methods of sequential, regional delivery of multiple cyctotoxic agents and directed assembly of wound repair tissues: An implantable delivery system includes a macrostructure formed of bioresorbable material selected from a group of alphahydroxy acids and defined to include an internal architecture of intercommunicating void spaces. A first cytotoxic agent in the preferred form of cisplatin is joined to the macrostructure during formation. A microstructure in the... Agent: Kamrath & Associates P.A.
20080124376 - Ocular devices and methods of making and using thereof: Described herein are stable ocular devices that immobilize and deliver bioactive agents to the eye over sustained periods of time. Also described herein are methods of making and using the ocular devices.... Agent: Gardner Groff Greenwald & Villanueva. PC
20080124377 - Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents: Combinations of hydrophilic and hydrophobic entities in a biodegradable sustained release implant are shown to modulate each other's rate of release. Formulations of a therapeutically active agent and modulator provide substantially constant rate of release for an extended period of time.... Agent: Allergan, Inc.
20080124378 - Therapeutic contact lenses with anti-fungal delivery: A drug delivery system is disclosed. The drug delivery system includes a recognitive polymeric hydrogel through which a drug is delivered by contacting biological tissue. The recognitive polymeric hydrogel is formed using a bio-template, which is a drug or is structurally similar to the drug, functionalized monomers, preferably having complexing... Agent: Haverstock & Owens LLP
20080124379 - Compositions and methods for making therapies delivered by viral vectors reversible for safety and allele-specificity: The present invention is directed to compositions methods and kits for regulation of gene therapies, including, without limitation, reversible gene therapies and allele-specific therapies.... Agent: Fox Rothschild, LLP
20080124380 - Contraceptives based on sp22 and sp22 antibodies: Oral, topical and injectable contraceptives, which are based on sperm protein 22 kDa (SP22) polypeptides and antibodies and infertility diagnostics are provided.... Agent: Foley Hoag, LLP Patent Group (w/isa)
20080124381 - Dissolvable adhesive films for delivery of pharmaceutical or cosmetic agents: The invention provides integratable adhesive films containing a mixture of high molecular weight and low molecular weight water soluble components; and a pharmaceutically or cosmetically active ingredient. Optionally, the films contain a starch component, a polysaccharide component, a filler, a plasticizer and/or humectant. The films are preferably in the form... Agent: Dickstein Shapiro LLP
20080124382 - Packaging two different substrates: A co-packaged product and containers for co-packaging two different substrates is disclosed. The co-packaged product comprises a first substrate wound into a roll having an interior space, and a second substrate is located within at least a portion of the interior space. In one embodiment, a paper towel roll has... Agent: Kimberly-clark Worldwide, Inc. Catherine E. Wolf
20080124384 - Heteroaryl substituted piperazinyl-pyridine analogues: Substituted biaryl piperazinyl-pyridine analogues are provided, of the Formula: wherein variables are as described herein. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological receptor activation in humans, domesticated... Agent: Edwards Angell Palmer & Dodge LLP
20080124383 - Use of anti-cytokine agents for treating carpal and tarsal tunnel syndrome: Methods for treating carpal tunnel syndrome and tarsal tunnel syndrome in a subject involve providing an effective amount of an anti-cytokine agent at or near inflammation in the carpal or tarsal tunnel. Anti-cytokine agents, such as, TNF-a inhibitors, NF-κB inhibitors, IL-1 inhibitors, IL-6 inhibitors, IL-8 inhibitors, IL-12 inhibitors, IL-15 inhibitors,... Agent: Fox Rothschild, LLP
20080124386 - Apoptosis-mimicking synthetic entities and use thereof in medical treatment: Synthetic and semisynthetic bodies having a three-dimensional structure, sized and shaped to resemble apoptotic cells and apoptotic bodies, and having phosphatidyl serine (PS) molecules on the surface thereof, are administered to a patient, to alleviate a variety of disorders such as T-cell mediated disorders (autoimmune conditions). The bodies are believed... Agent: Foley & Lardner LLP
20080124385 - Methods for transmembrane treatment and prevention of otitis media: Methods for treating and preventing middle ear infections by transmembrane administration of medicament-containing transmembrane carrier compositions, such as liposomes and other lipid vesicles, to the tympanic membrane. Medicaments useful for treating pain, inflammation or infection in the outer ear may be co-administered. If utilized for transmembrane administration, the liposomes or... Agent: Dla Piper US LLP
20080124387 - Methods and formulations for enhancing the absorption and decreasing the absorption variability of orally administered drugs, vitamins and nutrients: A method and composition of preparing bioavailable hydrophobic, poorly water soluble drugs. It uses for example, lecithin, sterol, and solvent; mixing and then the solvent driven off; the ratios used differ from others, and maximize performance.... Agent: Mckee, Voorhees & Sease, P.L.C
20080124388 - Pharmaceutical composition and method for neoangiogenesis/revascularization useful in treating ischemic heart diseases: A pharmaceutical composition and a method of treating ischemic heart diseases by growing new blood vessels that supply oxygen and nutrients to infarcted heart tissues throughout the entire infarct zone and for preventing cardiomyocyte apoptosis in ischemic events. The pharmaceutical composition contains an active ingredient compound with a backbone structure... Agent: Evan Law Group LLC
20080124389 - Nanoparticulate and controlled release compositions comprising cyclosporine: The present invention is directed to a composition comprising a nanoparticulate cyclosporine having improved bioavailability. The nanoparticulate cyclosporine particles of the composition have an effective average particle size of less than about 2000 nm in diameter and are useful in the prevention and treatment of organ transplant rejection and autoimmune... Agent: Fox Rothschild, LLP
20080124390 - Pharmaceutical compositions containing lithium carbonate: Once daily pharmaceutical compositions containing lithium carbonate in the form of coated granules.... Agent: Foley And Lardner LLP Suite 500
20080124391 - Algal and algal extract dietary supplement composition: A human dietary supplement composition comprising the dried biomass of blue-green algae (Spirulina platensis) and astaxanthin is disclosed, The composition is stable, effective and convenient for supporting the health and well-being of either healthy or health-challenged humans. Further, a method of ameliorating viral infections in human subjects by administering the... Agent: Allen, Dyer, Doppelt, Milbrath & Gilchrist P.A.
20080124392 - Extended release formulation: This invention relates to a 24 hour extended release dosage formulation and unit dosage form thereof of venlafaxine hydrochloride, an antidepressant, which provides better control of blood plasma levels than conventional tablet formulations which must be administered two or more times a day and further provides a lower incidence of... Agent: Wyeth Patent Law Group
20080124393 - Controlled release nanoparticulate compositions: Described are controlled release nanoparticulate formulations comprising a nanoparticulate agent to be administered and a rate-controlling polymer which functions to prolong the release of the agent following administration. The novel compositions release the agent following administration for a time period ranging from about 2 to about 24 hours or longer.... Agent: Foley & Lardner LLP
20080124394 - Controlled-release formulations: The present invention relates to formulations of a lipid based controlled-release matrix, a polyhydroxy component and a bioactive agent. Such formulation are useful in the delivery of the bioactive compounds. The invention also relates to the use of a polyhydroxy component for increasing the solubility of a bioactive compound, especially... Agent: Nixon Peabody, LLP
20080124395 - Formulations and devices for treatment or prevention of neural ischemic damage: A formulation is provided for treatment or prevention of neural ischemic damage, or for treatment of stroke, hemorrhage, trauma, epilepsy, tumor, or any disease of the brain, the formulation comprising a mixture of a substantially solid, substantially water-insoluble, biocompatible, polymeric material, and a gap junction inhibitor such as carbenoxolone. The... Agent: Schwegman, Lundberg & Woessner, P.A.
20080124396 - Inhibition of xenoreactive antibodies: One aspect of the present invention relates to methods and compositions for attenuating xenograft rejection by administering, to an animal receiving the xenograft, an amount of a polymer-derivatized xenoantigen (hereinafter “xenopolymer”) effective for inhibiting or lessening the severity of hyperacute rejection response (HAR), or other immunological response to the graft,... Agent: Fish & Richardson P.C.
20080124397 - System for reconstituting pastes and methods of using same: Disclosed herein is an efficient and cost-effective system for reconstituting bone pastes comprising a first syringe containing a reconstitution fluid and second syringe containing paste components, wherein said first and second syringes are communicatingly interconnectable. Also disclosed are novel methods for producing and storing bone pastes. Alternatively, a mixing syringe... Agent: Mcandrews Held & Malloy, Ltd
20080124398 - Modified release dosage forms of skeletal muscle relaxants: A unit dosage form, such as a capsule or the like, for delivering a skeletal muscle relaxant, such as cyclobenzaprine hydrochloride, into the body in an extended or sustained release fashion comprising one or more populations of drug-containing particles (beads, pellets, granules, etc.) is disclosed. At least one bead population... Agent: Cooley Godward Kronish LLP Attn: Patent Group
20080124399 - Modified release dosage forms of skeletal muscle relaxants: A unit dosage form, such as a capsule or the like, for delivering a skeletal muscle relaxant, such as cyclobenzaprine hydrochloride, into the body in an extended or sustained release fashion comprising one or more populations of drug-containing particles (beads, pellets, granules, etc.) is disclosed. At least one bead population... Agent: Cooley Godward Kronish LLP Attn: Patent Group
20080124400 - Microparticles with high loadings of a bioactive agent: The present invention discloses compositions, devices and methods for the production, use and administration of compositions that comprise microparticles that are loaded with a drug at a concentration of greater than 50% (weight drug/weight microparticle).... Agent: Seed Intellectual Property Law Group PLLC
20080124401 - Method of treating endothelial injury: The use of human erythropoietin (EPO) to prevent or treat endothelial injury due to chemotherapy, radiation therapy, mechanical trauma, or to a disease state which damages the endothelium (such as inflammation, heart disease or cancer) is described. The use of EPO in conjunction with the administration of chemotherapeutic agents is... Agent: Myers Bigel Sibley & Sajovec
20080124402 - N-(pyridin-3-yl)-2-phenylbutanamides as androgen receptor modulators: Compounds of structural formula (I) are modulators of the androgen receptor (AR) in a tissue selective manner. These compounds are useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis,... Agent: Merck And Co., Inc
20080124403 - Deacetylase inhibitor therapy: The present invention relates to deacetylase inhibitor (e.g., histone deacetylase inhibitor) therapies and demonstrates that individuals with low electrolyte levels may have increased susceptibility to certain unwanted side effects such as cardiac side effects. In some embodiments, the invention provides methods of administering DAC or DAC inhibitor therapy that includes... Agent: Choate, Hall & Stewart LLP
20080124404 - Hypolipidemic and/or hypocholesteremic compounds obtainable from the goldenseal plant: The invention features bioactive compounds obtainable from goldenseal and methods of use of such compounds in reducing lipid (at least one of total cholesterol, LDL-cholesterol, free fatty acids, or triglycerides) in a patient having or suspected of having hyperlipidemia.... Agent: Bozicevic, Field & Francis LLP Stanford University Office Of Technology Licensing
20080124405 - Composition for prophylaxis or treatment of urinary system infection and method thereof: The present invention relates to a composition for prophylaxis or treatment of urinary system infection, comprising a matrix metalloproteinase inhibitor. The present invention also relates to a method for prophylaxis or treatment of urinary system infection, comprising administering to a patient in need of such treatment an effective amount of... Agent: Wpat, PC Intellectual Property Attorneys
20080124406 - Spray mixture for soothing a cow udder: An udder soothing mixture preferably includes water, peppermint oil, menthol, tea tree oil, an emulsifying agent and a carrier. The peppermint oil, menthol and tea tree oil are organic active ingredients. The emulsifying agent is preferably Simulgel, but other emulsifying agents may also be used. The carrier is preferably Glycerin... Agent: Donald J. Ersler, S.c.
20080124407 - Inhibiting cyp3a4 induction: with R1, X, and n defined herein, binds to a Pregnane X Receptor or Steroid and Xenobiotic Receptor (SXR or NR1I2) under conditions effective to inhibit CYP3A4 gene induction. The present invention also include a method of administering a compound, described herein, together with the CYP3A4 inducer to prevent a... Agent: Nixon Peabody LLP - Patent Group
20080124408 - Echinacea formulation: The present invention relates to an Echinacea formulation which includes an alkylamide fraction comprising a 2-ene alkylamide fraction and a 2,4-diene alkylamide fraction and the weight ratio of the 2-ene alkylamide fraction to the 2,4-diene alkylamide fraction is between about 1:15 to about 2:1.... Agent: Edwards Angell Palmer & Dodge LLP
20080124409 - Topical skin compositions, their preparation, and their use: Topical skin compositions include a complex containing components to provide a defense against the various pathway mechanisms of free radicals, reactive oxygen species, reactive nitrogen species, and other oxidizing species on the human body including the skin. The compositions may be administered by topically applying them in an amount to... Agent: In Re: Alticor Inc. 28533 Brinks, Hofer, Gilson & Lione
20080124410 - Use of lavender oil for the prophylaxis and treatment of neurasthenia, somatization disorders and other stress-associated diseases: The present invention relates to the prophylactic and therapeutic use of lavender oil for the treatment of neurasthenia, somatization disorders and other stress-associated diseases as well as medicaments, dietetic food products, preparations and capsules containing lavender oil as oral administration forms.... Agent: Edwards Angell Palmer & Dodge LLP
20080124411 - Throat spray: An orally administered composition for relieving or eliminating snoring is described. The composition generally has four mechanisms of action for combating snoring. The composition includes a tissue-firming or astringent agent to firm up throat tissue. The composition also includes a soothing agent to soothe irritated or inflamed tissues. Also included... Agent: Fulbright & Jaworski L.L.P.
20080124412 - Methods for reducing circulating glucose levels: The invention relates to methods of reducing circulating glucose levels with compositions obtained from botanical sources. More specifically, the invention relates to methods of treating individuals whom wish to reduce their circulating glucose levels, particularly individuals having elevated circulating glucose levels, with an extract product of Aframomum melegueta.... Agent: Marshall, Gerstein & Borun LLP
20080124413 - Novel composition containing extracts of butyrospermum parkii and the use of such a composition for preparing a medicament or a dietary supplement for the treatment or prevention of inflammation hypersensitivity or pain: The present invention relates to a composition comprising an extract or a concentrate of Butyrospermum parkii as a dietary supplement or a pharmaceutical composition and to the use of such compositions for the preparation of a medicament or a dietary supplement for the suppression of hypersensitivity and/or inflammatory reaction. The... Agent: Foley And Lardner LLP Suite 500
20080124414 - Use of knotwood extracts: The use of i) finely divided knotwood, or ii) an extract, obtained by extracting knotwood with a polar solvent and recovering the extract, as an antioxidative agent. A fraction of the extract may also be used as an antioxidative agent.... Agent: James C. Lydon
20080124415 - Fat combustion accelerator: The present invention provides a novel fat combustion accelerator which can promote lipid metabolism without changing the total consumption calories, characterized in that said fat combustion accelerator comprises proanthocyanidin as an active ingredient.... Agent: Drinker Biddle & Reath (dc)
20080124416 - Therapeutic composition from goji (lycium barbarum l.), methods of making and using: The present invention relates to herbal-derived compositions comprising extracts of polysaccharides and carotenoids from Goji species for management of ocular disorders, diabetes, bone metabolism, arthritis, muscle loss, cardiovascular disorders, immunological disorders, fatigue, body weight, sexual disorders, aging disorders, dermatological disorders and neurological disorders. Further provided are methods for making the... Agent: Greenberg Traurig LLP (la)05/22/2008 > patent applications in patent subcategories. archived by USPTO category
20080118432 - Monitoring cancer stem cells: The present invention is directed to methods of monitoring cancer stem cells in patients undergoing cancer therapy to determine whether the cancer therapy is an effective cancer therapy. The present invention relates to methods for monitoring the amount of cancer stem cells prior to, during, and/or following cancer treatment of... Agent: Jones Day
20080118433 - Preparation and method utilizing radiolabeled chlorotoxin: The inventors propose to label a chlorotoxin with I-123 or I-124 for a diagnostic agent, and with I-124 or I-131 for a therapeutic agent to reduce tumors and then to use a process they previously invented to stabilize the radiopharmaceutical. The inventors propose to reconstitute the preferred agents and administer... Agent: Brooke Schumm Iii Daneker, Mcintire, Schumm, Prince, Goldstein Et Al
20080118434 - Genes commonly regulated by different classes of antidepressants: The present invention provides methods for diagnosing mental disorders. The invention also provides methods of identifying modulators of mental disorders as well as methods of using these modulators to treat patients suffering from mental disorders.... Agent: Townsend And Townsend And Crew, LLP
20080118437 - Diagnosis and treatment o prostate cancer: The present invention relates to compositions and methods for cancer diagnosis, treatment and research, including but not limited to, cancer markers and uses of cancer markers. In particular, the present invention provides compositions and methods for targeting MCP-1 in prostate cancer.... Agent: Medlen & Carroll, LLP
20080118438 - Loss of function mutations in calcium channel polypeptides associated with sudden cardiac death: Previously unknown mutations of the CACNA1C and CACNB2b genes are disclosed which are involved in ion channel disruptions associated with shorter than normal QT interval and ST segment elevation syndrome. These mutations are utilized to diagnose and screen for shorter than normal QT interval and ST segment elevation syndrome, thus... Agent: Carter, Deluca, Farrell & Schmidt, LLP
20080118436 - Pathological animal model for non-alcoholic fatty hepatitis: An object of the present invention is to provide a pathologic model animal more accurately reflecting the pathologic conditions of nonalcoholic steatohepatitis patients, and the present invention provides the pathologic model animal for nonalcoholic steatohepatitis produced by continuously administering a tetracycline antibiotic to an animal having its body weight significantly... Agent: Merck And Co., Inc
20080118439 - Systems and methods for high-resolution in vivo imaging of biochemical activity in a living organism: This invention relates to multifunctional detection agents useful for providing high-resolution, in vivo imaging of biochemical activity in a living organism. Methods of using these multifunctional detection agents may comprise administering them into a living organism, and then estimating the localization of the detection agent using one modality (i.e., MRI),... Agent: General Electric Company Global Research
20080118440 - Imaging cellular nucleic acids: A reporter conjugate for non-invasive imaging of gene expression in vivo is disclosed. The conjugate includes a targeting nucleic acid linked to a contrast agent, such as a paramagnetic label that can be used with magnetic resonance imaging (MRI). The targeting nucleic acid can be an anti-sense strand that hybridizes... Agent: Fish & Richardson Pc
20080118441 - Compositions and methods for the treatment of gastrointestinal conditions: Gastrointestinal conditions, such as gastroesophageal reflux disease, heartburn, acid indigestion, constipation, irritable bowel syndrome, stomach and intestinal ulcers, gastrointestinal tract inflammation, thrush, diverticulitis, ulcerative colitis, Crohn's disease, diarrhea and cancers of the esophagus, pancreas, stomach, intestines and colon, may be treated or prevented by administration of compositions containing a therapeutically... Agent: Lathrop & Gage Lc
20080118442 - Aerosol formulations for delivery of dihydroergotamine to the systemic circulations via pulmonary inhalation: Pharmaceutical aerosol formulations of dihydroergotamine, or pharmaceutically acceptable salts thereof, to administer dry powders and propellant suspensions via pulmonary aerosol or nasal spray inhalation. Such formulations may be used for the treatment of various disease states and conditions, including, but not limited to, migraine headaches. The dihydroergotamine particles are produced... Agent: Morrison & Foerster LLP
20080118443 - Novel odorant compounds, synthesis method, and uses of said compounds: A compound of general formula (I) with or without the double bond illustrated by the dotted line. In formula (I), X is a CHO, CH2OH, CH2OC(O)R or CH(OR)2 group, and R represents a linear or branched C1-C5 alkyl or alkenyl chain. The synthesis method for the compound, and especially the... Agent: Young & Thompson
20080118444 - Lactobacillus paracasei-containing product: A Lactobacillus paracasei-containing product used for inhibiting dental diseases caused by bacteria is provided, which comprises a plurality of Lactobacillus paracasei for inhibiting the growth of bacteria of dental diseases. Particularly, foods, oral hygiene products or oral treatment medicine containing the Lactobacillus paracasei when being administered or applied to a... Agent: Birch Stewart Kolasch & Birch
20080118446 - Smile shower: The present invention is a spray product used in the oral cavity. The present invention does not require brushing and it can be used outside the bathroom as opposed to conventional “toothpaste products”. The product of the present invention can be used to promote whitening, stain removal, anti caries, anti... Agent: Weiss & Weiss
20080118447 - Metal activated tooth whitening compositions: A two component aqueous whitening dentifrice composition is disclosed which comprises a first component containing a peroxygen compound such as hydrogen peroxide and a second dentifrice component containing an essentially insoluble transition metal oxide complexed with metal chelating agents to form a peroxide activation complex, which activates the peroxygen compound... Agent: Christie, Parker & Hale, LLP
20080118448 - Colored metal pigments, method for the production thereof, use of the colored metal pigments in cosmetics, and cosmetic containing these: The invention relates to a colored, platelet-shaped metal pigment comprising a base pigment comprising metal, a layer of silicon dioxide, and, subsequently, a layer or two or more layers comprising one or more coloring materials. The invention further relates to a method for the production of a colored metal pigment... Agent: Ostrolenk Faber Gerb & Soffen
20080118449 - Cosmetic formulations of piceatannol and retinoids and methods of use thereof: A cosmetic composition for skin care containing retinol and piceatannol is disclosed. In embodiments of the cosmetic composition piceatannol is preferably present in an amount of 0.001 to 10% by weight, and more preferably 0.1 to 1% by weight, based on the total weight of the composition. The piceatannol-containing cosmetic... Agent: Alvin Ronlan
20080118451 - Hygienic and cosmetic compositions for treating sensitive skins: A hygienic and cosmetic compositions which, without a particular pharmacologic activity, are suitable for a functional differentiated and specific use on skins susceptible to cause symptoms related to sensitive, hyper-reactive dehydrated, dry hyper-keratosic skins typical of the senile age and confined to bed persons. The subject hygienic and cosmetic compositions... Agent: Hedman & Costigan P.c.
20080118450 - Sunscreen lotions containing inorganic crystalline compounds that absorb ultraviolet and shortwave visible light: A sunscreen lotion employing a technology utilizing inorganic crystalline compounds that absorb ultraviolet light and short wave visible light and dissipate their absorbed energy as visible light.... Agent: Robert D. Bibb
20080118452 - Cosmetic comprising multi-colored lustrous pearlescent pigments: A cosmetic containing a pearlescent pigment comprising a substrate and a first layer, wherein the first layer comprises iron oxide, wherein the iron has from about 1% to about 30% Fe(II) and from about 70% to about 99% Fe(III).... Agent: Frost Brown Todd, Llc
20080118453 - Film-forming solutions comprising vitamin d or derivative thereof and a corticosteroid and dermatological applications thereof: Topically applicable film-forming solutions, e.g., nail varnishes, useful for such dermatological applications as the prevention or treatment of nail psoriasis, contain, as active agents solubilized therein, vitamin D or derivative thereof and a corticosteroid, formulated into a topically applicable, physiologically acceptable medium therefor.... Agent: Buchanan, Ingersoll & Rooney Pc
20080118454 - Ester derivatives of ascorbic and 2-keto acid saccharides: Novel ester derivatives of ascorbic acid and 2-keto-acid saccharides are provided wherein the ester is introduced by ester bond formation between at least one hydroxy-functionality on the ascorbic acid or 2-keto-acid saccharide and a carboxy-functional organosiloxane, or between a 2-keto-gulonic acid and a hydroxy-functional organosiloxane, as well as methods for... Agent: Dinsmore & Shohl LLP
20080118456 - Styling emulsion composition: The present invention is related to a styling emulsion composition for keratin fibres especially hair for conditioning, styling and restyling purposes. The compositions comprise at least one oil and/or wax, at least one natural starch and at least one emulsifier. Furthermore hair fixing polymers are part of the compositions.... Agent: Norris, Mclaughlin & Marcus, P.a.
20080118455 - Alkylene carbonate dilution, alkylene carbonate for preparing the dilution, and aqueous reducing chemical agent: An object of the invention is to provide an aqueous solution of a No. 1 permanent waving agent through reconstitution upon use in a simple manner, which solution contains a cyclic mercapto compound as a reducing agent and realizes excellent characteristics such as high waving effect and good appearance of... Agent: Young & Thompson
20080118457 - Epilatory compositions: An epilatory composition of the adhesive type comprises: a from 50 to 90 percent by weight of a rosinous material or hydrocarbon resin; b. from 0.5 to 20 percent by weight of water, and c. an emulsifier and/or surfactant. The composition is particularly suitable for heating, prior to application to... Agent: Traskbritt, P.c./reckitt Benckiser
20080118458 - Agent containing l-carnitine or l-carnitine derivatives and at least one other specific substance: Compositions, in particular, for the treatment of the hair or of the skin, comprising at least one compound which is selected from L-carnitine or L-carnitine derivatives and at least one further substance which is selected from the group formed from active ingredients obtainable from the plants of the genus Echinacea,... Agent: Paul & Paul
20080118459 - Eraser composition for de-flakes: An eraser composition for de-flakes is disclosed. The composition comprises (i) a SEBS copolymer (styrene-ethylene-butylene-styrene) and SBS copolymer (styrene-butadiene-styrene) and TPE ethane's rubber and other compositions, and the weight percentage being 10 to 35%; (ii) organic fillers of sodium carbonate, and pearl powder, and the weight percentage being about 30... Agent: Leong C Lei
20080118460 - Conjugates of polymer and pharmacologically active agents and a novel polymer blend: The instant invention provides a novel conjugate of a synthetic, biodegradable, exceedingly hydrophilic and non-proteinaceous polymer, whereby each of the above attributes is defined in the specification, and various pharmacologically active agents. The instant invention also provides methods for the identification of said polymers, and methods for the preparation of... Agent: Evgeny Vulfson
20080118462 - Biomarkers for melanoma: The present invention relates to methods of determining melanoma status in a subject. The invention also relates to kits for determining melanoma status in a subject. The invention further relates to methods of identifying biomarker for determining melanoma status in a subject.... Agent: Edwards Angell Palmer & Dodge LLP Client: Jhu
20080118464 - Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides: Disclosed herein are non-natural amino acids and polypeptides that include at least one non-natural amino acid, and methods for making such non-natural amino acids and polypeptides. The non-natural amino acids, by themselves or as a part of a polypeptide, can include a wide range of possible functionalities, but typical have... Agent: Wilson Sonsini Goodrich & Rosati
20080118463 - Light pharmaceutical water and therapeutic compositions and methods thereof: This invention relates to pharmaceutical water, which comprises from 99.760 to 99.999% of light isotopologue 1H2 16O and up to 100% of residual isotopologues 1H2 17O, 1H2 18O, 1H2H16O, 1H2H17O, 1H2H 18O, 2H2 16O, 2H2 17O, and 2H2 18O, for the production of finished product, intermediate reagent preparation, and analytical... Agent: Notaro And Michalos
20080118465 - Methods and devices for administration of substances into the intradermal layer of skin for systemic absorption: Methods and devices for administration of substances into the intradermal layer of skin for systemic absorption.... Agent: Jones Day
20080118466 - Treatment of rheumatoid arthritis with soluble fas-ligand cross-linkers: The invention encompasses novel methods of treating rheumatoid arthritis and its symptoms and novel methods of identifying and screening for drugs useful in the treatment of rheumatoid arthritis and its clinical symptoms. Targeted manipulation of a computer model of a human rheumatic joint provided the surprising result that cross-linking soluble... Agent: Entelos, Inc. C/o Law Offices Of Karen E. Flick
20080118468 - Novel salmonella bacteriophage and uses thereof: The present invention is directed to isolated Salmonella bacteriophage, and methods of using Salmonella bacteriophage, or polynucleotides and polypeptides derived therefrom, to control the growth or contamination of food products by Salmonella. The present invention also contemplates the use of Salmonella bacteriophage, and polynucleotides and polypeptides derived therefrom, for the... Agent: Hunton & Williams LLP Intellectual Property Department
20080118480 - Methods and compositions for directing migration of neural progenitor cells: Method for modulating the migration of neural progenitor cells in a mammal by exposing the cells to a VEGFR-2 ligand and FGF-2. Methods of treating neurological disorders by exposing the mammal to a VEGFR-2 ligand in the presence of FGF-2 are also provided. A composition including a biocompatible matrix associated... Agent: Lucas & Mercanti, LLP
20080118481 - Mononuclear phagocytes in therapeutic drug delivery: The invention relates to the exploitation of the migratory behaviour of mononuclear phagocytes with a view to targeting therapeutic drug delivery. The invention therefore concerns the attachment or incorporation of a therapeutic agent to or into a mononuclear phagocyte and the subsequent migration of the mononuclear phagocyte to a target... Agent: Frommer Lawrence & Haug
20080118472 - Method of growing bacteria to deliver bioactive compounds to the intestine of ruminants: Methods for increasing the resistance to rumen inactivation of a cultured Gram positive bacteria strain useful for gastrointestinal delivery of bioactive compounds to ruminants, which includes the steps of growing a culture of the bacteria strain through at least one passage in a growth medium containing an amount of lysozyme... Agent: Synnestvedt Lechner & Woodbridge LLP
20080118473 - Methods of treating a respiratory condition comprising probiotic treatment: Disclosed herein are methods for treating a respiratory condition in a mammal, such as a human. The methods employ use of a composition comprising a Bifidobacterium probiotic.... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.
20080118482 - Treating mouth ulcer with live bacteria: This invention relates to using live beneficial bacteria for treating mouth ulcer.... Agent: Occhiuti Rohlicek & Tsao, LLP
20080118483 - Method for preventing or treating the development of respiratory allergies: The present invention is directed to a novel method for preventing or treating the development of respiratory allergies. The method comprises prenatal and/or postnatal administration of a therapeutically effective amount of LGG.... Agent: Bristol-myers Squibb Company - Mead Johnson
20080118484 - Method for preventing or treating the development of respiratory allergies: The present invention is directed to a novel method for preventing or treating the development of respiratory allergies. The method comprises prenatal and/or postnatal administration of a therapeutically effective amount of LGG.... Agent: Bristol-myers Squibb Company - Mead Johnson
20080118485 - Method for preventing or treating the development of respiratory allergies: The present invention is directed to a novel method for preventing or treating the development of respiratory allergies. The method comprises prenatal and/or postnatal administration of a therapeutically effective amount of LGG.... Agent: Bristol-myers Squibb Company - Mead Johnson
20080118474 - Cultured periodontal membrane cell sheet, process for producing the same and method of use thereof: A cultured periodontal ligament cell sheet is produced by a process comprising culturing cells on a cell culture support composed of a base material whose surface is coated with a temperature-responsive polymer having an upper limit or lower limit critical dissolution temperature in water of 0 to 80° C. under... Agent: Nixon & Vanderhye, Pc
20080118478 - Hair undifferentiated cells: An embodiment of the invention includes methods for the long-term augmentation and/or repair of skin defects (scars, skin laxness, skin thinning, and skin augmentation), cellulite, breast tissue, wounds and burns, urological and gastroesophageal sphincter structures, hernias, periodontal disease and disorders, tendon and ligament tears and baldness, by the injection or... Agent: Dardi & Associates, Pllc
20080118476 - Mite composition, use thereof, method for rearing a phytoseiid predatory mite, rearing system for rearing said phytoseiid predatory mite and methods for biological pest control on a crop: The present invention relates to a novel mite composition comprising a population of a phytoseiid predatory mite species and a factitious host population, which may be employed for rearing said phytoseiid predatory mite species or for releasing the pyrltoseiid predatory mite species in a crop. According to further aspects the... Agent: Bozicevic, Field & Francis LLP
20080118475 - Model system for testing the efficacy of pharmaceutical preparation on inflammatory processes in the nervous system: Live cells obtained from a mammalian tissue or organ. The cells are maintained ex vivo on a porous membrane having a pore size of ≧0.02 μm at a physiologically acceptable pH, in the presence of a culture gas, in culture and in a culture medium. The inter-neighbour relationships and the... Agent: Greenblum & Bernstein, P.L.C
20080118477 - Umbilical cord mesenchymal stem cells support cord blood hematopoiesis: Hematopoietic stem cells (HSC) are routinely obtained from bone marrow, mobilized peripheral blood, and umbilical cord blood. Traditionally, bone marrow has been utilized as a source of mesenchymal stem cells (MSC). The use and expansion of umbilical cord MSC to support the growth, viability, and maintenance of cord blood derived... Agent: Barnes & Thornburg LLP
20080118486 - Process to carry out a cellular cardiomyoplasty: m
20080118488 - Multiple antioxidant micronutrients in the management of diabetes mellitus: Formulations for minimizing damage to at least one of cells, organs and systems within the body of a subject afflicted with Diabetes Mellitus. The invention additionally encompasses methods for minimizing said damage which comprise administering to subjects in need thereof a therapeutic amount of a formulation(s) according to the invention.... Agent: Ostrolenk Faber Gerb & Soffen
20080118487 - Myostatin isoform: The present invention provides splice variants of myostatin that promote muscle growth, and include polynucleotides and polypeptide sequences, constructs comprising the sequences and compositions for regulating muscle growth and treating diseases associated with muscle tissue. The splice variants include the consensus sequence X1 I F L E X2 X3 X4... Agent: Knobbe Martens Olson & Bear LLP
20080118489 - Charge-modified lysozyme antimicrobial compositions, surfactants, and methods for infections and cystic fibrosis: The invention comprises charge modified antimicrobials, including charge modified lysozymes, as well as compositions and methods for potentiating antimicrobial activity by modifying a net charge level of the antimicrobial. Also provided is a method of treating microbial infections, including infections associated with cystic fibrosis, comprising administering or co-administering a compound... Agent: Greenlee Winner And Sullivan P C
20080118490 - Combined use of triglycerides containing medium chain fatty acids and exogenous lipolytic enzymes as feed supplements: The present invention provides a feed composition comprising about 0.01% to about 20% by weight of triglycerides and about 1 ppm to about 10,000 ppm of exogenous active lipolytic enzyme, wherein the triglycerides contain about 50% to about 100% of C6-C10 medium chain fatty acids. The present invention also provides... Agent: Howrey LLP
20080118491 - Xylanase gene sequences from the genomic dna of unpurified rumen microorganisms: A xylanase gene, denoted xynR8, encoding a novel xylanase (XynR8) obtained from the unisolated rumen microorganisms is provided. The DNA sequence of the xynR8 gene, xylanase, is also provided, the enzyme is thermo-tolerable, and highly specific for xylans with high activity. Transformation of microbial hosts with the xynR8 gene is... Agent: Birch Stewart Kolasch & Birch
20080118492 - Method of treatment using aspergillus oryzae protease: A method for treating various diseases, conditions and injuries with a protease preparation derived from Aspergillus orzyze and made using potato dextrin as the carbohydrate source is described. The method comprises orally administering the Aspergillus oryzae protease preparation on an empty stomach and in an amount greater than about 2,000,000... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.
20080118435 - Composition comprising low density microspheres: Low density microspheres, methods for preparing same, and use of same as contrast agents are described. The microspheres have a void which contains a gas or the vapor of a volatile liquid selected from the group consisting of aliphatic hydrocarbons, chlorofluorocarbons, tetraalkyl silanes and perfluorocarbons.... Agent: Louis J. Wille Bristol-myers Squibb Company
20080118445 - Dental appliance cleaners and methods for making and using them: The addition of the Iodide ion by way of iodide salts, such as sodium iodide and potassium iodide, to a peroxide such as hydrogen peroxide in a basic medium yields free radical oxygen and water; generating large amounts of heat and depleting the Hydrogen Peroxide in a matter of minutes.... Agent: Geoffrey E. Dobbin, Patent Attorney
20080118461 - Sprayable controlled-release, male annihilation technique (mat) formulation and insect control: A male annihilation insecticide formulation, having a viscosity appropriate for use in aerial or backpack spray applications and suitable for on-crop or off-crop uses, comprises an insect toxicant and a male-specific attractant, such as a parapheromone, for a target insect species, such as fruit fly, dispersed and entrapped in an... Agent: Dow Agrosciences Llc
20080118469 - Anti-angiogenic methods and compositions: Disclosed herein are methods and compositions for treatment of conditions requiring inhibition of angiogenesis. Such conditions include those characterized by neovascularization, such as retinopathies, macular degeneration and various malignancies.... Agent: Robins & Pasternak
20080118471 - Constitutive gene expression in conjunction with ionizing radiation: The present disclosure demonstrates the successful use of constitutive promoters operatively linked to genes encoding radiosensitizing or radioprotecting factors, administered to cells, tissues, or patients in conjunction with radiation exposure. Also disclosed are pharmacological preparations to be used to increase the levels of radiosensitizing compounds such as TNF-α, or radioprotective... Agent: Michael Best & Friedrich LLP
20080118470 - Oncolytic adenoviral vectors encoding gm-csf: Selectively replicating oncolytic adenoviral vectors comprising an adenoviral packaging signal, a termination signal sequence, an E2F responsive promoter operably linked to an adenoviral coding region, a heterologous coding sequence encoding GM-CSF and a right ITR are provided. The oncolytic adenoviral vectors are useful for expressing GM-CSF in transduced cells and... Agent: Ropes & Gray LLP
20080118479 - Cell lines: The present invention relates to cells obtainable from cell lines having the ECACC Accession Nos 04091601, 04110301 and 04092302.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association
20080118494 - Compositions for detection of latent hiv reactivation and methods of using the same: Provided herein are compositions and methods that allow for the study of HIV latency and reactivation. Further provided are compositions and methods for in vitro screening of agents for their ability to reactivate, suppress reactivation or inhibit transcription of HIV. Compositions for and methods for activating a cell are also... Agent: Needle & Rosenberg, P.c.
20080118493 - Elevated hedgehog pathway activity in digestive system tumors, and methods of treating digestive sytem tumors having elevated hedgehog pathway activity: Elevated Hedgehog (Hh) pathway activity, including ligand stimulated Hh pathway activity, was detected in digestive tract cancers, including esophagus, stomach, biliary tract, and pancreatic cancer, and determined to be associated with growth and proliferation of the cancer cells. Accordingly, methods are provided for treating a digestive tract cancer associated with... Agent: Dla Piper Us LLP
20080118498 - Humanized anti-ghrelin antibodies: Humanized antibodies, or antigen-binding portions thereof, that preferentially bind acylated ghrelin with respect to unacylated ghrelin, are disclosed. These molecules have high affinity and a slow off rate for acylated ghrelin, and neutralize acylated ghrelin activity. These antibodies, or antigen-binding portions thereof, are useful for neutralizing acylated ghrelin activity, e.g.,... Agent: Eli Lilly & Company
20080118497 - Regulating expression of transient receptor potential channel genes: The present invention relates to compositions related to a polynucleotide encoding a transient receptor potential cation gene. Also disclosed is the use of this polynucleotide, its homologs, fragments, variants and its resultant polypeptides in the diagnosis, prevention and treatment of disease, particularly idiopathic pulmonary arterial hypertension (IPAH). This invention also... Agent: Biotactica, Llc
20080118499 - Regulation of bace degradation: The invention relates to methods and products for diagnosing, preventing, and treating Alzheimer's disease and abnormal production of amyloid β.... Agent: Wolf Greenfield & Sacks, P.c.
20080118500 - Sustained releasing composition via local injection for treating eye diseases: The invention provides a sustained release composition for intravitreal injection to the eye of a subject in need thereof. The sustained release composition contains an effective amount of a therapeutic agent in association with a nanosphere. The nanosphere contains a particle that comprises a particle-forming component capable of forming a... Agent: Panitch Schwarze Belisario & Nadel LLP
20080118496 - Uses and compositions for treatment of juvenile rheumatoid arthritis: The invention provides methods, uses and compositions for the treatment of juvenile rheumatoid arthritis (JRA). The invention describes methods and uses for treating JRA, wherein a TNFα inhibitor, such as a human TNFα antibody, or antigen-binding portion thereof, is used to prevent flare-ups associated with JRA. Also described are methods... Agent: Lahive & Cockfield, LLP
20080118495 - Mammalian genes involved in infection: The present invention relates to nucleic acid sequences and cellular proteins encoded by these sequences that are involved in infection or are otherwise associated with the life cycle of a pathogen. The invention also relates to modulators of nucleic acid sequences and cellular proteins encoded by these sequences that are... Agent: Needle & Rosenberg, P.c.
20080118501 - Antibodies with enhanced antibody-dependent cellular cytotoxicity activity, methods of their production and use: The invention relates, in part, to antibodies with increased ADCC activity. Methods of producing such antibodies are also provided. The antibodies of the invention are produced in mammary epithelial cells, such as those in a non-human transgenic animal engineered to express and secrete the antibody in its milk. The antibodies... Agent: Gtc Biotherapeutics, Inc, C/o Wolf, Greenfield & Sacks, P.c.
20080118504 - Compositions and methods using md-2 mutants and chimeric proteins: The invention provides compositions and methods for the targeted bacteriostatic and antibacterial agents and for treatment of sepsis caused by infectious diseases, such as bacterial and fungal diseases. In one aspect, the invention provides methods and compositions for decreasing the levels of LPS in the circulation of an individual, e.g.,... Agent: Morrison & Foerster LLP
20080118506 - Humanized anti-factor d antibodies and uses thereof: The invention relates to humanized anti-human Factor D monoclonal antibodies, their nucleic acid and amino acid sequences, the cells and vectors that harbor these antibodies and their use in the preparation of compositions and medicaments for treatment of diseases and disorders associated with excessive or uncontrolled complement activation. These antibodies... Agent: Genentech, Inc.
20080118503 - Leptin antagonist and method for quantitative measurement of leptin: Antibody A or a fusion protein thereof specifically binding to a leptin receptor (leptin-R) or a leptin-binding protein (leptin-BP), as well as compositions and methods for the use of these antibodies or fusion proteins for quantitative analysis, for therapeutic purposes and for the preparation of therapeutic drugs. Also disclosed is... Agent: Womble Carlyle Sandridge & Rice, Pllc Attn: Patent Docketing 32nd Floor
20080118507 - Methods and devices for administration of substances into the intradermal layer of skin for systemic absorption: Methods and devices for administration of substances into the intradermal layer of skin for systemic absorption.... Agent: Jones Day
20080118505 - Reagents and treatment methods for autoimmune diseases: The invention concerns treatment methods using anti-CD22 monoclonal antibodies with unique physiologic properties. In particular, the invention concerns methods for the treatment of B-cell malignancies and autoimmune diseases by administering an effective amount of a blocking anti-CD22 monoclonal antibody specifically binding to the first two Ig-like domains, or to an... Agent: Jones Day
20080118502 - Tissue repair by modulation of beta-1 integrin biological function: The present invention methods and novel compounds for facilitating tissue repair and regeneration when the extracellular matrix is damaged. Specifically, binding of the beta 1 integrin is shown to provide a modulation of its functional activity resulting in up regulation of extracellular matrix anabolism. The invention therefore provides a method... Agent: Ip Group Of Dla Piper Us LLP
20080118508 - Complement pathway inhibitors binding to c5 and c5a without preventing formation of c5b: The invention relates to inhibitors that bind to C5 and C5a, but which do not prevent the activation of C5 and do not prevent formation of or inhibit the activity of C5b. One example of such an inhibitor molecule is the monoclonal antibody designated MAb137-26, which binds to a shared... Agent: Nikolaos C. George Jones Day
20080118509 - Monoclonal antibody sc104 and derivative thereof specifically binding to a sialyltetraosyl carbohydrate as a potential anti-tumor therapeutic agent: The present invention provides an isolated specific binding member capable of binding a sialyltetraosly carbohydrate and directly inducing cell death without the need for immune effector cells. Such a binding member may be an antibody or a part thereof. Also provided are the use of such binding members in medicine... Agent: Elmore Patent Law Group, Pc
20080118510 - Vegf-related protein: A human VEGF-related protein (VRP) has been identified and isolated that binds to, and stimulates the phosphorylation of, the receptor tyrosine kinase Flt4. The VRP is postulated to be a third member of the VEGF protein family. Also provided are antibodies that bind to VRP and neutralize a biological activity... Agent: Genentech, Inc. Att: Wendy M. Lee
20080118512 - Antibodies binding to the extracellular domain of the receptor tyrosine kinase alk: The present invention concerns an antibody specific for human ALK (Anaplastic Lymphoma Kinase), in particular a scFv, a nucleic acid sequence encoding it, its production and its use as a pharmaceutical or for diagnostic purposes. Said antibody is suitable for the local treatment of tumors, in particular glioblastoma.... Agent: Lahive & Cockfield, LLP
20080118511 - Pd-l2 molecules: novel pd-1 ligands and uses therefor: The invention provides isolated nucleic acids molecules, designated PD-L2 nucleic acid molecules, which encode novel B7-related molecules which are ligands for PD-1. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing PD-L2 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman... Agent: Foley Hoag, LLP Patent Group, World Trade Center West
20080118513 - Treatment of immune disorders with antibodies to costimulating polypeptide of t cells: A polypeptide (8F4 molecule) with a T-cell costimulating biological activity is disclosed, as well as monoclonal antibodies against the 8F4 molecule and hybridoma cells which produce the monoclonal antibodies, the use as medicaments of substances which inhibit the biological activity of the 8F4 polypeptide, in particular monoclonal antibodies, natural or... Agent: Jones Day
20080118514 - Neutralizing antibodies and methods of use thereof: This invention provides monoclonal antibodies that recognize the Toll-like Receptor 4/MD-2 receptor complex, and monoclonal antibodies that recognize the TLR4/MD2 complex as well as TLR4 when not complexed with MD-2. The invention further provides methods of using the monoclonal antibodies as therapeutics. This invention also provides soluble chimeric proteins, methods... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c.
20080118516 - Method of treating respiratory virus-induced asthma with th2 lymphocyte nkg2a receptor agonists: We previously reported that NKG2A, a key inhibitory ligand for HLA-E, is expressed on activated TH2, but not TH1, cells. Here we measured cytokine expression in ex vivo TH2 cells and in a mouse model of asthma upon activation with antiCD3/28 and challenge with an NKG2A-specific agonist We show that... Agent: Dr. Melvin Blecher
20080118515 - Regulatory t-cells containing galectins for the therapy and diagnosis of diseases: The invention relates to regulator T-cells containing galectins, in particular, the use thereof as markers and for the therapy and diagnosis of diseases, in particular, of allergies and autoimmune diseases, in particular rheumatoid arthritis, multiple sclerosis or Crohn's disease, chronic inflammation, asthma, immune deficiency diseases, AIDS, transplant rejection, cancer diseases... Agent: Connolly Bove Lodge & Hutz, LLP
20080118517 - Human monoclonal antibodies against interleukin 8 (il-8): Isolated human monoclonal antibodies which bind to IL-8 (e.g., human IL-8) are disclosed. The human antibodies can be produced in a hybridoma, transfectoma or in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also... Agent: Lahive & Cockfield, LLP
20080118518 - Cancer stem cell-targeted cancer therapy: The present invention provides methods for stabilizing, reducing or eliminating cancer cells. In particular, the present invention provides prophylactically and/or therapeutically effective regimens for the prevention, treatment and/or management of cancer, the regimens comprising administering one or more cancer therapies to a subject to reduce a cancer cell population. The... Agent: Jones Day
20080118519 - Copper lowering treatment of inflammatory and fibrotic diseases: The present invention relates generally to the field of prophylaxis and therapy for inflammatory and/or fibrotic diseases which include responses to injuries. In particular, the present invention is related to agents that can bind or complex copper such as thiomolybdate, and to the use of these agents in the prevention... Agent: Casimir Jones, S.c.
20080118520 - Anti-notch3 agonist antibodies and their use in the treatment of notch3-related diseases: The present invention relates to agonist antibodies that specifically bind to Notch 3 and activate signaling. The present invention includes antibodies binding to an epitope comprising the first Lin12 domain. The present invention also includes uses of these antibodies to treat or prevent Notch 3 related diseases or disorders.... Agent: Genentech, Inc.
20080118521 - Gene expression associated with osteoblast differentiation: The present invention identifies genes whose expression pattern is altered when pre-osteoblastic cells undergo differentiation into mature osteoblasts. The genes identified may be used as markers for the differentiation process. The present invention also provides methods to screen agents that are capable of modulating the differentiation process. The present invention... Agent: Novartis Institutes For Biomedical Research, Inc.
20080118522 - Naturally occuring igm antibodies that bind lymphocytes: Human and animal serum contains naturally occurring autoantibodies that develop at birth in absence of deliberate immunization. These antibodies are predominantly of IgM isotype but can include all immunoglobulin isotypes such as IgD, IgA and IgG. Here we describe IgM anti-lymphocyte autoantibodies (IgM-ALA) and show that these antibodies are heterogenous... Agent: Peter I. Lobo
20080118524 - Anti-ige vaccines: Materials and methods for inducing an IgG anti-IgE response in a human. The methods can include administering to a human subject a polypeptide comprising a human CH3 domain of IgE located between an opossum CH2 domain of IgE and an opossum CH4 domain of IgE, wherein the polypeptide is administered... Agent: Fish & Richardson P.c.
20080118525 - Novel peptides for treating and preventing immune-related disorders, including treating and preventing infection by modulating innate immunity: In one aspect, the present invention provides isolated novel peptides that can be used to modulate innate immunity in a subject and/or for the treatment of an immune-related disorder, including treating and preventing infection by modulating innate immunity. Also provided are an agent reactive with the peptide, a pharmaceutical composition... Agent: Mccarthy Tetrault LLP
20080118523 - Polypeptide ligands for targeting cartilage and methods of use thereof: Ligands that specifically bind to articular cartilage tissues are disclosed, including uses for targeting therapeutics towards articular cartilage tissue and new materials for articular cartilage. The ligands are effective in vivo to target therapeutic materials to articular cartilage.... Agent: Dardi & Associates, Pllc
20080118526 - Chimeric osteogenic factor containing proteins capable of increased nuclear localization and methods of use thereof: Compositions comprising osteogenic factors fused with membrane transduction domains of viral proteins are provided. Also provided are methods of expression and use of such compositions. Further, the methods of making such compositions are also provided. The methods involve transfecting the cells with an isolated nucleic acid comprising a nucleotide sequence... Agent: Fox Rothschild, LLP
20080118527 - Novel composition: Novel combined vaccine compositions are provided, comprising a hepatitis B viral antigen and a HPV antigen and optionally in addition one or more of the following: an EBV antigen, a hepatitis A antigen or inactivat3ed attenuated virus, a herpes simplex viral antigen, a VZV antigen, a HCMV antigen, a Toxoplasma... Agent: Glaxosmithkline Corporate Intellectual Property - Uw2220
20080118529 - Adjuvation through cross -beta structure: The invention relates to novel methods and means for providing proteinaceous substances, such as peptides, polypeptides, glycoproteins, lipoproteins and complex compounds comprising the former in combination with other substances, such as nucleic acids, membrane structures, carbohydrate structures, with cross-β structures, which enhance the immunogenicity of said proteinaceous substance. The resulting... Agent: Trask Britt
20080118528 - Synthesis and purification of west nile virus virus-like particles: The present invention relates to virus-like particles derived from West Nile Virus and to methods for generating the same. These particles are useful in diagnostic applications, and as components of vaccines directed at preventing the incidence of disease.... Agent: Knobbe, Martens, Olson & Bear, LLP
20080118530 - Modulation of replicative fitness by deoptimization of synonymous codons: Methods of producing a pathogen with reduced replicative fitness are disclosed, as are attenuated pathogens produced using the methods. In particular examples, the method includes deoptimizing one or more codons in a coding sequence, thereby reducing the replicative fitness of the pathogen. Methods of using the attenuated pathogens as immunogenic... Agent: Klarquist Sparkman, LLP
20080118531 - Avian influenza viruses, vaccines, compositions, formulations, and methods: A vaccine composition and method which is effective in preventing or ameliorating Avian Influenza Virus infection is set forth herein. The vaccine contains at least two inactivated strains of avian influenza virus, wherein the combined hemagglutinin (HA) total is at least about 200 HA/dose of the vaccine composition, and wherein... Agent: Wyeth C/o Darby & Darby, P.c.
20080118532 - Determining and reducing immunoresistance to a botulinum toxin therapy using botulinum toxin b peptides: The present invention provides BoNT/B peptides, BoNT/B peptide compositions, tolerogizing compositions, immune response inducing compositions, as well as methods of determining immunoresistance to botulinum toxin therapy in an individual, methods of treating immunoresistance to botulinum toxin therapy in an individual, methods of reducing anti-botulinum toxin antibodies in an individual and... Agent: Allergan, Inc.
20080118534 - Therapy for obsessive compulsive head banging: Methods for treating a head banging disorder by local administration of a Clostridial toxin. The local administration can be by intramuscular, transdermal, intradermal or subdermal administration of a low dose of botulinum toxin.... Agent: Allergan, Inc.
20080118533 - Treatment of chronic chalazion and hordeolum with botulinum toxin: Chalazia and hordeola are the most common lesions occurring in the human eyelid, and often recurrences are managed by surgical intervention to remove fatty inclusions within the lid with associated inflammatory reaction. The present invention provides non-surgical methods of treating chalazia, hordeola and cutaneous infections comprising the administration of compositions... Agent: Milbank, Tweed, Hadley & Mccloy LLP
20080118535 - Surface protein of neisseria bacteria: Present invention provides a monoclonal antibody binding to Neisseria bacteria and its target antigen Ag473, which include the sequences of its polynucleotide and its amino acid, wherein the Neisseria bacteria can be Neisseria meningitidis or Neisseria gonorrhoeae; and wherein Ag473 can be made into a vaccine or a diagnostic or... Agent: Birch Stewart Kolasch & Birch
20080118536 - Method for isolating and purifying grass pollen allergens: The invention relates to a method for quickly and effectively isolating and purifying five, namely the group 1, 2, 3, 10 and 13 allergens from grass pollen. The purification of said grass pollen is based on the inventive combination of hydrophobic interaction chromatography, gel filtration and cation exchange chromatography. The... Agent: Millen, White, Zelano & Branigan, P.c.
20080118537 - Cosmetic composition containing hydrophilic spherical polymethylsilsesquioxane powder: A cosmetic composition is disclosed containing hydrophilic, spherical powder of polymethylsilsesquioxane having a particle size ranged from 1-20 microns with a narrow particle size distribution. The hydrophilic, spherical powder in the composition is prepared by a process comprising (1) hydrolyzing and condensing methyltrimethoxysilane in water in the presence of a... Agent: K.f. Ross P.c.
20080118538 - Oil dispersion of powder being surface-treated with specific half ester oil, and cosmetic composition containing the same: Provided are a dispersion excellent in the dispersibility of powder particles, dispersion stability, storage stability, and versatility; and a cosmetic blended with such dispersion. An oil dispersion of a surface-treated powder, comprising a surface-treated powder coated with a half ester oil, and a lipophilic solvent as a dispersion medium, wherein... Agent: Westerman, Hattori, Daniels & Adrian, LLP
20080118539 - Anti-biocontaminant products and processes for making the same: The present invention relates to micro-sized particles having anti-biocontaminant properties. Each particle is comprised of a central metal core, or support structure, (for example, alumina oxide) and has on its surface, one or more anti-biocontaminant metals and at least one redox agent.... Agent: Hofmeister, Todd S., Holland & Knight, LLP
20080118540 - System and method for using nanoparticles for antimicrobial activity: A system and method for using nanoparticles for antimicrobial activity. The coding may include a polymeric film and a plurality of discreet first particles. The discreet particles may include silver metal, silver oxide or a combination of both. The discreet particles may be in contact with the polymeric film.... Agent: Akerman Senterfitt
20080118544 - Drug releasing coatings for medical devices: The invention relates to a medical device for delivering a therapeutic agent to a tissue. The medical device has a layer overlying the exterior surface of the medical device. The layer contains a therapeutic agent and an additive. The additive has a hydrophilic part and a hydrophobic part and the... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP
20080118542 - Growth factor composition: Also provided are a method of preparation in vitro of a bone graft substitute using the composition, a kit for carrying out the method, as well as use of the composition in the preparation of a medical device for generation of hard tissue in a mammalian subject in need thereof,... Agent: Birch Stewart Kolasch & Birch
20080118543 - Stent coatings comprising hydrophilic additives: A coating for implantable medical devices and a method for fabricating thereof are disclosed. The coating includes a mixture of a hydrophobic polymer and a polymeric hydrophilic additive, wherein the hydrophobic polymer and the hydrophilic additive form a physically entangled or interpenetrating system.... Agent: Squire, Sanders & Dempsey LLP
20080118541 - Use of a terpolymer of tetrafluoroethylene, hexafluoropropylene, and vinylidene fluoride in drug eluting coatings on medical devices: Medical devices are coated with terpolymers of tetrafluoroethylene, hexafluoropropylene, and vinylidene fluoride (THV). The mole fraction of tetrafluoroethylene can be in a range from about 0.005 to about 0.85, the mole fraction of hexafluoropropylene monomer can be in a range from about 0.005 to about 0.85, and the mole fraction... Agent: Workman Nydegger
20080118546 - Bioabsorbable polymeric composition for a medical device: A biodegradable and biocompatible nontoxic polymeric composition is provided which includes a base material such as a crystallizable polymer, copolymer, or terpolymer, and a copolymer or terpolymer additive. Medical devices manufactured from the composition are also provided.... Agent: Kelley Drye & Warren LLP
20080118545 - Sustained-release composition, process for producing the same and use of the same: A sustained-release composition which comprises (i) a physiologically active substance and (ii) a lactic acid-glycolic acid copolymer in which the weight-average molecular weight (Mw) is about 8,000 to about 11,500, the ratio of the weight-average molecular weight (Mw) to the number-average molecular weight (Mn) is greater than 1.9, and the... Agent: Foley And Lardner LLP Suite 500
20080118547 - Sustained release intraocular implants and methods for treating ocular vasculopathies: Biocompatible intraocular implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix,... Agent: Birch Stewart Kolasch & Birch
20080118548 - Sustained release intraocular implants and methods for treating ocular vasculopathies: Biocompatible intraocular implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix,... Agent: Birch Stewart Kolasch & Birch
20080118549 - Sustained release intraocular implants and methods for treating ocular vasculopathies: Biocompatible intraocular implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix,... Agent: Birch Stewart Kolasch & Birch
20080118550 - Coated surgical mesh: A surgical mesh is formed of a biocompatible mesh structure with a coating that provides anti-inflammatory, non-inflammatory, and anti-adhesion functionality for a implantation in a patient. The coating is generally formed of a fish oil, can include vitamin E, and may be at least partially cured. In addition, the coating... Agent: Lahive & Cockfield, LLP
20080118551 - Denatured human albumin biomaterial as dressing for burns and wounds of skin: The present invention provides biocompatible burn and wound dressing materials that are made from denatured human serum albumin. The burn and wound dressing materials can be constructed by molding of liquid human serum albumin into sheets or desired shapes. The burn and wound dressing materials can be impregnated with a... Agent: Elizabeth R. Hall
20080118552 - Finely divided composition containing poorly water soluble substance: A composition containing a poorly water soluble substance of the present invention can be prepared into a solid dosage form for oral administration in various forms such as tablet, powder, granule, capsule and the like. Therefore, using a composition containing a poorly water soluble substance of the present invention, for... Agent: Hamre, Schumann, Mueller & Larson, P.c.
20080118554 - Pharmaceutical compositions comprising a combination of piperidinoalkanol and decongestant: A pharmaceutical composition comprising a first therapeutic agent and a second therapeutic agent is described. A plurality of particles comprising (i) an interior comprising the second therapeutic agent and (ii) an exterior comprising a material for controlling the release of the second therapeutic agent may be disposed within a mixture,... Agent: Kenyon & Kenyon LLP
20080118553 - Tannate salt form of polypeptide mixtures, their preparation and use: The subject invention provides a composition comprising a mixture of polypeptides in the form of a tannate salt wherein each polypeptide is a copolymer of the amino acids L-glutamic acid, L-alanine, L-tyrosine and L-Lysine, methods of preparation and uses thereof.... Agent: Cooper & Dunham, LLP
20080118555 - Stable pharmaceutical composition containing desloratadine: Stable pharmaceutical compositions for oral administration are provided comprising an anti-allergic effective amount of descarbonylethoxy-loratadine or a pharmaceutically acceptable salt thereof, a lactose-based excipient and a pharmaceutically acceptable filler wherein the composition is substantially free of a pharmaceutically acceptable basic salt and wherein the composition contains less than about 1%... Agent: M. Carmen & Associates, Pllc
20080118556 - Modified release of compositions containing a combination of carbidopa, levodopa and entacapone: The invention relates to a multiparticulate modified release composition that, upon administration to a patient, delivers a combination of carbidopa, levodopa and entacapone in a bimodal, multimodal or continuous manner. The multiparticulate modified release composition comprises a first component and at least one subsequent component, the first component comprising a... Agent: Fox Rothschild, LLP
20080118557 - Sustained-release formulations of topiramate: Pharmaceutical compositions of topiramate for once-a-day oral administration are provided. The formulations comprise a sustained-release component and an optional immediate-release component, the compositions of which can be selectively adjusted, respectively, to release the active ingredient along a pre-determined release profile. Method of treating or preventing pathological disorders in mammalian subjects... Agent: Foley And Lardner LLP Suite 500
20080118558 - N-arylshydroxyalkylidene carboxamide compositions and methods: N-(Substituted-aryl-hydroxyalkylidene)-cycloalkyl carboxamide compositions are disclosed that target molecular elements on sensory nerves. These compounds, preferably administered topically, inhibit the perception of itch and pain and have prolonged duration of action.... Agent: Edward T. Wei
20080118559 - Pharmaceutical composition containing an anti-nucleating agent: Pharmaceutical compositions suitable for oral administration in solid dosage forms are described. The compositions comprise an effective amount of a drug compound in the form of a salt, wherein the drug salt is characterized by conversion to a less soluble form of the drug compound under certain pH conditions, and... Agent: Merck And Co., Inc
20080118560 - Novel modified release formulation: The present invention is directed to a multiparticulate, modified release solid dispersion formulation, comprising a drug substance having a pH-dependent solubility, said drug substance being a compound of the formula I, or a pharmaceutically acceptable salt thereof; a hydrophobic matrix former which is a water-insoluble, non-swelling amphiphilic lipid; and a... Agent: White & Case LLP Patent Department
20080118561 - Materials and methods for minimally-invasive administration of a cell-containing flowable composition: The disclosed invention is based on the discovery that a cell-based therapy can be used to treat, ameliorate, manage and/or reduce the progression of clinical sequelae associated with vascular interventions or cardiovascular diseases, particularly occlusive thrombosis, restenosis, intimal hyperplasia, inflammation and vasodilation. The invention further benefits from the additional discovery... Agent: Kirkpatrick & Lockhart Preston Gates Ellis LLP (formerly Kirkpatrick & Lockhart Nicholson Graham)
20080118562 - Bis(thiohydrazide amides) formulation: Disclosed herein are compositions and methods useful for the in vivo delivery bis(thiohydrazide amides), encased in a polymeric biocompatible shell.... Agent: Hamilton, Brook, Smith & Reynolds, P.c.
20080118564 - Pharmaceutical composition containing candesartan cilexetil as lipophilic crystalline substance: New composition of candesartan cilexetil is prepared using up to 20% of carrageenan which suitably stabilized the active ingredient against degradation during the tableting.... Agent: Novartis Corporate Intellectual Property
20080118563 - Preparation of chitin and derivatives thereof for cosmetic and therapeutic use: The invention relates to novel chitin derivatives and their use in medical treatments of plastic surgery, dermocosmesis and therapy, in particular it relates to natural chitin derivatives, like chitin in nanofibrillar form, oxychitin and other chemical derivatives of chitin, chitosan-hyaluronate and associations for use as subcutaneous fillers or skin protectants.... Agent: Nixon & Vanderhye, Pc
20080118568 - Benefit agent containing delivery particle: The present invention relates to benefit agent containing delivery particles, compositions comprising said particles, and processes for making and using the aforementioned particles and compositions. When employed in compositions, for example, compositions for cleaning, fabric care, or coating onto various substrates, textiles or surfaces, such particles increase the efficiency of... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.
20080118565 - Controlled release ceramic particles, compositions thereof, processes of preparation and methods of use: Controlled release ceramic particles, processes for their preparation, controlled release ceramic particles prepared by such processes, compositions comprising such controlled release ceramic particles and methods of using controlled release ceramic panicles are described. In one form each of the controlled release ceramic panicles has an active material(s) substantially homogeneously dispersed... Agent: Foley And Lardner LLP Suite 500
20080118567 - Medicaments for chemotherapeutic treatment of disease: New chemotherapeutic medicaments and certain medical uses and methods for use of such chemotherapeutic medicaments for treatment of disease in human or animal tissue are described, wherein a primary active component of such medicaments is a halogenated xanthene or halogenated xanthene derivative. Preferably, the halogenated xanthene is Rose Bengal or... Agent: Cook, Alex, Mcfarron, Manzo, Cummings & Mehler Ltd
20080118566 - Preparation of powder agglomerates: The invention relates to a method of producing an agglomerate of drug and solid binder. The process involves producing individual agglomerate particles and then converting the convertible amorphous content of same, following agglomeration, by the application of, for example, moisture. Agglomerates capable of conversion as well as the finished agglomerates... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)
20080118569 - Injectable microspheres for tissue construction: The present invention relates to injectable compositions comprising biocompatible, hydrophilic, non-toxic and substantially spherical microspheres associated with stem cells useful for tissue construction and generation. The invention also relates to methods of tissue construction and generation, for the treatment of various tissue damage and defects, using the injectable compositions.... Agent: Jones Day
20080118570 - Polymer coated drug-ion exchange resins and methods: Included are compositions, and methods of making, coated controlled-release drug and ion exchange resin form complexes. Methacrylate coatings, which can be free of plasticizers particularly with Eudragit® NE type polymer, are preferred to enhance the control of drug release from the drug-resin complexes. Liquid formulations including the coated resin forms... Agent: Winston & Strawn LLP Patent Department
20080118571 - Modified release analgesic suspensions: A pharmaceutical dosage form comprising non-steroidal-anti-inflammatory drugs, in particular propionic acid derivatives such as ibuprofen, along with a second active ingredient having a shorter therapeutically effective plasma concentration duration, such as phenylephrine, and methods of administering the same are provided. This method provides improved therapeutic effect, in particular pain relief... Agent: Philip S. Johnson Johnson & Johnson
20080118572 - Methods and compositions for reducing the risk of adverse cardiovascular events associated with the administration of artificial blood: Methods and compositions are provided for reducing the risk of adverse cardiovascular (CV) events associated with the administration of artificial blood. The methods involve the administration of a composition comprising artificial blood and one or more preventative pharmaceutical agents for reducing the risk of adverse CV events. In specific embodiments,... Agent: Baker Botts L.l.p.
20080118573 - Use of heavy metals in the treatment of biofilms: The present invention is directed to a method of treating biofilms by exposure to heavy metals selected from the group comprising metal cations such as manganese, cobalt, nickel, copper, zinc, aluminum, silver, mercury, lead, cadmium and tin; metal oxyanions such as molybdate, tungstate and chromate; and metalloid oxyanions, alone or... Agent: Fulbright & Jaworski L.l.p.
20080118574 - Crystalloid electrolyte water formulation: A fortified liquid composition, comprising purified water, molecular oxygen at a level between 30 and 60 mg/l, and a combination of minerals in that purified water. The minerals include at least 0.002 mg/l boron, at least 0.0001 mg/l chromium, at least 0.045 mg/l cobalt, at least 0.019 mg/l copper, at... Agent: Daniel N. Christus, Esq. Wallenstein Wagner & Rockey, Ltd.
20080118575 - Antimicrobial composition useful for preserving wood: Antimicrobial compositions useful for preserving wood, and comprising a variety of antimicrobial compounds.... Agent: Rohm And Haas Company Patent Department
20080118576 - Prediction of an agent's or agents' activity across different cells and tissue types: The present invention relates to a novel algorithm that uses molecular profile signatures to extrapolate the physiological processes of one type of cell set (e.g., cell line, tissue, normal or diseased) to predict the activity of an agent or agents against another type of cell set that has never been... Agent: Feldmangale, P.a.
20080118577 - Composition for regulating autonomic nerves and method for using the same: The seawater mineral-containing composition of the present invention is characterized in that it contains seawater minerals obtained by treating seawater and is capable of regulating autonomic nerves. The seawater mineral-containing composition of the present invention preferably has a magnesium concentration of 70 mg/L or higher and a sodium concentration of... Agent: Drinker Biddle & Reath (dc)
20080118578 - topical medicaments and methods for photodynamic treatment of disease: New photodynamic, topically-applicable medicaments and certain medical uses of such photodynamic medicaments for treatment of human or animal tissue are described, wherein a primary active component of such medicaments is a halogenated xanthene. The halogenated xanthenes constitute a family of potent photosensitizers that become photoactivated upon illumination of the treatment... Agent: Cook, Alex, Mcfarron, Manzo, Cummings & Mehler Ltd
20080118579 - Medical device and its use: The invention relates to a medical device comprising non-sintered bioactive glass particles or fibres having a diameter in the range 5-100 μm, bioactive glass comprising SiO2, Na2O, CaO, K2O, MgO, B2O3 and P2O5, wherein the amount of SiO2 is 50-65 wt-% of the final total weight, Na2O is 5-26 wt-%... Agent: James C. Lydon
20080118580 - Adhesion inhibition of fungi: The invention relates to the use of substances that influence fungal dimorphism for reducing the adhesion of fungi to surfaces. The invention also relates to washing and/or cleaning agents, textile treating agents and cleaning agents for mouth, teeth or dentures and to the use of said substances in said agents.... Agent: Woodcock Washburn LLP
20080118581 - Method for preparing a centella asiatica extract rich in madecassoside and in terminoloside: The invention concerns an extract of Centella asiatica comprising more than 75 wt. % of a mixture of madecassoside, terminoloside and asiaticoside, relative to the extract total weight, an extract of Centella asiatica comprising more than 95 wt. % of a mixture of madecassoside and terminoloside relative to the extract... Agent: Lerner, David, Littenberg, Krumholz & Mentlik
20080118582 - Synergistic inmune phyto-nutraceutical composition: Phytoceutical composition for the prevention and treatment of immune disorders. A specific combination of extracts of plants is taught, as well as the formulations based on categorizing plants into one of three groups, Energy, Bio-Intelligence and Organization. Such combination has synergistic effects, with minimal side effects.... Agent: Jose Olalde Rangel
20080118583 - Phyto-nutraceutical synergistic composition for parkinson's disease: A Phytoceutical composition for the prevention and treatment of Parkinson's disease is provided. A specific combination of extracts of plants and nutraceuticals is based on categorizing plants and nutraceuticals into one of three groups, Energy, Bio-Intelligence, and Organization. Such combination has synergistic effects, with minimal side effects.... Agent: Jose Olalde Rangel
20080118584 - Renal synergistic phyto-nutraceutical composition: A Phytoceutical composition for the prevention and treatment of renal disorders is provided. A specific combination of extracts of plants is taught, as well as principles for varying the formulations based on categorizing plants into one of three groups, Energy, Bio-Intelligence, and Organization and selecting several plants from each group.... Agent: Jose Olalde Rangel
20080118585 - Natural compositions for killing parasites on a companiion animal: The present invention relates to a method for killing parasites that includes topically applying onto a companion animal a composition including a natural, non-synthetic active ingredient. The composition may be applied to the animal in various forms, such as a spot-on, shampoo, an on animal spray, or an on animal... Agent: Polsinelli Shalton Flanigan Suelthaus Pc
20080118586 - Medicated cream for topical application: A topical cream specially formulated for the treatment of at least one of insect bites, skin irritations and rashes. Such topical cream comprising corticosteroid cream present therein in an amount of between about 40.0 weight percent to about 60.0 weight percent, a moisturizing cream present therein in an amount of... Agent: James Ray & Associates
20080118587 - Anti-arthritic herbal composition and method thereof: The invention provides a novel herbal composition for treatment of arthritis and inflammation. The herbal composition comprises a therapeutically effective combination of extracts obtained from the plants Terminalia chebula, Pluchea lanceolata, Desmodium gangeticum, Vitex negunto and Zingiber officinale, optionally along with pharmaceutically acceptable additives. The invention further comprises methods of... Agent: Alston & Bird LLP
20080118588 - Anti-arthritic herbal composition and method thereof: The invention provides a novel herbal composition for treatment of arthritis and inflammation. The herbal composition comprises a therapeutically effective combination of extracts obtained from the plants Terminalia chebula, Pluchea lanceolata, Desmodium gangeticum, Vitex negunto and Zingiber officinale, optionally along with pharmaceutically acceptable additives. The invention further comprises methods of... Agent: Alston & Bird LLP
20080118589 - Pharmaceutical formulations of rhodiola crenulata and methods of use thereof: Isolated extracts of Rhodiola crenulata and their constituents sensitize tumor cells to cancer therapies, such as tamoxifen, retinoids, and radiation, and act to potentiate radiation therapy in the treatment of cancer, with or without adjuvant chemotherapy. Methods are provided for inhibiting the P13kinase/AKT pathway in cancer cells, a general survival... Agent: Bromberg & Sunstein LLP
20080118590 - Using composition containing camp (cyclic adenosine monophosphate), nicotinic acid, prostaglandin, gamma linolenic acid and xanthines in weight loss and/or reducing elevated triglyceride: o
20080118591 - Bactericidal formulations: The invention relates to bactericidal formulations that come into contact with human body, particularly wash formulations including liquid soaps, comprising perfume ingredients active against gram-negative bacteria. Such compositions contact the target site, for example the skin surface, only for a short time, usually not longer than 30 seconds. Therefore the... Agent: Norris, Mclaughlin & Marcus
20080118592 - Use of a botulinum neurotoxin to alleviate various disorders: Methods for treating obsessions and compulsions by local administration of a Clostridial toxin. The obsessions or compulsions can be eye poking, body rocking, finger biting, counting, checking and related disorders treated by low dose, intramuscular administration of a botulinum toxin.... Agent: Allergan, Inc.05/15/2008 > patent applications in patent subcategories. archived by USPTO category
20080112886 - Engineering shape of polymeric micro- and nanoparticles: Compositions containing polymeric micro- and nanoparticles with non-spherical shapes and methods for making and using such particles are described herein. The particles have a size range from an average diameter of about Compositions containing polymeric micro- and nanoparticles with non-spherical shapes and methods for making and using such particles are... Agent: Patrea L. Pabst Pabst Patent Group LLP
20080112885 - System and method for acoustic data transmission: Embodiments of the present invention are directed to acoustic data transmission using a spreading code. A system for acoustic data transmission includes an ingestible capsule and an acoustic receiver. The ingestible capsule includes a modulator, a spreader, and an acoustic transmitter. The modulator modulates data according to a modulation scheme.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.
20080112890 - Fetal pulmonary cells and uses thereof: Isolated mixed populations of fetal pulmonary cells, engineered three-dimensional tissue constructs of these cells, and uses thereof in identifying therapeutic agents which augment, repair, and/or replace dysfunctional native lung and to perform in vitro studies such as pharmaceutical screening, models for lung development and disease and characterization of chemical or... Agent: Kathleen A. Tyrrell Licata & Tyrrell P.c.
20080112887 - Pancreatitis: The present invention provides methods of identifying candidate therapeutic agents for use in the treatment of acute pancreatitis.... Agent: Fish & Richardson Pc
20080112889 - Uses of selective inhibitors of hdac8 for treatment of t-cell proliferative disorders: Described herein are methods for treating a subject suffering from a T-cell lymphoma by administering to the subject a pharmaceutical composition containing a therapeutically effective amount of a selective inhibitor of histone deacetylase 8. Also described herein are methods for treating a subject suffering from a T-cell lymphoma by administering... Agent: Wilson Sonsini Goodrich & Rosati
20080112891 - Encapsulated (chelate or ligand) dendritic polymers: An encapsulated chelate dendritic polymer and an encapsulated ligand dendritic polymer are disclosed which have unique properties. These encapsulated chelate dendritic polymers may have associated with its dendritic polymer surface target directors, proteins, DNA, RNA (including single strands) or any other moieties that will assist in diagnosis, therapy or delivery... Agent: Technology Law, Pllc
20080112892 - X-ray visible drug delivery device: The subject invention provides an X-ray visible drug delivery device for subdermal administration of a contraceptive or hormone replacement therapy.... Agent: Organon Usa, Inc. Patent Department
20080112893 - Atmosphere modifying method and spray agent and spray device used in the same: A solution including a solute of γ-aminobutyric acid dissolved in a solvent is sprayed in a space.... Agent: Birch Stewart Kolasch & Birch
20080112894 - Biocompatible polymer compounds for medicinal formulations: wherein Z is —C(O)R1; each R1 is independently selected from a linear, branched, or cyclic alkyl, alkoxy, or aryl with 1 to 18 carbon atoms optionally substituted by carbonyl, oxy, thio, and/or nitrogen; each R2 is independently selected from hydrogen or a linear or branched hydrocarbon with 1 to 4... Agent: 3m Innovative Properties Company
20080112895 - Aqueous dronabinol formulations: A room temperature stable aqueous cannabinoid formulation is disclosed. In preferred embodiments, the cannabinoid formulation comprises dronabinol in a mixture of buffer solution, and organic cosolvents such as ethanol, propylene glycol and polyethylene glycol.... Agent: Davidson, Davidson & Kappel, Llc
20080112897 - Product release system to atomize cosmetic hair or skin compositions containing uv filters: A product release system for atomizing cosmetic hair or skin compositions is described, which has (a) pressure-resistant packaging, (b) a capillary-containing spray head, and (c) a propellant-containing cosmetic composition containing at least one UV filter. The atomization is done using the capillary. The capillary preferably has a diameter of 0.1... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.
20080112898 - Product release system to atomize polymer-containing cosmetic hair compositions: A product release system for atomizing cosmetic hair compositions is described, which has (a) pressure-resistant packaging, (b) a capillary-containing spray head, and (c) a propellant-containing cosmetic composition, which contains at least one hair-setting or hair-conditioning nonionic, anionic, amphoteric, or zwitterionic polymer. The atomization is done using the capillary. The capillary... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.
20080112899 - Carboxamides and their use: p
20080112902 - protective dental balm and method: A dental balm composition and method prevents damage to teeth which are prone to prolonged exposure to air or other drying conditions and which are therefore susceptible to tooth decay. The dental balm composition and uses an active decay preventing agent such as fluoride ion, xylitol or glycerin dispersed in... Agent: Calhelha & Doyle Llc
20080112901 - Dental compositions with sensitivity relief: d
20080112903 - Topical oral care compositions: Embodiments of the present invention are directed to topical oral care compositions including a free radical scavenging precursor compound.... Agent: Discus Dental Impressions, Inc.
20080112905 - Flavonoid complexes: The invention relates to complexes of certain flavonoid derivatives, of the formula (1), where R1 and R2 are selected from H and OR11, where OR11 stands, independently of one another, for OH, straight-chain or branched C1- to C20-alkoxy groups, straight-chain or branched C3- to C20-alkenyloxy groups, straight-chain or branched C1-... Agent: Millen, White, Zelano & Branigan, P.c.
20080112904 - Sunscreen compositions and methods of use: The invention encompasses additives for addition to a bodywash, where the additives contain one or more sunscreens, and where a bodywash which contains the additive imparts to the skin an SPF of at least about 2, in some cases at least about 5, or 10, or 15. Also described are... Agent: Wilson Sonsini Goodrich & Rosati
20080112908 - Anti-fungal nail lacquer: An anti-fungal nail lacquer composition contains a film-forming agent, a solvent, pigments and/or dyes, a glacial acetic acid of appropriate concentration dissolved in the composition. A method of utilizing the anti-fungal lacquer comprises the application of the composition to a fingernail or toenail, and allowing it to remain in contact... Agent: Boniard I. Brown
20080112911 - Vinyl alcohol-n-vinyl amine copolymer and its preparation process: A process for manufacturing a highly water-soluble vinyl alcohol-N-vinyl amine copolymer with a degree of hydrolysis higher than 93%, including a hydrolysis reaction of a vinyl alcohol-N-vinyl formamide copolymer with an alkaline metal hydroxide in methanol wherein the process is carried out with more than 1.5 mol of the alkaline... Agent: Berenbaum, Weinshienk & Eason, P.c
20080112912 - Composition for hair care: wherein the total quantity of components a to f is 100 wt %. The invention also relates to a process for producing a composition, the composition obtainable as a result of this process, a process to treat hair, the use of a composition to treat hair, as well as the... Agent: Michael J. Striker
20080112913 - Low-irritation compositions and methods of making the same: Provided are compositions comprising a low molecular weight, non-crosslinked, linear acrylic copolymer and at least one surfactant selected from the group consisting of anionic surfactants, amphoteric surfactants, and combinations of two or more thereof, and methods of using such compositions.... Agent: Philip S. Johnson Johnson & Johnson
20080112914 - Compostion for skin external use containing omega-3 fatty acid: Stable preparations containing omega-3 fatty acid as an effective ingredient are disclosed. Further, uses of omega-3 fatty acid in preventing or alleviating skin aging, moisturizing skin, improving skin roughness, restoring or strengthening skin barrier function, improving skin elasticity, recovering or preventing skin damage induced by UV are disclosed.... Agent: Merchant & Gould Pc
20080112915 - Dna delivery with gemini cationic surfactants: The invention provides a delivery system for a biologically active agent comprising a gemini surfactant in admixture with the biologically active agent in a topical formulation for treatment of skin disorders or metabolic diseases. The invention also provides pharmaceutical compositions in topical formulations comprising the delivery system as set out... Agent: Perkins Coie LLP
20080112918 - Method for treating gout and binding uric acid: e
20080112917 - Sphingolipids' polyalkylamines conjugates:
20080112916 - Chemically modified polycation polymer for sirna delivery: The present invention provides a unique non-viral carrier for nucleic acid delivery in vitro and in vivo, and methods of using thereof.... Agent: Paul D. Yasger Abbott Laboratories
20080112920 - Microbicide combinations containing silver: A synergistic microbicidal composition. The composition comprises a silver-containing copolymer comprising polymerized units of a monomer X and a monomer Y; wherein monomer X is an ethylenically unsaturated compound having a substituent group selected from an unsaturated or aromatic heterocyclic group having at least one hetero atom selected from N,... Agent: Rohm And Haas Company Patent Department
20080112921 - Method and use for increasing efficacy of anti-adhesive compositions in controlling inflammation and pain: A method and kits thereof for increasing the efficiency of anti-adhesive compositions by parenterally administering a composition comprising an effective amount of at least one pharmaceutically-acceptable anti-adhesive non-ionic polymer to a site of injury, controlling inflammation at the site of injury, and reducing pain.... Agent: Fox Rothschild, LLP
20080112924 - Dendritic cells loaded with heat shocked melanoma cell bodies: The present invention includes compositions and methods for the isolation, purification and preparation of immunogenic antigens for the production of customized cancer vaccines that include dendritic cells that are contacted with an antigen that includes heat-shocked cancer cells.... Agent: Chalker Flores, LLP
20080112926 - Gag binding proteins: e
20080112925 - Qs-21 and il-12 as an adjuvant combination: Adjuvant compositions comprising an effective amount IL-12 and QS-21 are disclosed. Immunogenic, vaccine and pharmaceutical compositions comprising a mixture of antigen and an adjuvant composition comprising an effective amount of IL-12 and QS-21 are also disclosed. These compositions elicit functional cell-mediated and humoral immune responses against at least one antigen.... Agent: Wyeth Patent Law Group
20080112928 - Bacterial vector: The present invention relates to a combination of compounds for introducing nucleic acids and/or protein into animal cells, tissue, organs or organisms in vitro, extracorporal, or in vivo. This combination comprises preparations suitable for administration to an animal or human for medical purposes, comprising as one component a bacterial vector... Agent: Greer, Burns & Crain
20080112939 - Kidney-derived cells and methods of use in tissue repair and regeneration: Isolated or purified mammalian kidney-derived cell populations from mammalian kidney tissue are provided. Methods are provided for the isolation and purification of the mammalian kidney-derived cell population. Methods for treating kidney disease are provided by administration of the isolated or purified mammalian kidney-derived cell population to a mammalian subject.... Agent: Woodcock Washburn LLP
20080112937 - Method of producing autologous embryonic stem cells: Aspects of the present invention relate to compositions and methods of reprogramming a somatic cell to give rise to an autologous embryonic stem cell. These methods involve providing a somatic cell of a donor subject, introducing the somatic cell into an embryo of a recipient subject to produce a chimeric... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP
20080112938 - Recombinant eukaryotic cells stably expressing (sid-1) proteins for high throughput gene screening: This invention provides a eukaryotic cell that stably expresses exogenous, ectopic SID-1 to confer enhanced polynucleotide, e.g. siRNA or dsRNA, uptake. Thus, in one aspect, this invention provides a eukaryotic cell which stably expresses exogenous SID-1 polynucleotide and is. The cells stably expressing SID-1 are particularly useful for high throughput... Agent: Foley & Lardner LLP
20080112933 - Methods and compositions for increasing stem cell homing using gas activators: The present invention provides methods for increasing engraftment of stem cells in a subject by treating the cells with a Gαs activator. The invention further provides methods for identifying Gαs activators for use in increasing engraftment of stem cells in a subject.... Agent: Ewards Angell Palmer & Dodge LLP
20080112934 - Methods to identify, prepare, and use naive t cell recent thymic emigrants: A method of purifying a subpopulation of naive T cells that have recently emigrated from the thymus, comprising (a) contacting a biological sample susceptible of containing T cells with at least four different ligands, namely ligands directed to the markers CD3, CD4, CD45RA, and CD31; (b) sorting the cells so... Agent: Goudreau Gage Dubuc
20080112943 - Biosynthetic polypeptide fusion inhibitors: Modified biosynthetic polypeptide fusion inhibitors, methods for manufacturing, and uses thereof are provided.... Agent: Attn: John W. Wallen, Iii Ambrx, Inc.
20080112946 - Catalytically active recombinant memapsin and methods of use thereof: Methods for the production of purified, catalytically active, recombinant memapsin 2 have been developed. The substrate and subsite specificity of the catalytically active enzyme have been determined. The substrate and subsite specificity information was used to design substrate analogs of the natural memapsin 2 substrate that can inhibit the function... Agent: Morrison & Foerster LLP
20080112884 - Contrast agents for myocardial perfusion imaging: The present disclosure is directed, in part, to compounds and methods for imaging myocardial perfusion, comprising administering to a patient a contrast agent which comprises a compound that binds MC-1, and an imaging moiety, and scanning the patient using diagnostic imaging.... Agent: Louis J. Wille Bristol-myers Squibb Company
20080112888 - Igfbp2 biomarker: The present invention provides method for quickly and conveniently determining if a given treatment regimen of IGF1R inhibitor is sufficient, e.g., to saturate IGF1R receptors in the body of a subject. Several clinically relevant determinations may be made based on this point, including, for example, whether the dosage of the... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)
20080112896 - Therapeutic compositions for pulmonary delivery: Microparticles that are obtainable by spray-freeze-drying a solution comprising a water-soluble, matrix-forming polymer and a therapeutic agent may be useful for pulmonary delivery of the therapeutic agent.... Agent: Saliwanchik, Lloyd & Saliwanchik
20080112900 - Chewable antiplaque confectionery dental composition: A chewable confectionery dental composition delivering to the mouth a unit dose of a plaque reducing enzyme the composition comprising an enzyme and a non-cariogenic sweetener, the enzyme being incorporated in the composition at a temperature less than about 80° C.... Agent: Colgate-palmolive Company
20080112907 - Dispersible cationic polygalactomannan polymers for use in personal care and household care applications: The present invention relates to polygalactomannan compositions, and more particularly cationic guar gum compositions, which, when crosslinked with glyoxal, from discrete guar particles which are capable of being easily dispersed in water which permits subsequent processing of the guar, such as washing. The guar and its derivatives are desirable for... Agent: Hercules Incorporated Hercules Plaza
20080112906 - Dispersible non-borate metal salt or chelate treated polygalactomannan polymers for use in personal care and household care applications: The present invention relates to polygalactomannan compositions, and more particularly guar gum compositions, which, when crosslinked with organic chelating agents, such as non-borate metal salt or chelates, to form discrete guar particles which are capable of being easily dispersed in water which permits subsequent processing of the guar, such as... Agent: Hercules Incorporated Hercules Plaza
20080112909 - Compositions for providing color to animate objects and related methods: Methods for providing color to animate objects, i.e., living things, as well as compositions, such as personal care compositions and agrochemical compositions, suitable for application to such animate objects. The compositions include colorants that include a radiation diffraction material comprising an ordered periodic array of particles held in a matrix,... Agent: Ppg Industries Inc Intellectual Property Dept
20080112919 - Tnp-470 polymer conjugates and use thereof: The present invention relates to conjugates of water-soluble polymers and o-(chloracetyl-carbamoyl) fumagillol (TNP-470) and use of those conjugates as specific intracellular carriers of the TNP-470 into tumor vessels. The present invention further relates to use of those conjugates to lower the neurotoxicity of TNP-470. Preferably, the polymer has a molecular... Agent: David S. Resnick
20080112922 - Ocular therapy using alpha-2 adrenergic receptor anterior compounds having enhanced clearance rates: Ophthalmically therapeutic materials, such as liquid-containing compositions and polymeric drug delivery systems, include a therapeutic component which includes an alpha 2 adrenergic receptor agonist that is cleared from the anterior segment of an individual's eye to which the material is administered. The alpha 2 adrenergic receptor agonist may have a... Agent: Birch Stewart Kolasch & Birch
20080112923 - Ocular therapy using alpha-2 adrenergic receptor anterior compounds having enhanced clearance rates: Ophthalmically therapeutic materials, such as liquid-containing compositions and polymeric drug delivery systems, include a therapeutic component which includes an alpha 2 adrenergic receptor agonist that is cleared from the anterior segment of an individual's eye to which the material is administered. The alpha 2 adrenergic receptor agonist may have a... Agent: Birch Stewart Kolasch & Birch
20080112927 - Cells and methods utilizing same for modifying the electrophysiological function of excitable tissues: A method of treating a movement disorder in a subject is disclosed. The method comprises administering to the subject a therapeutically effective amount of cells capable of modifying a neuronal discharge of the subject, thereby treating the movement disorder in the subject, wherein said administering is effected at a site... Agent: Martin D. Moynihan Prtsi, Inc.
20080112930 - Methods of treating restenosis: Restenosis in a subject can be treated by administering to a tissue, e.g., a blood vessel, of the subject an agent that increases SERCA activity. For example, a stent that is coated with the agent can be introduced into a blood vessel.... Agent: Ewards Angell Palmer & Dodge LLP
20080112929 - Shielded adenoviral vectors and methods of use: The present invention encompasses replication deficient or a replication competent adenoviral vectors which may comprise moieties covering and shielding the vector from the effects of humoral immune responses, as well as a method of constructing and using such vectors. The preferred viral constructs may incorporate the shielding moieties into the... Agent: Frommer Lawrence & Haug
20080112940 - Notch2 signaling as a breast cancer suppressor pathway: The present invention relates to the ability of constitutively active Notch 2 to function as an inhibitor of breast cancer. The invention provides methods and compositions for inhibiting breast cancer cells by using hNotch2ICD polypeptides.... Agent: Drinker Biddle & Reath Attn: Intellectual Property Group
20080112941 - Method for increasing lactose tolerance in mammals exhibiting lactose intolerance: The method for increasing lactose tolerance in subjects exhibiting lactose intolerance symptoms implements a protocol where the subjects ingest a gradually increasing amount of lactose containing product over a six week period. At various points during the six week period the subject ingests the lactose containing product once a day... Agent: Wilson Sonsini Goodrich & Rosati
20080112942 - Methods for the dietary management of irritable bowel syndrome and carbohydrate malabsorption: The invention relates generally to digestive disorders, and in particular to methods for treating irritable bowel syndrome by increasing carbohydrate absorption by administering a composition containing a Bacillus coagulans bacterium.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c.
20080112931 - Methods and reagents for the enhancement of virus transduction in the bladder epithelium: Agents and methods for enhancing recombinant virus transduction in the bladder epithelium are described. A first method involves contacting the luminal surface of the bladder with a composition comprising a transduction enhancing agent and an oncolytic virus. Alternatively, the luminal surface of the bladder can be contacted first with a... Agent: Ropes & Gray LLP
20080112932 - Methods and reagents for the enhancement of virus transduction in the bladder epithelium: Agents and methods for enhancing recombinant virus transduction in the bladder epithelium are described. A first method involves contacting the luminal surface of the bladder with a composition comprising a transduction enhancing agent and an oncolytic virus. Alternatively, the luminal surface of the bladder can be contacted first with a... Agent: Ropes & Gray LLP
20080112935 - Augmentation and repair of spincter defects with cells including fibroblasts: An embodiment of the invention includes methods for the long-term augmentation and/or repair of skin defects (scars, skin laxness, skin thinning, and skin augmentation), cellulite, breast tissue, wounds and burns, urological and gastroesophageal sphincter structures, hernias, periodontal disease and disorders, tendon and ligament tears and baldness, by the injection or... Agent: Dardi & Associates, Pllc
20080112936 - Methods of implanting mesenchymal stem cells for tissue repair and formation: The invention relates to methods of isolating and implanting mesenchymal stem cells for tissue repair or formation, without prior culture expansion of the mesenchymal stem cells. In particular, the invention relates to methods of isolating mesenchymal stem cells from bone marrow, for repairing or inducing formation of bone, without prior... Agent: Martin D. Moynihan Prtsi, Inc.
20080112944 - Compositions and methods for the treatment of autism: Compositions that may be usefully employed to alleviate symptoms resulting from deficiencies in carbohydrate enzymes, together with methods for the treatment of disorders that are characterized by such deficiencies, such as autism, are provided. The compositions preferably comprise transglucosidase isolated from A. niger.... Agent: Speckman Law Group Pllc
20080112945 - Synergistic compositions and methods for enhancing potency and/or for prolonging the duration of action of anesthetics: Taught is a composition for enhancing potency and/or for prolonging the duration of action of an anesthetic comprising dexamethasone, compound vitamin B, metronidazole, berberine, etamsylate, gentamicin, chymotrypsin, methylene blue trihydrate, and 5% sodium bicarbonate aq. When administered with an anesthetic, the composition shortens the onset time of the anesthetic, and... Agent: Matthias Scholl
20080112947 - I kappa b kinase complex as a target for the treatment of huntington's disease: The present invention provides methods and compositions for protecting cells from the toxicity of mutant huntingtin (Htt) protein and for treatment of Huntington's disease (HD). The methods generally involve administering to cells or a patient an effective amount of an IKK inhibitor. In addition, methods are provided for identifying therapeutics... Agent: Knobbe Martens Olson & Bear LLP
20080112948 - Water-soluble globulin concentrate for improving growth in animals: A water soluble globulin concentrate is described. The globulin concentrate is administered through the animals' water supply and is effective in increasing growth and weight gain in animals. The concentrate is especially effective in reducing morbidity in underweight, stressed pigs, post-weaning.... Agent: Schwegman, Lundberg & Woessner, P.a.
20080112949 - Optimized dosing with anti-cd4 antibodies for tolerance induction in primates: The present invention is based, at least in part, on the finding that tolerance can be induced by inhibition of CD4+ cells (and optionally CD8+ cells). Accordingly, the optimized dosing methods of the invention are useful in treating a primate, e.g., a human, by inhibiting CD4+ T cells to induce... Agent: Lahive & Cockfield, LLP
20080112950 - Naturally occurring igm antibodies that bind lymphocytes: Human and animal serum contains naturally occurring autoantibodies that develop at birth in absence of deliberate immunization. These antibodies are predominantly of IgM isotype but can include all immunoglobulin isotypes such as IgD, IgA and IgG. Here we describe IgM anti-lymphocyte autoantibodies (IgM-ALA) and show that these antibodies are heterogenous... Agent: Peter I Lobo
20080112952 - Anti-vegf treatment for radiation-induced vasculopathy: An anti-VEGF method for treating undesirable conditions resulting from radiation-induced vasculopathy. In a specific application, the method is applied to these undesirable conditions found in an eye.... Agent: William B. Gowanlock
20080112951 - Glycoconjugates and their use as potential vaccines against infection by shigella flexneri: A conjugate molecule comprising an oligo- or polysaccharide covalently bound to a carrier and its use as potential vaccine against infection by S. Flexneri.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP
20080112955 - Method and composition for preventing pain in sickle cell patients: A method of preventing pain in a sickle cell patient is disclosed. The method includes orally administering to the patient, an amount of an active agent effective on oral administration to inhibit binding of the patient's sickle erythrocytes to P-selectin on the patient's vascular endothelium. The inhibition may be evidenced... Agent: Wong, Cabello, Lutsch, Rutherford & Brucculeri, L.l.p.
20080112954 - Method for treating chronic pain: The present invention provides a method for treating a chronic pain by administering to an individual in need of such treatment with a pharmaceutically effective amount of a blocking reagent for ephrinB-EphB signaling. Preferably, the chronic pain comprises a neuropathic pain.... Agent: Howrey LLP
20080112953 - Stable formulations: The invention provides a formulation including an acetic acid buffer, a glutamic acid buffer or a succinic acid buffer with a pH from about 4.5-7.0, at least one excipient comprising a sugar or a polyol and an effective amount of a therapeutic antibody. The buffer can include a salt of... Agent: Amgen Inc.
20080112956 - Method of detecting liver cancer, diagnostic for liver cancer and remedy for cancer: Disclosed are a method for detecting liver cancer capable of detecting liver cancer with high specificity and a diagnostic therefor, as well as a novel therapeutic drug for cancer having an excellent anticancer effect. The method for detecting liver cancer cells in a sample utilizes as an index the expression... Agent: Birch Stewart Kolasch & Birch
20080112957 - Anti-erbb2 antibodies: Anti-ErbB2 antibodies are described which bind to an epitope in Domain 1 of ErbB2 and induce cell death via apoptosis. Various uses for these antibodies are also described.... Agent: Merchant & Gould Pc
20080112958 - Gene detection assay for improving the likelihood of an effective response to an erbb antagonist cancer therapy: The invention provides a method for more effective treatment of patients susceptible to or diagnosed with tumors overexpressing ErbB, as determined by a gene amplification assay, with an ErbB antagonist. Such method comprises administering a cancer-treating dose of the ErbB antagonist, preferably in addition to chemotherapeutic agents, to a subject... Agent: Genentech, Inc.
20080112960 - Mn/ca ix and egfr pathway inhibition: The invention is based upon the discovery that the EGFR pathway can stimulate a previously unknown tumorigenic function of CA IX, via phosphorylation of the sole tyrosine residue present in CA IX's intracellular domain. EGFR-phosphorylated CA IX then interacts with the p85 subunit of PI3K to activate Akt, which in... Agent: Leona L. Lauder Attorney At Law
20080112959 - Smallpox monoclonal antibody: Humanized monoclonal antibodies against the vaccinia virus B5R surface antigen. The antibodies are effective in treating smallpox infection. Also disclosed are nucleic acids that encode the heavy and light chains of such antibodies and cells that express them.... Agent: Occhiuti Rohlicek & Tsao, LLP
20080112961 - Identification and engineering of antibodies with variant fc regions and methods of using same: The present invention relates to methods of treating or preventing cancer and other diseases using molecules, particularly polypeptides, more particularly immunoglobulins (e.g., antibodies), comprising a variant Fc region, wherein said variant Fc region comprises at least one amino acid modification relative to a wild-type Fc region, which variant Fc region... Agent: Edell, Shapiro & Finnan, Llc
20080112963 - Ablative immunotherapy: The invention disclosed herein relates generally to immunotherapy and, more specifically, to the use of immunotherapy for treating tumors and pathogen infected tissues by first priming patients with allogeneic cells designed to be rejected by a Th1 mediated mechanism, then inducing necrosis or apoptosis in a tumor or pathogen infected... Agent: Westman Champlin & Kelly, P.a.
20080112962 - Dendritic cells loaded with heat shocked melanoma cell bodies: The present invention includes compositions and methods for the isolation, purification and preparation of immunogenic antigens for the production of customized cancer vaccines that include dendritic cells that are contacted with an antigen that includes heat-shocked cancer cells.... Agent: Chalker Flores, LLP
20080112964 - Mutant pneumolysin proteins: The invention relates to immunogenic compositions comprising mutant Streptococcus pneumoniae pneumolysin proteins. The invention further relates to such proteins and nucleic acids encoding these proteins. In particular embodiments, the invention is directed to an isolated mutant pneumolysin (PLY) protein, wherein the mutant PLY protein differs from the wild type PLY... Agent: Dann, Dorfman, Herrell & Skillman
20080112965 - Chlamydia omp antigen: The present invention provides purified and isolated polynucleotide molecules that encode Chlamydia polypeptides which can be used in methods to prevent, treat, and diagnose Chlamydia infection. In one form of the invention, the polypeptides relate to the 98 KDa OMP antigen designated CPN100686 RY 54 (SEQ ID No:14, encoded in... Agent: Smart & Biggar P.o. Box 2999, Station D
20080112966 - Extracts and methods comprising ganoderma species: The present invention relates to extracts of ganoderma species plant material prepared by supercritical CO2 extractions.... Agent: Foley Hoag, LLP Patent Group, World Trade Center West
20080112967 - Process for refining ganoderma spore polysacchoride: The present invention discloses a process for refining Ganoderma spore polysacchoride. The process comprise the step of: Remove the impurity in the Ganoderma spores, warm water extraction, alcohol precipitation, separate precipitate, obtain the impure polysacchoride, adjust pH to 7.5-8.5, centrifuge to removal deposit, take out supernatent, add H2O2 to decolor,... Agent: Global Ip Services
20080112968 - Nicotinamide compositions for treatment of skin diseases and disorders: The present invention is directed to compositions of nicotinamide derivatives combined with wakame seaweed, wakame extracts, or glycosaminoglycans, and their use in treating skin diseases and disorders.... Agent: Lahive & Cockfield, LLP
20080112969 - Recombinant herpesvirus useful in vaccine production: The present invention provides a novel avian herpesvirus (NAHV) vector and recombinant vaccines made therefrom that are useful to immunize avian species against Marek's disease, infectious laryngotracheitis and Newcastle disease. Methods of immunizing an avian species against Marek's disease, infectious laryngotracheitis and Newcastle disease are also provided.... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)
20080112970 - Heat treated bacterins, and emulsion vaccines prepared from such heat treated bacterins: Heat treated bacterins, a method of producing heat treated bacterins, and emulsion vaccines prepared from such heat treated bacterins are disclosed.... Agent: Pharmacia & Upjohn
20080112975 - Ablative immunotherapy: The invention disclosed herein relates generally to immunotherapy and, more specifically, to the use of immunotherapy for treating tumors and pathogen infected tissues by first priming patients with allogeneic cells designed to be rejected by a Th1 mediated mechanism, then inducing necrosis or apoptosis in a tumor or pathogen infected... Agent: Westman Champlin & Kelly, P.a.
20080112973 - Chimeric papillomavirus-like particles: The present invention provides a papillomavirus-like particle, characterized as having conformational epitopes, comprising a papillomavirus L1 product and a papillomavirus L2 fusion product; and related synthetic DNA molecules, host cells, methods and vaccines.... Agent: Knobbe, Martens, Olson & Bear, LLP
20080112974 - Method for inducing mucosal humoral and cell-mediated immune responses by sublingual administration of antigens: Described are methods for inducing both a mucosal and a systemic immune response in the respiratory, digestive or urogenital tracts of a mammal to a microbial pathogen. The methods comprise topically administering onto the sublingual mucosa of the mammal an amount of an antigen effective to induce the mucosal and... Agent: Darby & Darby P.c.
20080112972 - Preservation of bioactive materials by freeze dried foam: This invention provides methods and compositions to preserve bioactive materials in a dried foam matrix. Methods provide non-boiling foam generation and penetration of preservative agents at temperatures near the phase transition temperature of the membranes.... Agent: Quine Intellectual Property Law Group, P.c.
20080112971 - Promoters for expression in modified vaccinia virus ankara: The invention concerns promoters, in particular for the expression of genes and/or coding sequences in vaccinia viruses such as Modified vaccinia virus Ankara (MVA). The invention further concerns expression cassettes comprising said promoter, vectors comprising said expression cassettes as well as pharmaceutical compositions and vaccines.... Agent: Law Office Of Salvatore Arrigo
20080112976 - Directional induction of immune response by co-administration of antigens with chemokines: The present invention relates to compositions and methods of using same to direct an immune response thereby enhancing the efficacy of an antigen containing vaccine by combining a chemokine in conjunction with the vaccine, wherein the choice of the chemokine directs the immune response in either the Th1 or Th2... Agent: Moore & Van Allen Pllc
20080112977 - Supertype epitopes, oligonucleotides coding the same which induce effective ctl response against hcv and the use thereof: The present invention relates to a supertype epitope which effectively induce a cell-mediated immune response and its use, specifically, a supertype epitope which effectively induce the cytotoxic T lymphocytes specific to HCV and come from conservative region of a HCV polyprotein, an expression vector comprising the oligonucleotide coding the said... Agent: Sughrue Mion, Pllc
20080112978 - Method for treatment of hiv infection: A method for treatment of HIV infection includes administering at least one anti-HIV drug, such as a reverse transcriptase inhibitor, to a patient in need of such treatment and administering an extract from inflammatory tissue inoculated with vaccinia virus to the patient following the administration of the at least one... Agent: Greenblum & Bernstein, P.L.C
20080112980 - Lawsonia intracellularis of european origin and vaccines, diagnostic agents and methods of use thereof: The present invention relates to Lawsonia intracellularis vaccines and methods for protecting against and diagnosing L. intracellularis infection. The products and processes of the invention are attainable, in part, as the result of an improved method for cultivating large scale supplies of L. intracellularis, including both a novel isolate of... Agent: Michael P. Morris Boehringer Ingelheim Corporation
20080112979 - Oral killed vaccines and method for providing same: There is described a method for selecting microbial isolates for use in oral killed vaccines against abnormal microbial colonisation of mucosal surfaces by the microbes. The method comprises evaluating capacity of a plurality of different isolates of a microbe to activate antigen responsive cells to provide activation data for each... Agent: Fulbright & Jaworski L.l.p
20080112981 - Treatment of fine wrinkles with clostridia neurotoxins: Methods of using clostridial toxins and other biological agents to thin skin and control fine wrinkles in humans are provided. In preferred embodiments the methods provide beneficial effects in humans.... Agent: Omri M. Behr
20080112982 - Methods and compositions related to bacterial flagellum and nanotube formation: Disclosed are compositions and methods relating to bacterial flagella and uses thereof.... Agent: Needle & Rosenberg, P.c.
20080112983 - Barn dust extract providing protection from allergies: The present invention describes a process for preparing an extract for the treatment of allergic diseases, in which process no heat is supplied during all of the preparation process, an extract which has been prepared by this process, and the use of this extract for preparing a medicament.... Agent: Knobbe Martens Olson & Bear LLP
20080112984 - Novel hydrogels based on polyvinyl alcohols and polyvinyl alcohol copolymers: The invention relates to hydrogels containing polyvinyl alcohols and/or polyvinyl alcohol copolymers having special geometries, methods for the production of said hydrogels, and the use of the hydrogels as materials in the biomedical and pharmaceutical field, for producing contact lenses, for the controlled release of active substances, as a carrier... Agent: Connolly Bove Lodge & Hutz, LLP
20080112985 - Controlled release sterile injectable aripiprazole formulation and method: A controlled release sterile freeze-dried aripiprazole formulation is provided which is formed of aripiprazole of a desired mean particle size and a vehicle therefor, which upon constitution with water and intramuscular injection releases aripiprazole over a period of at least about one week and up to about eight weeks. A... Agent: Sughrue Mion, Pllc
20080112986 - Controlled release sterile injectable aripiprazole formulation and method: A controlled release sterile freeze-dried aripiprazole formulation is provided which is formed of aripiprazole of a desired mean particle size and a vehicle therefor, which upon constitution with water and intramuscular injection releases aripiprazole over a period of at least about one week and up to about eight weeks. A... Agent: Sughrue Mion, Pllc
20080112987 - Coating for oxygen sensitive materials: The invention relates to coating and encapsulation composition useful for protecting core material from oxidative and/or hydrolytic damage. The coating composition comprises a lipid polymer and a lipid-based anti-oxidant, wherein the anti-oxidant is soluble in the lipid polymer.... Agent: National Starch And Chemical Company
20080112988 - Composition and method for cosmetic vitalization and stabilization: A composition and method for vitalizing and stabilizing a cosmetic product, comprising: an inner cosmetic layer; and an outer shell including: metal ions; and an anhydrous cosmetic product. The metal ions are selected from the group consisting of: copper ions, silver ions, and gold ions. The concentration of the metal... Agent: Advantia Law Group
20080112989 - Encapsulation method: A method of loading liquid lipophilic compounds to capsules having a hydrogel shell and an oil core, wherein said compound, said capsules, and water and a solvent that is miscible with both water and lipophilic compound are thoroughly mixed and incubated for a sufficient time to provide capsules loaded with... Agent: Curatolo Sidoti Co., Lpa
20080112990 - Cosmetic compositions: A cosmetic composition comprising in a preblend; or in a the resting state prior to application to a keratinous surface, at least one peptide, at least one collagen containing compound, at least one penetration enhancer, at least one mucopolysaccharide, and at least one proteoglycan; wherein said ingredients are operable to... Agent: Julie Blackburn Revlon Consumer Products Corporation
20080112991 - Method of enhancing skin absorption of nutrients and active agents: The present invention relates to a cosmetic composition which contains electric carriers apart from specific active agents and auxiliaries. According to the present invention, the composition contains 0.1 to 10% by weight of a cosmetically acceptable, solid electret material with a particle size of 0.05 to 100 μm, which electret... Agent: Akerman Senterfitt
20080112993 - High-dose, long-lasting ectoparasiticide for extended control: e
20080112992 - Method for controlling the application of an insecticide and composition thereof: The invention relates to a method for controlling the application of an insecticide on a surface, which comprises the use of an insecticide composition including a pH indicator colorant in an aqueous medium changing the colorless after drying in the air on said surface, and the recoloration of the insecticide... Agent: Snell & Wilmer L.l.p. (main)
20080112994 - Formulations having increased stability during transition from hydrophobic vehicle to hydrophilic medium: A suspension formulation for therapeutic use includes a non-aqueous, hydrophobic vehicle exhibiting viscous fluid characteristics, a dry particle formulation comprising a biomolecule dispersed in the vehicle, and a surfactant incorporated in at least one of the vehicle and dry particle formulation. A dry particle formulation includes an interferon, a buffer,... Agent: Intarcia Therapeutics, Inc.
20080112995 - Implantable bioreactors and uses thereof: An implantable bioreactor device and methods of use are provided. The device comprises a first compartment being configured capable of fluidic communication with a vasculature of a subject; and a second compartment configured for containing cells, said second compartment being separated from said first compartment by a membrane.... Agent: Martin D. Moynihan Prtsi, Inc.
20080112996 - Bone cell delivery device: Bone cages are disclosed including devices for biocompatible implantation. The structures of bone are useful for providing living cells and tissues as well as biologically active molecules to subjects.... Agent: Searete Llc Clarence T. Tegreene
20080112998 - Innovative bottom-up cell assembly approach to three-dimensional tissue formation using nano-or micro-fibers: The present invention provides a synthetic tissue scaffold, the scaffold comprising alternating layers of electrospun polymers and mammalian cells sandwiched within. A novel method is also provided for generating a three-dimensional tissue by electrospinning polymers and seeding cells in alternating layers on an aqueous solution in a desired shape. This... Agent: Hongjun Wang Apt C
20080112997 - Methods for coating stents with dna and expression of recombinant genes from dna coated stents in vivo: The present invention describes DNA coated stents and methods of using the same to treat or prevent vascular diseases, such as restenosis.... Agent: Brinks Hofer Gilson & Lione
20080113000 - Compositions and methods for coating medical implants: Medical implants are provided which release an anthracycline, fluoropyrimidine, folic acid antagonist, podophylotoxin, camptothecin, hydroxyurea, and/or platinum complex, thereby inhibiting or reducing the incidence of infection associated with the implant.... Agent: Seed Intellectual Property Law Group Pllc
20080112999 - N-substituted monomers and polymers: Described herein are N-substituted monomers and polymers, methods of making such monomers and polymers, and methods of using them in various applications, such as medical devices. In preferred embodiments, the medical device is a stent.... Agent: Knobbe Martens Olson & Bear LLP
20080113001 - Tissue separating device with reinforced support for anchoring mechanisms: A barrier layer device is formed of an underlying biocompatible structure having a barrier layer coating that can exhibit anti-inflammatory properties, non-inflammatory properties, and/or adhesion-limiting properties, as well as generate a modulated healing effect on injured tissue. As implemented herein, the barrier layer is a non-polymeric cross-linked gel derived at... Agent: Lahive & Cockfield, LLP
20080113002 - Contact lens compositions: In one embodiment, the invention provides a contact lens comprising a lipid or phospholipid moiety bound optionally via a spacer to a physiologically acceptable monomer, dimer, oligomer, or polymer via an ester or amide bond, and/or a pharmaceutically acceptable salt or a pharmaceutical product thereof.... Agent: Pearl Cohen Zedek Latzer, LLP
20080113003 - Sinapic acid supplementation: An animal feed composition for monogastric non-human animals is disclosed comprising supplemental sinapic acid or derivatives thereof. Sinapic acid may be supplemented at a level of from 0.0005% to 3% of the feed composition by weight. The feed composition has the beneficial effect of promoting favourable intestinal microbial ecology by... Agent: Borden Ladner Gervais LLP Gail C. Silver
20080113004 - Local administration of gallium compositions to treat pain: Provided are methods of treating pain, including neuropathic pain, in human and veterinary individuals. These methods employ locally administrable pharmaceutical gallium compositions, including pharmaceutical gallium compositions suitable for administration to the skin and mucous membranes. The compositions comprise pharmaceutically acceptable gallium compounds, such as gallium maltolate or gallium nitrate, together... Agent: Lawrence R. Bernstein
20080113005 - Composition comprising an extract of gramineae plant for the prevention and treatment of ischemic diseases and degenerative brain diseases and the use thereof: The present invention relates to a composition comprising extracts of Gramineae plant that improves cell viability under hypoxic conditions by inhibiting apoptosis. Thus, the extract of Triticum aestivum L., one of the Gramineae plant, of the present invention, in particular, prevents damage of brain, heart and kidney in animal models... Agent: Kirk Hahn
20080113008 - Absorbent fabric implant: The present invention is a method and device for treating a tissue defect, disease or abnormality. The device includes an absorbent container adapted to be placed at a tissue site, the container constructed and arranged to absorb a bioactive solution prior to the placement at the tissue site and to... Agent: Patterson, Thuente, Skaar & Christensen, P.a.
20080113007 - Sheet-shaped composition utilizing amnion and method of preparing the same: A sheet-shaped composition that is applicable to a wide spectrum of uses and can be transplanted through simple and easy transplanting technique. There is provided a sheet-shaped composition comprising amniotic membrane and, attached to the surface thereof, fibrinogen and thrombin. In one form, a cell layer is formed on the... Agent: Edwards Angell Palmer & Dodge LLP
20080113006 - Transparent sheet-like cleansing agent: According to the present invention, it is possible to provide a transparent sheet-like cleansing agent that is excellent in transparency, can be formed thin, has good solubility, is excellent in foaming properties, and leaves no residual substance.... Agent: Ndq&m Watchstone LLP
20080113009 - Packing elements for evaporative coolers with resistance to biofilm formation: Disclosed is a polyvinyl chloride packing material for evaporative coolers, which packing material has incorporated therein an amount effective to prevent biofilm formation of one or more antimicrobials selected from the group consisting of the metal containing zeolites and the supported metals, where the metal of the metal containing zeolites... Agent: Joann Villamizar Ciba Corporation/patent Department
20080113010 - Nonaqueous preparation for percutaneous absorption containing nonsteroidal anti-inflammatory analgesic: The present invention relates to nonaqueous preparation for percutaneous absorption prepared by laminating an adhesive layer comprising a nonsteroidal anti-inflammatory analgesic in an alkali metal salt form, and an inorganic acid which is strongly acidic compared with the nonsteroidal anti-inflammatory analgesic in a free form, together with a nonaqueous base,... Agent: Oliff & Berridge, Plc
20080113011 - Compositions and methods for enhanced mucosal delivery of interferon beta: Compositions and methods are provided for intranasal delivery of interferon-β yielding improved pharmacokinetic and pharmacodynamic results. In certain aspects of the invention, the interferon-β is delivered to the intranasal mucosa along with one or more intranasal delivery-enhancing agent(s) to yield substantially increased absorption and/or bioavailability of the interferon-β and/or a... Agent: Nastech Pharmaceutical Company Inc
20080113012 - Method for using transdermal system with fentanyl: m
20080113013 - Transdermal, therapeutic system with activatable oversaturation and controlled permeation promotion: A transdermal therapeutic system (TTS) that is essentially composed of two compartments and is provided with activatable oversaturation and controlled permeation promotion. The invention more particularly relates to a TTS wherein an oversaturated active ingredient solution is produced in an active-substance-containing polymer matrix when the system is applied to the... Agent: D. Peter Hochberg Co. L.p.a.
20080113016 - Method for prevention or treatment of inflammatory disease: Methods are provided for prevention or treatment of inflammatory disease in a mammal by administering an inhibitor of mitogen activated (MAP) kinase system to the mammal in a therapeutic amount to the mammal in need thereof. The MAP kinase inhibitor is targeted to the central nervous system of the mammal.... Agent: Woodcock Washburn LLP
20080113014 - Method for screening for compounds safe for gastric mucosa: A method for screening for compounds or salts thereof, in particular nonsteroidal anti-inflammatory compounds or salts thereof, that are safe for gastric mucosa and cause little gastrointestinal side effects. The method uses a particular liposome to serve as a cell membrane model. The liposome encapsulates a fluorescent dye, in particular,... Agent: Ostrager Chong Flaherty & Broitman Pc
20080113017 - Sterol derivatives, liposomes comprising sterol derivatives and method of loading liposomes with active substances: A sterol derivative with a pKa value of between 3.5 and 8, according to the general formula cation-spacer 2-Y-spacer 1-X-sterol, wherein Y and X represent linking groups, is suggested, as well as liposomes comprising such sterol derivatives.... Agent: Akerman Senterfitt
20080113015 - Superloaded liposomes for drug delivery: The present invention relates to liposomes for drug delivery, wherein a liposome includes molecules of at least one desired drug distributed within an aqueous phase in the interior of the liposome and wherein the liposome further includes molecules of the same or of another drug attached to either or both... Agent: Rothwell, Figg, Ernst & Manbeck, P.c.
20080113018 - Encapsulation method for compounds: e
20080113019 - Composition for capsule coating: The present invention provides a composition that is suitable for producing a plant-derived, practical capsule shell sheet having both sufficient strength and elongation as a capsule shell, superior adhesiveness and transparency, and a low burden on a drying step. The present invention also provides a capsule shell sheet obtained using... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.c.
20080113021 - Ibuprofen composition: The invention relates to an immediate release tablet capable of being chewed or disintegrated in the oral cavity, which comprises a plurality of particles in a matrix. The particles contain an active ingredient, such as ibuprofen, and a first water soluble acid having a solubility greater than about 10 g/100... Agent: Philip S. Johnson Johnson & Johnson
20080113020 - Solid pharmaceutical composition comprising telithromycin: The invention relates to a novel solid pharmaceutical composition of telithromycin which facilitates swallowing by the patient.... Agent: Andrea Q. Ryan Sanofi-aventis U.s. Llc
20080113022 - Pharmaceutical composition based on idazoxan, salts, hydrates or polymorphs thereof: Pharmaceutical composition comprising 5 to 20% of an idazoxan salt or of idazoxan hydrate, 10 to 40% of microcrystalline cellulose, 1 to 5% of lubricant, 0.1 to 0.5% of colloidal silica and from 29.5% to 84.8% of lactose, with respect to the total mass.... Agent: Birch Stewart Kolasch & Birch
20080113023 - Bilayer tablet comprising telmisartan and diuretic: The invention relates to a bilayer pharmaceutical tablet comprising a first layer containing 3 to 50 wt. % of telmisartan dispersed in a dissolving tablet matrix and a second layer containing a diuretic in a disintegrating tablet matrix as well as a processes for producing same.... Agent: Michael P. Morris Boehringer Ingelheim Corporation
20080113024 - Methods and compositions for treating platelet-related disorders: Provided are prophylactic and therapeutic methods of treatment of subjects for the purpose of inhibiting vaso-occlusive events, including embolism, by administering agents, including anagrelide and anagrelide derivatives, which reduce the number of circulating platelets to low normal to below normal levels. Methods and pharmaceutical preparations comprising such agents are provided.... Agent: Fish & Richardson, Pc
20080113025 - Compositions comprising nanoparticulate naproxen and controlled release hydrocodone: The invention relates to a compositions comprising a nanoparticulate naproxen composition in combination with a multiparticulate modified release hydrocodone composition that, upon administration to a patient, delivers a hydrocodone in a bimodal or multimodal manner. The multiparticulate modified release composition comprises a first component and at least one subsequent component;... Agent: Fox Rothschild, LLP
20080113026 - Layered pharmaceutical formulations: In one embodiment a layered pharmaceutical formulation includes two or more pharmaceutical layers and an intermediate layer disposed between at least two of the two or more pharmaceutical layers, the intermediate layer configured to dissolve in vivo to thereby leave the two or more pharmaceutical layers substantially intact. In one... Agent: Knobbe Martens Olson & Bear LLP
20080113027 - Water insoluble polymer matrix for drug delivery: Disclosed is a pharmaceutical composition comprising (a) a bioerodible water insoluble polymer matrix comprising a polyester polymer, wherein the polymer matrix has a melting point of less than 60° C. and (b) an active agent dispersed within the polymer matrix, wherein the composition is formulated to controllably release the active... Agent: Alcon
20080113028 - Novel block copolymer, micelle preparation, and anticancer agent containing the same as active ingredient: A medicinal preparation is desired which has no harmful side effects such as hypersensitive reaction, heightens the water solubility of a sparingly water-soluble anticancer agent, maintains a high drug concentration in the blood, accumulates a drug in a tumor tissue at a high concentration, heightens the pharmacological effect of the... Agent: Nields & Lemack
20080113029 - Color-coded and sized loadable polymeric particles for therapeutic and/or diagnostic applications and methods of preparing and using the same: Polymeric particles are provided for use in therapeutic and/or diagnostic procedures. The particles include poly[bis(trifluoroethoxy) phosphazene] and/or a derivatives thereof which may be present throughout the particles or within an outer coating of the particles. The particles may also include a core having a hydrogel formed from an acrylic-based polymer.... Agent: Sutherland Asbill & Brennan LLP
20080113031 - Minicapsule formulations: A formulation comprises a plurality of seamless minicapsules, the minicapsules having a diameter of from 0.5 mm to 5 mm, the minicapsules having a core containing an active entity and an encapsulating body, the active entity being in the form of any one or more of: a microemulsion, a nanoemulsion,... Agent: Jacobson Holman Pllc
20080113030 - Sustained release tamsulosin formulations: A sustained release tamsulosin formulation contains tamsulosin, a hydrophobic polymer, a microsphere forming agent and a diluent. The hydrophobic polymers include pH-dependent and pH-independent polymers are used as the release-modulating agent to control the dissolution profile of tamsulosin formulation so that the formulation releases tamsulosin slowly and continuously as the... Agent: Frenkel & Associates, P.c.
20080113032 - Scalp desensitizing formulation: A method of desensitizing the scalp prior to a generally painful hair treatment or manipulation procedure by application of a composition containing a therapeutically effective amount of solubilized topical anesthetic and scalp/skin conditioning oils. The composition can be used for the conditioning and desensitization of scalp and skin areas which... Agent: Victor E. Vandell
20080113033 - Topical treatment and manufacturing method: A topical treatment for psoriasis, eczema and other disorders and conditions includes beeswax, coconut oil, shea butter and cocoa butter. Optional ingredients can also be included. A method of manufacturing the composition includes the steps of preheating and liquifying the beeswax, adding other ingredients, slowly stirring the resulting composition at... Agent: Mark Brown
20080113034 - Composition for promoting growth of animal comprising extracts of artemisia capillaris thunberg, acanthopanax and garlic and feed composition for promoting growth comprising the composition: The present invention relates to a composition for promoting the growth of animals, comprising extracts of Artemisia capillaris thunberg., Acanthopanax and garlic, as well as a feed composition comprising the same. The composition for promoting the growth of animals shows the excellent effect of promoting the secretion of growth hormone.... Agent: Thomas M. Galgano Galgano & Associates
20080113035 - Compositions and methods for treating or preventing inflammatory diseases: Methods and compositions for treating or preventing inflammatory diseases such as psoriasis or multiple sclerosis are provided, comprising the step of delivering to the site of inflammation an anti-microtubule agent, or analogue or derivative thereof.... Agent: Seed Intellectual Property Law Group Pllc
20080113036 - Bleach activator mixtures: t
20080113037 - Topical compositions comprising polyhydroxy acids and/or lactones for improved cutaneous effects of oxidative therapeutic drugs: Embodiments relate generally to topical compositions useful for treating or preventing a variety of cosmetic conditions and dermatological disorders, where the composition comprises an oxidative pharmaceutical drug and an antioxidant polyhydroxy acid or polyhydroxy lactone. The polyhydroxy acid or polyhydroxy lactone improves the cutaneous effects of the drug. The embodiments... Agent: Goodwin Procter LLP
20080113038 - Composition for promoting osteogenesis and increasing bone mineral content: It is to provide a composition for promoting osteogenesis and increasing bone mineral content with a function of (promoting) osteogenesis and increasing bone mineral content, having a significant effect, which promotes actively osteogenesis to prevent/treat bone diseases, a preventative/therapeutic agent for bone diseases, a functional food or food material for... Agent: Davis, Brown, Koehn, Shors & Roberts, P.c. The Financial Center
20080113039 - Combination therapy: The present invention relates to a method for the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal such as a human which is optionally being treated with ionising radiation, particularly a method for the treatment of a cancer, particularly a cancer involving a solid tumour,... Agent: Morgan Lewis & Bockius LLP
20080113040 - Process for producing aqueous chlorine dioxide for surface disinfection and decontamination: The present invention provides for a method of generating an aqueous solution comprising chlorine dioxide using a chlorine-containing chemical oxidant; an effector having the capacity to reduce said chlorine-containing chemical oxidant; a chemical reductant; and water, and operating in either batch or continuous-flow modes. In batch mode, the aqueous chlorine... Agent: Natick Soldier Rdec
20080113041 - Calcium supplementation to reduce prostate cancer risk: A method for promoting prostate health in a subject comprising administering a dose of calcium to the subject. Particularly provided is a method for reducing the risk of prostate carcinomas, comprising administering a dose of elemental calcium effective to reduce the risk of prostate cancer. In an example, 1200 mg... Agent: Wyeth C/o Darby & Darby, P.c.
20080113042 - Pharmaceutical composition and method for cancer treatment based on combinational use of conventional anticancer agents and geranium oil or compounds thereof: A cancer treatment composition includes geranium oil or its chemical constituents and a chemotherapeutic agent or plant extract selected from the group consisting of plant-derived bioactive compounds. The cancer is selected from the group consisting of lung, breast, ovary, prostate, colon, liver, gastrointestinal, head-and-neck, cervix, kidney, neuroblastoma, leukemia, lymphoma, and... Agent: Evan Law Group Llc
20080113043 - Method for producing ginseng fruit and ginseng flower stalk with high content of ginsenoside: Disclosed is a method for producing ginseng fruits and flower stalks with high content of ginsenoside. More particularly, the present invention provides a method for producing ginseng fruits and flower stalks with high contents of ginsenoside Rb1, ginsenoside Rb2, ginsenoside Rc, ginsenoside Rd, ginsenoside Re and other ginsenoside ingredients. According... Agent: Technology & Intellectual Property Strategies Group Pc (dba Tips Group)
20080113044 - Extracts and methods comprising green tea species: The present invention relates to extracts of green tea species plant material prepared by supercritical CO2 extractions methods.... Agent: Foley Hoag, LLP Patent Group, World Trade Center West
20080113045 - Composition for enhancing male fertility: The present invention relates to compositions for enhancing fertility in a male individual comprising extracts of radish seeds, celery seeds, black seeds and ginger rhizome, methods of enhancing fertility in a male individual comprising the step of administering said composition, and the use of said composition as a medicament.... Agent: Knobbe Martens Olson & Bear LLP
20080113046 - Use of omega-3 fatty acid(s) for treating hypercholesterolemia caused by anti-retroviral treatment of hiv-infected patients: The invention relates to the use of omega-3 fatty acid(s) or the marine and/or vegetable omega-3 fatty acid(s) source for preparing a drug for treating a hypercholesterolemia caused by the anti-retroviral treatment of patients infected by human immunodeficiency virus (HIV) by limiting a non-HDL fraction of circulating lipoproteins and to... Agent: Birch Stewart Kolasch & Birch
20080113047 - Herbal composition for tinea infection: Compositions containing extract of hedychium spicatum are useful for treating Tinea infections by topical application. Extracts from rhizomes of hedychium spicatum are particularly useful.... Agent: Hamre, Schumann, Mueller & Larson, P.c.
20080113048 - Application for hop acids as anti-microbial agents: The alkali metal salts form of β-acids dissolved in propylene glycol is used to control microbial growth in food products, process streams and other applications, including in cosmetic formulations.... Agent: Hayes Soloway P.c.
20080113049 - Compositions and methods for uterine relaxing: A method for treating/relief of women's menstruation pain. The pain is reduced or relieved by externally administering an effective amount of an essential oil obtained from anthopogon.... Agent: Birch Stewart Kolasch & Birch
20080113050 - Hibiscus anthocyanins for inhibiting cancers: This invention provides a composition for inhibiting cancer cell growth comprising Hibiscus anthocyanins extracted from Hibiscus sabdariffa. This invention also provides a method for treating cancer comprising administering a patient with an effective amount of Hibiscus anthocyanins.... Agent: Wpat, Pc Intellectual Property Attorneys
20080113051 - Methods for alleviating tattoo pain: The present invention features a method for alleviating pain associated with a placement or removal of a tattoo. In some embodiments, the method comprises the step of locally administering a neurotoxin (e.g., a botulinum toxin) to the anatomical site at where the tattoo is to be placed or removed.... Agent: Allergan, Inc.05/08/2008 > patent applications in patent subcategories. archived by USPTO category
20080107595 - Anti-ccr5 antibody: The invention is directed an anti-CCR5 antibody which comprises (i) two light chains, each light chain comprising the expression product of a plasmid designated pVK:HuPRO140-VK (ATCC Deposit Designation PTA-4097), and (ii), two heavy chains, each heavy chain comprising an expression product of either a plasmid designated pVg1:HuPRO140 HG2-VH (ATCC Deposit... Agent: Cooper & Dunham, LLP
20080107596 - Novel method of diagnosing, monitoring, staging, imaging and treating breast cancer: The present invention provides new markers and methods for detecting, diagnosing, monitoring, staging, prognosticating, imaging and treating breast cancer.... Agent: Kathleen A. Tyrrell Licata & Tyrrell P.c.
20080107598 - Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications: Novel methods of synthesis of chelator-targeting ligand conjugates, compositions comprising such conjugates, and therapeutic and diagnostic applications of such conjugates are disclosed. The compositions include chelator-targeting ligand conjugates optionally chelated to one or more metal ions. Methods of synthesizing these compositions in high purity are also presented. Also disclosed are... Agent: Fulbright & Jaworski L.l.p.
20080107600 - Gene marker and composition for diagnosis and treatment of neurological disorders and diseases and use of the same: The present invention provides a marker, kit and method for determining the level of axon outgrowth and/or fasciculation, or conditions, disorders or diseases associated with the level of axon outgrowth and/or fasciculation. The present invention was achieved by unexpectedly finding the relationship between DISC1 and FEZ1 and KIAA0844 and unexpectedly... Agent: Cozen O'connor, P.c.
20080107601 - Nanobodies tm against amyloid-beta and polypeptides comprising the same for the treatment of degenerative neural diseases such as alzheimer's disease: The present invention relates to anti-A-beta polypeptides comprising at least one Nanobody, or a functional fragment thereof, directed against A-beta, for the treatment of diseases or disorders mediated by A-beta or dysfunction thereof, or mediated by amyloid plaque formation.... Agent: Wolf Greenfield & Sacks, P.c.
20080107603 - Neuroprotectant methods, compositions, and screening methods thereof: The present invention relates in general to methods of protecting a mammalian central nervous system cell from damage, and to methods of treating or ameliorating neurodegenerative diseases. The invention further relates to screening for neuro-protective agents that may alone, or in combination with other neuroprotective agents, aid in protecting cells... Agent: David A . Jackson Klauber & Jackson
20080107606 - Bifunctional chelators for sequestering lanthanides: The present invention relates to a method for preparing a bifunctional chelator for lanthanide. The method comprises the steps of providing a starting material which has an amino and carboxyl group; protecting the amino with an amino protecting group and the carboxyl with a carboxyl protecting group to produce a... Agent: Morrison & Foerster LLP
20080107607 - Targeting vector-phospholipid conjugates: Peptide vectors having high KDR binding affinity and processes for making such vectors are provided. The peptide vectors may be conjugated to phospholipids and included in ultrasound contrast agent compositions. Such ultrasound contrast agents are particularly useful in therapeutic and diagnostic methods, such as in imaging KDR-containing tissue and in... Agent: Kramer Levin Naftalis & Frankel LLP
20080107611 - Mouthwash containing fluorine and calcium ions: Mouthwash containing fluorine and calcium ions. The mouthwash has a pH value between 4.5 and 6.5 and does not contain any calcium ion sequestrants having a chelating constant with the calcium ion greater than 104. This way a mouthwash can be obtained having a high stability over time and a... Agent: Sughrue Mion, Pllc
20080107616 - Composition for keratin fibres: Present invention relates to a non-aqueous aerosol composition for keratin fibres, especially for hair. It has surprisingly been found out that a water free aerosol composition comprising one or more volatile and/or non-volatile silicone oil at a concentration of at least 10% by weight, calculated to total composition, at least... Agent: Norris, Mclaughlin & Marcus, P.a.
20080107615 - Detackified compositions: The present invention relates to compositions including a detackifying effective amount of at least one polyurethane/poly(meth)acrylate graft copolymer as well as to methods of using such compositions and to kits comprising such compositions.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.c.
20080107618 - Use of fullerenes for the treatment of mast cell and basophil-mediated disease: Mast cell (MC) and peripheral blood basophil (PBB)-associated diseases are treated or prevented, or their symptoms are alleviated by the administration of water soluble fullerenes (buckeyballs) to the individual under conditions sufficient to inhibit MC and PBB responses. MC and PBB responses are associated with, for example, various allergies including... Agent: Whitham, Curtis & Christofferson & Cook, P.c.
20080107619 - Carbohydrate based cellulase inhibitors as feeding stimulants in termites: A method, composition and system for controlling termites wherein single carbohydrate-based compounds are used as both cellulase inhibitors and feeding stimulants. Di-saccharides, cellobioimidazole (CBI), fluoro-methyl cellobiose (FMCB), and mono-saccharides, fluoro-methyl glucose (FMG) and analogs thereof inhibit termite cellulose digestion, which leads to starvation or stimulates termite feeding to cause mortality.... Agent: Law Offices Of Brian S Steinberger
20080107620 - Human cytomegalovirus immunotherapy: An isolated protein construct comprising a polyepitope derived from multiple human cytomegalovirus protein antigen epitopes conjugated to an extracellular domain of glycoprotein B, which isolated protein is capable of eliciting a cytotoxic T-lymphocyte immune response as well as a neutralizing antibody response to human cytomegalovirus. Also provided are pharmaceutical compositions... Agent: Knobbe Martens Olson & Bear LLP
20080107622 - Galactose-pronged polysaccharides in a formulation for antifibrotic therapies: Methods and compositions for reducing fibrosis and cirrhosis are provided in which an effective dose of an admixture of a polysaccharide compound and, for example, a compound selected from the group consisting of antibodies specific to intracellular or cell-surface: (i) beta-PDGF receptors; (ii) synaptophysin; (iii) zvegf3; (iv) CCR1 receptors; (v)... Agent: Barry Schindler C/o Greenberg Traurig, LLP
20080107621 - Use of il - 6 in microvascular complicaitions: The present invention relates to the use of IL-6 or a fragment, variant, fusion protein, functional derivative or salt thereof in microvascular complications.... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw
20080107634 - Probiotic bacteria based composition and use thereof in the prevention and/or treatment of respiratory pathologies and/or infections and in the improvement of the intestinal functionality: The object of the present invention is a probiotic bacteria based composition and use thereof in the prevention and/or treatment of respiratory pathologies and/or infections and in the contemporaneous improvement of the intestinal functionality, which can be compromised by therapeutic treatments adopted for re-solving said pathological conditions. Besides that, aim... Agent: Pearne & Gordon LLP
20080107631 - Formulation of adenovirus for gene therapy: The present invention addresses the need to improve the long-term storage stability (i.e. infectivity) of vector formulations. In particular, it has been demonstrated that for adenovirus, the use of bulking agents, cryoprotectants and lyoprotectants imparts desired properties that allow both lyophilized and liquid adenovirus formulations to be stored at 4°... Agent: Fulbright & Jaworski L.l.p.
20080107630 - Human matrix metalloproteinase-8 gene delivery enhances the oncolytic activity of a replicating adenovirus: The present invention discloses a method of treating cancer in a subject. This involves co-administering a replicating virus and a matrix metalloproteinase to the subject under conditions effective to treat cancer. It also relates to a method of enhancing the delivery to and distribution within a tumor mass of therapeutic... Agent: Nixon Peabody LLP - Patent Group
20080107632 - Fibrin glue composition for repairing nerve damage and methods thereof: The present invention relates to a fibrin glue composition for repairing nerve damage, and/or enhancing the functional recovery of a damaged nerve which includes fibrin glue and an amount of bone marrow stem cells (BMSCs) effective for repairing the nerve damage and/or enhancing at least partially the functional recovery. The... Agent: Panitch Schwarze Belisario & Nadel LLP
20080107639 - Use of a dg147 protein product for preventing and treating metabolic disorders: The present invention discloses novel uses for energy homeostasis regulating proteins and polynucleotides encoding this in the diagnosis, study, prevention, and treatment of metabolic diseases and disorders.... Agent: Rothwell, Figg, Ernst & Manbeck, P.c.
20080107597 - Isolation of antibodies that cross-react and neutralize rankl originating from multiple species: The invention provides specific binding members (e.g., antibodies or antigen-binding fragments thereof) which bind to RANKL originating from multiple species. An epitope recognized by the specific binding members can be selected from surface exposed loop domains that bind to and activate its cognate receptor, RANK (Receptor Activator of NFkB), on... Agent: Wilson Sonsini Goodrich & Rosati
20080107599 - Radiolabelled benzamide analogues, their synthesis and use in diagnostic imaging: Fluoroalkoxybenzamide compounds which selectively bind Sigma-2 receptors are disclosed. These compounds, when labelled with 18F, can be used as radiotracers for imaging of tumors by positron emission tomography (PET). In addition, these compounds, when labelled with 123I, can be used as radiotracers for imaging of tumors by single photon emission... Agent: Sonnenschein Nath & Rosenthal LLP
20080107602 - Neospora caninum isolate: The present invention relates to a novel Neospora caninum isolate from Nowra and extracts thereof. The strain is useful in the development of diagnostic assays for the detection of parasites in animals. The present invention also relates to pharmaceutical compositions, using live or killed organisms or extracts thereof, for the... Agent: Nixon & Vanderhye, Pc
20080107605 - Biologically active synthetic thyrotropin and cloned gene for producing same: Substantially pure recombinant TSH has been prepared from a clone comprising complete nucleotide sequence for the expression of the TSH. Diagnostic and therapeutic applications of the synthetic TSH are described.... Agent: Knobbe, Martens, Olson & Bear, LLP
20080107604 - Method for the prediction of the risk potential for cancerous diseases and inflammatory intestinal diseases and corresponding tests: The invention relates to a method for the prediction of the risk potential and/or diagnosis of cancerous diseases or inflammatory intestinal diseases, whereby a DNA sample is tested for the presence of polymorphic UGT1A7 allele. A positive result for a mutation is a positive indication of a sensitivity to cancerous... Agent: Whitham, Curtis & Christofferson & Cook, P.c.
20080107608 - 5-substituted-2-arylpyridines: Novel 5-substituted-2-arylpyridine compounds are provided. Such compounds can act as selective modulators of CRP receptors. The 5-substituted-2-arylpyridine compounds provided herein are useful in the treatment of a number of CNS and periphereal disorders, particularly stress, anxiety, depression, cardiovascular disorders, and eating disorders. Methods of treatment of such disorders and well... Agent: Neurogen Corporation
20080107609 - Pulmonary disease treatment: The invention relates to treating chronic obstructive pulmonary disease, involving the administration by inhalation of mometasone furoate particles in daily doses where at least about 250 μg of the inhaled particles have sizes equal to or less than 6.5 μm.... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)
20080107610 - Breath freshening and oral cleansing product with magnolia bark extract: A chewing gum composition for oral cleansing, breath freshening, and anti-microbial benefits includes Magnolia Bark extract. In a treatment process, effective amounts of Magnolia Bark extract are delivered to the oral cavity by the chewing gum composition for convenient oral cleansing and breath freshening benefits. A method of making the... Agent: Wrigley & Dreyfus 28455 Brinks Hofer Gilson & Lione
20080107612 - Anti-caries dental material: A sustained-release, dental fluoride varnish material includes about 5 percent by weight of NaF; up to about 10 percent by weight of glycerin; up to about 5 percent by weight of fumed silica; and optionally, an amount of varnish additives selected from the group consisting of flavorants, rosins, gums and... Agent: Dentsply International Inc
20080107614 - Peptide-based conditioners: Peptides have been identified that bind with high affinity to hair, skin, and nails. The peptide-based conditioners consist of a body surface-binding peptide coupled to a conditioning peptide. Conditioning peptides are typically derived from proteins and peptide having repeating amino acid sequences. Personal care compositions containing these peptide-based conditioners are... Agent: E I Du Pont De Nemours And Company Legal Patent Records Center
20080107617 - Surfactant-containing cosmetic, dermatological and pharmaceutical agents: The invention provides surfactant-containing cosmetic, dermatological, and pharmaceutical agents comprising at least one water-soluble or water-swellable copolymer obtainable by free-radical copolymerization of A) acryloyldimethyltaurine and/or acryloyldimethyltaurates, B) if desired, one or more further olefinically unsaturated, noncationic comonomers, C) if desired, one or more olefinically unsaturated, cationic comonomers, D) if desired,... Agent: Clariant Corporation Intellectual Property Department
20080107623 - Inhibitors of hepatitis c virus: e
20080107626 - Adjuvant agent for hepatitis c: An adjuvant agent is used in combination with interferon and ribavirin for treating hepatitis C. The adjuvant agent contains 50 to 90 wt % cordyceps sinensis, and also contains 10 to 50 wt % astragalus membranaceus. The cordyceps sinensis used to prepare the adjuvant agent is isolated from the culture... Agent: Birch Stewart Kolasch & Birch
20080107624 - Inhibitors of hepatitis c virus:
20080107625 - Inhibitors of hepatitis c virus:
20080107627 - Use of sarp-1 for the treatment and/or prevention of scleroderma: The invention relates to the use of SARP-1 for the preparation of a medicament for the treatment and/or prevention of scleroderma, in particular of systemic sclerosis.... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw
20080107628 - Phosphonate inhibitors of hcv: e
20080107629 - Methods and compositions for gene therapy: The present invention relates to improved methods for gene therapy, particularly gene therapy using PEGylated adenovirus. In particular the invention provides methods and compositions for mitigating the adverse effects associated with systemic administration of recombinant adenovirus for gene therapy.... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)
20080107633 - Cultures of human cns neural stem cells: The invention provides a cell culture including proliferating human neural stem cells with a doubling rate faster than thirty days. The invention also provides a cell culture media for proliferating mammalian neural cells including a standard defined culture medium, a carbohydrate source, a buffer, a source of hormones, one or... Agent: Ivor R. Elrifi Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c
20080107635 - Selection and use of lactic acid bacteria for reducing inflammation in mammals: Strains of lactic acid bacteria selected for their capability of reducing inflammation, such as intestinal bowel disease, a method of selecting such strains, and products containing such strains... Agent: Lynn E Barber
20080107636 - Induction of and maintenance of nucleic acid damage in pathogens using riboflavin and light: A process for damaging and maintaining damage to the nucleic acids of pathogens such as white blood cells, bacteria and viruses which may be contained in blood or blood components. This process comprises adding to the blood or blood component containing pathogens an effective amount of riboflavin, and exposing the... Agent: Gambro Bct, Inc Ip Department
20080107637 - Use of an agent that restores tissue perfusion and oxygenation: The presently disclosed subject matter provides methods for increasing perfusion in hypoxic regions of tissues in subjects. Also provided are methods for treating diseases and/or disorders associated with hypoxia in subjects, methods for increasing sensitivity of tumors to radiation and/or chemotherapy treatments, methods for delaying tumor growth in subjects, and... Agent: Jenkins, Wilson, Taylor & Hunt, P. A.
20080107638 - Methods of attenuating autoimmune disease and compositions useful therefor: The present invention relates to the reduction or attenuation a specific composition has on immunological tissue-destructive conditions associated with specific autoimmune diseases. The composition includes a long chain primary aliphatic alcohol, and one or more of three cofactors: a D Vitamin, a B12 Vitamin, a coenzyme Q, and an omega-3... Agent: Kirkpatrick & Lockhart Preston Gates Ellis LLP
20080107640 - Biological pesticide: Methods for exterminating pests using compositions comprising at least one protease enzyme. A detergent component may also be utilized in such compositions.... Agent: Price Heneveld Cooper Dewitt & Litton, LLP
20080107642 - Antibodies against gpr64 and uses thereof: GPR64 antibody compositions are provided. These antibodies may be used for diagnosis or treatment of cancer, especially ovarian cancer, Ewing's sarcoma, uterine cancer, and other GPR64 expressing tumor types.... Agent: Pdl Biopharma, Inc. Attn: Legal Department
20080107643 - Mammalian chemokines; receptors; reagents; uses: Novel chemokines and 7 transmembrane receptors from mammals, reagents related thereto, including purified proteins, specific antibodies, and nucleic acids encoding the chemokines and receptors are disclosed. Methods of using the chemokines, receptors, reagents and diagnostic kits are also provided.... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)
20080107641 - Method of treating stroke with thrombolytic agent: A method for treating acute ischemic stroke in a human comprises administering tenecteplase to the human in a total dose of about 0.05 to 0.5 mg/kg, given as (a) an initial bolus dose of about 0.015 to 0.15 mg/kg, followed by infusion of an amount equaling the total dose minus... Agent: Genentech, Inc.
20080107645 - Neospora caninum isolate: The present invention relates to a novel Neospora caninum isolate from Nowra and extracts thereof. The strain is useful in the development of diagnostic assays for the detection of parasites in animals. The present invention also relates to pharmaceutical compositions, using live or killed organisms or extracts thereof, for the... Agent: Nixon & Vanderhye, Pc
20080107644 - Pai-1 binding modulators for the treatment of ocular disorders: The invention concerns in one embodiment a method for treating glaucoma or elevated IOP in a patient comprising administering to the patient an effective amount of a composition comprising an agent that modulates PAI-1 binding to vitronectin. In another embodiment, the invention concerns a method of manufacturing a compound to... Agent: Alcon
20080107646 - Method for ameliorating pruritus: A method for preventing, treating, or ameliorating pruritus caused by skin, mucosa, or systemic disorder. The method comprises administering to a subject with pruritus or topically applying to an affected area with pruritus an effective amount of a formulation consisting essentially of a phenylbutyric acid or short-chain fatty acid derivative... Agent: Occhiuti Rohlicek & Tsao, LLP
20080107647 - Methods and compositions relating to ccr5 antagonist, inf-y and il-13 induced inflammation: The present invention includes compositions and methods for the treatment of Th1 and/or Th2 medicated inflammatory diseases, relating to inhibiting CCR5. This is because the present invention demonstrates, for the first time, that expression of IFN-γ, IL-13, and CCR5 mediates and/or is associated with Th1 and/or Th2 inflammatory diseases and... Agent: Morgan Lewis & Bockius LLP
20080107648 - Therapeutic methods for inhibiting tumor growth with dii4 antagonists: A therapeutic method for inhibiting tumor development or growth, comprising administering an agent capable of inhibiting human delta-like ligand 4 (DII4) activity to a subject in need thereof. In one embodiment, the agent is an anti-DII4 antibody or antibody fragment capable of inhibiting the binding of DII4 to a Notch... Agent: Regeneron Pharmaceuticals, Inc
20080107651 - Humanized neutralizing antibodies against hemolytic uremic syndrome: Novel human monoclonal antibodies derived from a transgenic mouse are disclosed as well as a process for the preparation of the novel monoclonals and a therapeutic method of treating an individual for hemolytic uremic syndrome or of protecting an individual against hemolytic uremic syndrome by administration of the monoclonals to... Agent: Patrea L. Pabst Pabst Patent Group LLP
20080107649 - Immunogenic compositions of cyclic peptides derived from the beta-amyloid peptide: The present invention relates to biologically active compositions and methods forelliciting an immune response, particularly against amyloid beta peptides by combinatory use of virosomes as adjuvants and a synthetic beta-peptide antigen.... Agent: Kathryn Doyle Drinker Biddle & Reath LLP
20080107650 - Method for treating inflammatory diseases of the digestive tract: A method for treating an inflammatory disease of the digestive tract, for example inflammatory bowel disease, in a subject comprises administering to the subject a therapeutically effective amount of a compound selected from the group consisting of (S,S)-2-[1-carboxy-2-[3-(3,5-dichlorobenzyl)-3H-imidazol-4-yl]-ethylamino]-4-methylpentanoic acid, pharmaceutically acceptable salts thereof and prodrugs thereof.... Agent: Harness, Dickey, & Pierce, P.l.c
20080107652 - Methods and compositions for control of disease in aquaculture: The invention discloses paratransgenesis methods for prevention, amelioration or treatment of a disease or disorder in an aquatic animal. The method comprises providing a genetically modified micro algae that expresses a recombinant molecule that specifically targets one or more key epitopes of a pathogen that infects the aquatic animal and... Agent: Law Offices Of Khalilian Sira, Llc
20080107654 - Humanized anti-cd47 antibody: The present invention relates to humanized antibodies binding to CD47; diabodies binding to human CD47, characterized in that a disulfide bond exists between diabody-forming fragments; genes encoding any one of said antibodies; vectors containing said genes; host cells containing said vectors; processes for preparing antibodies comprising the step of culturing... Agent: Foley And Lardner LLP Suite 500
20080107653 - Hybrid toxins comprising shiga-like toxin subunits fused to eschericihia coli heat labile enterotoxin subunits and vaccines thereof: The present invention relates to a hybrid bacterial toxin subunit, to a hybrid bipartite bacterial toxin and to nucleic acid molecules comprising a nucleotide sequence encoding such bacterial toxins. Furthermore, the invention relates to vaccines comprising said bacterial toxins and to their use in vaccines. Finally, the invention relates to... Agent: Intervet Inc. Patent Department
20080107655 - Human anti-ifn-gamma neutralizing antibodies as selective ifn-gamma pathway inhibitors: This invention provides antibodies that interact with or bind to human interferon-gamma (IFN-γ) and methods for treating IFN-γ mediated diseases by administering a pharmaceutically effective amount of antibodies to IFN-γ. Methods of detecting the amount of IFN-γ in a sample using antibodies to IFN-γ are also provided.... Agent: Brinks Hofer Gilson & Lione Utah Office
20080107656 - Immunogenic compositions and methods of use thereof: The present invention relates generally to a method of eliciting or otherwise inducing an immune response to a Plasmodium microorganism and compositions for use therein. More particularly, the present invention relates to a method of eliciting or otherwise inducing an immune response to a Plasmodium microorganism by administering an immunogenic... Agent: Seed Intellectual Property Law Group Pllc
20080107657 - Antibodies that bind to an epitope on the huntington's disease protein: The present invention relates generally to the generation and characterization of anti-huntingtin antibodies binding an epitope on the Huntington's disease protein. The invention further relates to the use of such anti-huntingtin antibodies in the diagnosis and treatment of Huntington's disease.... Agent: Knobbe Martens Olson & Bear LLP
20080107659 - Pharmaceutical compositions for the prevention and treatment of atherosclerosis and restenosis after ptca: The present invention provides a pharmaceutical composition for the prevention or treatment of angiostenosis, comprising a compound inhibiting the function of midkine (MK) in blood vessel tissues as an effective ingredient. The present invention is useful for the prevention or treatment of angiostenosis attributed to arteriosclerosis or restenosis after percutaneous... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association
20080107658 - Specific binding members for ngf: Specific binding members for Nerve Growth Factor (NGF), in particular anti-NGF antibody molecules, especially human antibody molecules, and especially those that neutralise NGF activity. Methods for using anti-NGF antibody molecules in diagnosis or treatment of NGF related disorders, including pain, asthma, chronic obstructive pulmonary disease, pulmonary fibrosis, other diseases of... Agent: Cooley Godward Kronish LLP Attn: Patent Group
20080107660 - Binding agents: The invention relates to binding agents which can be induced to aggregate in response to a specific stimulus. In preferred embodiments the binding agents comprise at least a binding member for a binding partner and the binding partner. At least one of the binding member and binding partner are reversibly... Agent: Dann, Dorfman, Herrell & Skillman
20080107661 - Muc1 and abl: The present disclosure provides methods of identifying and making compounds and pharmaceutical compositions thereof that inhibit the interaction between MUC1 and Abl. The invention also provides in vivo, in vitro, and ex vivo methods of inhibiting such an interaction. Also featured are in vitro and in vivo methods of stimulating... Agent: Fish & Richardson P.c.
20080107662 - Immunogenic peptides, nucleic acids encoding the same and use thereof in cancer treatment and diagnosis: The invention discloses alternative splice variants in Philadelphia chromosome positive leukemia, immunogenic peptides and proteins thereby produced and the use thereof in the preparation of antitumor agents.... Agent: Young & Thompson
20080107663 - Tri1 cells for use in atherosclerosis: The present invention relates to a method of treating or preventing atherosclerosis comprising administering to a mammal in need of such a treatment a) an antigen which has been used to activate in vitro a Tri cell population originating from said mammal, and b) the TO cell population activated by... Agent: Young & Thompson
20080107665 - Extracellular matrix materials as vaccine adjuvants for diseases associated with infectious pathogens or toxins: Disclosed are vaccines and vaccine adjuvants useful in the treatment and/or prevention of infection and diseases associated with infectious pathogens, such as tetanus, as well as diseases associated with biological toxins. Also provided are methods of preparing an adjuvant and the vaccine containing the adjuvant. Methods are also provided for... Agent: Bell, Boyd, & Lloyd LLP
20080107664 - Method for increasing cd8+ cytotoxic t cell responses and for treating multiple sclerosis: The present invention relates generally to the field of immunology and development of autologous vaccines. More specifically, the present invention is concerned with a method of treating autoimmune disease Multiple Sclerosis (MS) by means of immunizing patients with autologous CD8+ cells activated with fragments of Myelin Basic Protein (MBP). The... Agent: Polsinelli Shalton Flanigan Suelthaus Pc
20080107668 - Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer: The present invention relates to compositions and methods for the prevention, treatment, and diagnosis of cancer, especially carcinomas, such as breast carcinoma. The invention discloses peptides, polypeptides, and polynucleotides that can be used to stimulate a CTL response against breast or cancer.... Agent: Synnestvedt & Lechner, LLP
20080107669 - Method of producing an hiv-1 immune response: The present invention comprises novel and modified peptides capable of inducing an HIV-1 specific immune response without antagonizing the cytotoxic T-cell activity in order to achieve an effective prophylactic and therapeutic vaccine against HIV. The peptides are based on conserved regions of HIV gag p24 proteins. Antigens in free- or... Agent: Fitzpatrick Cella Harper & Scinto
20080107670 - Method of producing an hiv-1 immune response: The present invention comprises novel and modified peptides capable of inducing an HIV-1 specific immune response without antagonizing the cytotoxic T-cell activity in order to achieve an effective prophylactic and therapeutic vaccine against HIV. The peptides are based on conserved regions of HIV gag p24 proteins. Antigens in free- or... Agent: Fitzpatrick Cella Harper & Scinto
20080107666 - Non-glycosylated recombinant collagen-like polypeptides: The invention relates to recombinant collagen like polypeptides that are not glycosylated thereby reducing the immunogenicity of recombinant collagen-like polypeptides while at the same time preventing or reducing phosphorylation of these polypeptides. Such non-glycosylated polypeptides may be used in a wide variety of medical or cosmetic applications.... Agent: Foley And Lardner LLP Suite 500
20080107667 - Promiscuous her-2/neu cd4 t cell epitopes: The present invention relates to the discovery of novel T cell epitopes of the human HER-2/Neu protein that is promiscuous for at least 25 different HLA-DR alleles. The invention also relates to compositions that contain one of the novel epitopes or a fusion peptide of such a epitope and a... Agent: Townsend And Townsend And Crew, LLP
20080107672 - Hepatitis b virus surface antigen mutant and methods of detection thereof: The subject invention relates to a novel hepatitis B surface antigen mutant and methods of detecting this mutant, and/or antibodies thereto, in patient samples. In particular, the mutant contains a substitution of amino acid threonine for the amino acid alanine at position 123 in the amino acid sequence of the... Agent: Paul D. Yasger Abbott Laboratories
20080107671 - Yeast-based therapeutic for chronic hepatitis c infection: Disclosed are compositions, including vaccines, and methods for vaccinating an animal against hepatitis C virus (HCV) and for treating or preventing hepatitis C viral infection in an animal. The invention includes a variety of novel HCV fusion proteins that can be used directly as a vaccine or in conjunction with... Agent: Sheridan Ross Pc
20080107673 - Mutants of clostridium difficile toxin b and methods of use: An active, or passive vaccine utilizing purified non-toxic mutant TcdB toxins from Clostridium difficile for humans and animals against infections caused by C. difficile and/or C. sordellii. Persons most potentially affected by C. difficile infections include hospitalized patients, infants, and elderly persons. The TcdB toxin mutant of the vaccine preferably... Agent: Dunlap Codding & Rogers, P.c.
20080107674 - Proteinase k resistant surface protein of neisseria meningitidis: The identification of a highly conserved, immunologically accessible antigen at the surface of Neisseria facilitates treatment, prophylaxis, and diagnosis of Neisseria diseases. This antigen is highly resistant to Proteinase K and has an apparent molecular weight of 22 kDa on SDS-PAGE. Specific polynucleotides encoding proteins of this class have been... Agent: Seed Intellectual Property Law Group Pllc
20080107675 - Proteinase k resistant surface protein of neisseria meningitidis: The identification of a highly conserved, immunologically accessible antigen at the surface of Neisseria facilitates treatment, prophylaxis, and diagnosis of Neisseria diseases. This antigen is highly resistant to Proteinase K and has an apparent molecular weight of 22 kDa on SDS-PAGE. Specific polynucleotides encoding proteins of this class have been... Agent: Seed Intellectual Property Law Group Pllc
20080107676 - Proteinase k resistant surface protein of neisseria meningitidis: The identification of a highly conserved, immunologically accessible antigen at the surface of Neisseria facilitates treatment, prophylaxis, and diagnosis of Neisseria diseases. This antigen is highly resistant to Proteinase K and has an apparent molecular weight of 22 kDa on SDS-PAGE. Specific polynucleotides encoding proteins of this class have been... Agent: Seed Intellectual Property Law Group Pllc
20080107677 - Dermal drops: Dermal drops that, when applied topically to animal subjects, can ameliorate symptoms of conditions such as diabetes and Parkinson's disease are prepared as concentrates of the culture filtrate of a Basidiomycete fungus grown under appropriate conditions. The concentrate can also be used as a convenient source of liquid compost factor.... Agent: Morrison & Foerster LLP
20080107678 - Method for treating thrombotic disorders using sulfated polysaccharides: Methods for treating thrombotic disorders using sulfated polysaccharides such as fucoidans are disclosed.... Agent: Robins & Pasternak LLP
20080107679 - Skin care compositions including hexapeptide complexes and methods of their manufacture: Skin care compositions disclosed herein include, at a minimum, safe and effective amounts of at least one wrinkle reduction agent, which is a hexapeptide, and a natural exfoliating complex. The skin care compositions provide natural skin exfoliation, reduce fine lines and wrinkles, and improve skin elasticity and firmness.... Agent: Cislo & Thomas LLP
20080107680 - Modified human growth hormone: Modified growth hormone polypeptide and uses thereof are provided.... Agent: Attn: John W. Wallen, Iii Ambrx, Inc.
20080107681 - Feline vaccines against avian influenza: The present invention encompasses influenza vaccines, in particular avian influenza vaccines. The vaccine may be a recombinant poxvirus vaccine or an inactivated vaccine. The invention also encompasses recombinant poxvirus vectors encoding and expressing avian influenza antigens, epitopes or immunogens which can be used to protect animals, in particular felids, against... Agent: Judy Jarecki-black
20080107682 - Brucella melitensis mutants and methods: Certain attenuated mutants of Brucella, especially B. melitensis, B. abortus, B. suis and B. ovis, when administered to a human or animal trigger a protective immune response such that subsequent challenge with virulent Brucella of the same species does not result in disease or results in much less severe symptoms.... Agent: Greenlee Winner And Sullivan P C
20080107683 - Bacterial packaging strains useful for generation and production of recombinant double-stranded rna nucleocapsids and uses thereof: Bacterial packaging strains useful for generating recombinant double-stranded RNA nucleocapsids (rdsRNs) are provided. The packaging strains are useful for the production of RNA encoding vaccine antigens, bioactive proteins, immunoregulatory proteins, antisense RNAs, and catalytic RNAs in eukaryotic cells or tissues. Recombinant ssRNA is introduced into the strains and packaged to... Agent: Whitham, Curtis & Christofferson & Cook, P.c.
20080107684 - Composition comprising phosphatidyl serine and an antigen or allergen and the use thereof: Provided is a composition comprising a phosphatidyl serine receptor ligand for use in immune therapy. The composition may include an antigen or allergen together with the phosphatidyl serine receptor ligand. The compositions may be used for any type of immune therapy, such as immune modulation to an environmental antigen or... Agent: Law Office Of Karen Canaan
20080107685 - Live attenuated dengue 3 virus strains: The invention relates to live attenuated dengue serotype 3 virus strains which have been produced by site directed mutagenesis of an attenuated dengue 3 strain.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP
20080107686 - Vaccination with immuno-isolated cells producing an immunomodulator: The present invention relates to immuno-protected encapsulated cells producing an immunomodulator, for example GM-CSF (granulocyte-macrophage colony stimulating factor). The cells of the invention are particularly well adapted for providing an active adjuvant or immunomodulator, for example in the context of immunisation in humans and animals. These cells can be used... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c.
20080107687 - Feline vaccines against avian influenza: The present invention encompasses influenza vaccines, in particular avian influenza vaccines. The vaccine may be a recombinant poxvirus vaccine or an inactivated vaccine. The invention also encompasses recombinant poxvirus vectors encoding and expressing avian influenza antigens, epitopes or immunogens which can be used to protect animals, in particular felids, against... Agent: Judy Jarecki-black
20080107688 - Virulent systemic feline calicivirus: The present invention relates to a vaccine for immunization against a viral infection caused by a virulent systemic feline calicivirus (VS-FCV), a novel, atypical and unusually virulent form of a calicivirus that results in a highly contagious and fatal hemorrhagic fever syndrome. The present invention further encompasses methods of immunizing... Agent: Townsend And Townsend And Crew, LLP
20080107689 - Stable microbial inoculants and methods for production of them: The invention relates to an inoculant in the form of a stable storage paste including a microorganism, a solid carrier, one or more protective substances, and water. The invention further relates to a method for producing of the inoculant using a growth medium including a solid carrier.... Agent: Cantor Colburn, LLP
20080107690 - Compositions and methods for topical application and transdermal delivery of botulinum toxins: A composition for topical application of a botulinum toxin (including botulinum toxin derivatives) comprises a botulinum toxin and a carrier comprising a polymeric backbone comprising a long-chain polypeptide or nonpeptidyl polymer having attached positively charged branching or “efficiency” groups. The invention also relates to methods for reducing muscle paralysis and... Agent: Morgan & Finnegan, L.l.p.
20080107691 - Vibrio cholerae strains vcusm1 and vcusm4, method of producing same, and vaccine derivatives thereof: Metabolic auxotroph of Vibrio cholerae 0139 synonym Bengal which has a mutation in its hem A gene and which is not capable of synthesizing aminolevulinic acid (ALA) de novo and which is obtained from a parent strain originally isolated from a patient's coproculture having all the identifying characteristics of Vibrio... Agent: Lowe Hauptman Ham & Berner, LLP
20080107692 - Compositions and methods for the detection of trypanosoma cruzi infection: The invention provides antigenic T. cruzi polypeptides, polynucleotides, and fusions thereof, as well as compositions comprising same. Also provided are diagnostic kits and methods for the diagnosis of T. cruzi infection and in screening blood supplies.... Agent: Seed Intellectual Property Law Group Pllc
20080107693 - Hybrid or chimeric polynucleotides, proteins, and compositions comprising hepatitis b virus sequences: H-2 class I negative, HLA-A2.1 transgenic HHD mice were used for a comparative evaluation of the immunogenicity of HLA-A2.1 restricted human tumor-associated CTL epitopes. A hierarchy was established among these epitopic peptides injected into mice in IFA which correlates globally with their capacity to bind and stabilize HLA-A2.1 molecules. Co-injection... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP
20080107694 - Sustained release intraocular drug delivery systems comprising a water soluble therapeutic agent and a release modifier: A biocompatible, sustained release intraocular drug delivery system comprising a protein or polynucleotide therapeutic agent, a polymeric carrier for the therapeutic agent and a long chain fatty alcohol release modifier. The biocompatible, sustained release intraocular drug delivery system can be used to treat an ocular condition.... Agent: Allergan, Inc.
20080107695 - Long-wearing cosmetic composition: The present invention relates to a cosmetic composition particularly useful for the application of color such as in a foundation, lip gloss, lip stick, mascara, eye shadow, blush, and nail polish, for example. A cosmetic composition according to the present invention includes a film-forming silicone-containing polyurethane having a viscosity from... Agent: Avon Products, Inc.
20080107697 - Cosmetic composition comprising at least one polymer particle dispersed in at least one liquid fatty phase and at least one ester of at least one acid and at least one polyol ester: The present disclosure, in one embodiment, relates to a cosmetic composition for caring for or making up the skin and/or epidermal derivatives and/or lips, which comprises a physiologically acceptable medium comprising a) at least one liquid fatty phase, b) a dispersion of at least one polymer particle dispersed in the... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP
20080107696 - Film forming composition with spreading properties: A film forming composition with spreading properties derived from an aqueous emulsion comprising (I) colloidal silica core/silicone shell particles consisting of (a) 90 wt % to 10 wt % cores of colloidal silica and (b) 10 wt % to 90 wt % shells of polyorganosiloxane; (II) a polyalkyleneoxide modified trisiloxane;... Agent: Momentive Performance Materials Inc. Ip Legal
20080107698 - Antimicrobial cellulosic sheet: A cellulosic sheet for paper towel includes an anti-microbial lotion on the towel which increases water absorbency times (WAR) to further promote lotion transfer to the skin and increase lotion transfer effectiveness.... Agent: Patent Group Ga030-43 Georgia-pacific Llc
20080107699 - Method of using topical probiotics for the inhibition of surface contamination by a pathogenic microorganism and composition therefor: A method and composition is provided for application of probiotic microorganisms to a surface to prevent contamination by pathogenic microorganisms. The probiotic microorganisms may be bacteria, yeast or mold, such as bacteria of the Lactobacillus genus. Application of probiotic microorganisms may be to surfaces such as of the hands, or... Agent: Etherton Law Group, Llc
20080107701 - Solid composition for treating water: Solid water treatment compositions are provided comprising (a) a halogen-containing source; (b) a boron-containing source; and (c) a polyphosphate-containing source. Methods for their use are also provided.... Agent: Daniel Reitenbach Chemtura Corporation
20080107700 - Use of macrolides in pest control: There is now described a method of controlling pests with macrolide compounds; more specifically A) a method of controlling pests in and on transgenic crops of useful plants, such as, for example, in crops of maize, cereals, soya beans, tomatoes, cotton, potatoes, rice and mustard, with a macrolide compound, characterized... Agent: Syngenta Crop Protection , Inc. Patent And Trademark Department
20080107703 - Hydrogel for medical use: Disclosed is a substantially water-based medical hydrogel having at least 0.010 but no more than 50 crosslink points per molecule, as well as a dried material thereof. The hydrogel is obtained by crosslinking a gelatin having 20 to 30 amino groups per molecule and the same or greater number of... Agent: Birch Stewart Kolasch & Birch
20080107702 - Method for the immobilization of mediator molecules on inorganic and metallic implant materials: A mediator molecule is immobilized on the surface of a metallic or ceramic implant material. An anchor molecule (e.g., dialdehyde or cyanogen bromide) having a functional group that covalently binds the mediator molecule is covalently bound to the surface, and the mediator molecule is coupled to the functional group of... Agent: Foley & Lardner LLP
20080107704 - Block biodegradable copolymers for medical devices: Disclosed herein are implantable medical devices comprising controlled release biodegradable block copolymers or coated with controlled release block copolymers and at least one drug releasable from the block copolymer. The controlled release block copolymers comprise least two blocks selected from the group consisting of polyesters, polyethers, and polyurethanes.... Agent: Medtronic Vascular, Inc. Ip Legal Department
20080107705 - Chymopapain isoenzymes, compositions, and uses thereof: The present invention provides novel chymopapain isoenzymes, compositions thereof, and methods for locally ad-ministering recombinant chymopapain or synthetic chymopapain to treat a disc disorder. Recombinant chymopapain or synthetic chymopapain useful in the methods of the invention can be naturally occurring chymopapain or variant chymopapain, including the novel chymopapain isoenzmyes of... Agent: Merchant & Gould Pc
20080107706 - Osteogenic oligonucleotides and uses thereof: Oligonucleotides having the ability to stimulate osteogenesis in vertebrate animals, including humans, are disclosed. These osteogenic oligonucleotides can be used in a wide range of clinical procedures to replace and restore osseous and periodontal defects or to facilitate the successful implantation of prosthesis and distraction procedures in bones. Methods for... Agent: Jacobson Holman Pllc
20080107707 - Polymerizable antimicrobial composition: The present invention provides a polymerizable antimicrobial composition and a method for using the same. The polymerizable antimicrobial composition of the invention comprises an antimicrobial compound, a linker, and a polymerizable function group.... Agent: Don D. Cha
20080107709 - Radio-opaque polymeric biomaterials: Iodinated and/or brominated derivatives of aromatic dihydroxy monomers are prepared and polymerized to form radio-opaque polymers. The monomers may also be copolymerized with other dihydroxy monomers. The iodinated and brominated aromatic dihydroxy monomers can be employed as radio-opacifying, biocompatible non-toxic additives for other polymeric biomaterials. Radio-opaque medical implants and drug... Agent: Fox Rothschild LLP Princeton Pike Corporate Center
20080107708 - Tropoelastin-based protoelastin biomaterials: Biocompatible materials suitable for use in vascular applications have been engineered, combining human recombinant tropoelastin with other synthetic or natural biomaterials to form protoelastin. The materials can be in the form of elastin films on metal, bone, ceramic or polymer substrates, laminates of alternating polymer and elastin, blends of polymer... Agent: Patrea L. Pabst Pabst Patent Group LLP
20080107710 - Collagen carrier of therapeutic genetic material and method: A collagen matrix material is charged with a cell growth-promoting derived nucleic acid sequence. The nucleic acid sequence-charged collagen matrix material may be utilized in a method of promoting regeneration of surface cartilage of a joint. In the method, an area of injury is covered with the nucleic acid sequence-charged... Agent: Rothwell, Figg, Ernst & Manbeck, P.c.
20080107711 - Bioabsorbable implantable material fortified with antibiotics for localized delivery of drugs: A bioabsorbable, implantable, flexible sheet of material contains a predetermined quantity of one or more selected antibiotics. The sheet of material is adapted to be placed inside a body for delivery of antibiotics. The sheet of material may be an implantable plastic or other suitable implantable material. The antibiotics may... Agent: Gardere Wynne Sewell LLP Intellectual Property Section
20080107712 - Ocular implant made by a double extrusion process: The invention provides biodegradable implants sized for implantation in an ocular region and methods for treating medical conditions of the eye. The implants are formed from a mixture of hydrophilic end and hydrophobic end PLGA, and deliver active agents into an ocular region without a high burst release.... Agent: Allergan, Inc.
20080107713 - Contact lens as a sustained drug delivery implant: A drug delivery device includes a contact lens having an optical axis and a plurality of discrete drug delivery zones asymmetrically disposed about the optical axis. A weighted area is provided in the contact lens for maintaining a presence of the contact lens upper hemispherical region in position with an... Agent: Walter A. Hackler, Ph.d. Patent Law Office
20080107714 - Use of a vector comprising a nucleic acid encoding an anti-angiogenic factor for the treatment of corneal neovascularization: The invention concerns the use of a vector comprising a nucleic acid coding for an anti-angiogenic factor for preventing, improving and/or treating corneal neovascularization.... Agent: Andrea Q. Ryan Sanofi-aventis U.s. Llc
20080107715 - Pharmaceutical containing food compositions and uses thereof: A method of delivering nutrition and one or more pharmaceutical agents to a patient after obesity surgery to enhance the patient's nutritional intake and/or compliance with oral medication(s) may include: providing a food product in an amount suitable for fitting within a stomach of the patient after the obesity surgery,... Agent: Townsend And Townsend And Crew, LLP
20080107716 - Antimicrobial tissue products with reduced skin irritation potential: A non-irritating antimicrobial multi-layer or multi-ply tissue product made by treating an inner layer or ply or an inner surface of an inner layer or ply with one or more antimicrobial agents and treating the one or more outer layers or plies or the outer surfaces of the layers or... Agent: Kimberly-clark Worldwide, Inc. Catherine E. Wolf
20080107717 - Methods and materials including treating acne related applications: The present invention provides novel methods and materials including for treating acne and including methods comprising administering to a subject a composition comprising a therapeutically effective amount of XMP.629 or a pharmaceutically acceptable salt or derivative thereof.... Agent: Bell, Boyd, & Lloyd Llc
20080107718 - Wound covering and production process: The invention relates to a production process for a foam wound dressing having an external germ barrier, more particularly a film layer, and also to a wound dressing thus obtained, having, where appropriate, a pressure-sensitive adhesive layer. In the process according to the invention the germ barrier is produced by... Agent: Shoemaker And Mattare, Ltd
20080107719 - Transdermal drug delivery system: A transdermal drug delivery system includes a drug source, an adhesive for applying the system to a skin surface, a penetration enhancer for enhancing penetration of the drug into the skin surface, an energy source and a contact for conveying energy from said energy source through said adhesive and the... Agent: Walter A. Hackler, Ph.d. Patent Law Office
20080107720 - Topical delivery of codrugs: The present invention provides pharmaceutical compositions for topical delivery comprising a suitable carrier and a codrug capable of penetrating, or being transported across, the dermis. The codrug according to the invention comprises a first constituent moiety linked to a second constituent moiety, wherein the second constituent moiety is the same... Agent: Ropes & Gray LLP
20080107721 - Combination chemotherapy comprising a liposomal platinum complex: The present invention relates to methods for treating cancer comprising administering a combination of a liposomal platinum complex and one or more additional anticancer agents, pharmaceutical compositions comprising a liposomal platinum complex and one or more additional anticancer agents, and kits comprising unit doses of a liposomal platinum complex and... Agent: Jones Day
20080107722 - Method for loading multiple agents into delivery vehicles: This invention relates to encapsulation of drugs and other agents into preformed delivery vehicles.... Agent: Morrison & Foerster LLP
20080107724 - Method of inhibiting side effects of pharmaceutical compositions containing amphiphilic vehicles or drug carrier molecules: A method is provided for inhibiting or preventing toxicity and other unwanted effects (a) caused by solvents for pharmaceuticals which solvents or emulsifier which contain amphiphilic molecules such as polyethoxylated oils or a derivative thereof, or (b) caused by a drug in a vehicle containing amphiphilic molecules such as phopholipids... Agent: Venable LLP
20080107723 - Methods of treating pulmonary distress: Provided is a method of increasing the forced expiratory volume in one second (FEV1) in a subject comprising administering to the subject in need thereof a therapeutically effective amount of a liposomal formulation. In some embodiments, the liposomal formulation comprises empty liposomes. Also provided is a method of increasing FEV1... Agent: Foley Hoag, LLP Patent Group, World Trade Center West
20080107726 - Compositions comprising beta-adrenergic receptor antagonists and diuretics: Pharmaceutical compositions comprise beta-adrenergic receptor blocking agents for controlled release and diuretics for immediate release. In an embodiment, a composition comprising metoprolol succinate is coated onto inert particles, and the particles are further coated with a polymer to provide controlled release of metoprolol. The coated particles are coated, granulated, or... Agent: Dr. Reddy's Laboratories, Inc.
20080107725 - Pharmaceutical solid dosage forms comprising amorphous compounds micro-embedded in ionic water-insoluble polymers: The present invention provides novel pharmaceutical solid dosage forms for oral administration comprising a therapeutically effective amount of an unstable crystalline form or an amorphous form of a therapeutically effective compound micro-embedded into an ionic water-insoluble polymer. The therapeutically effective compounds, which have a tendency to gel, are micro-embedded into... Agent: Hoffmann-la Roche Inc. Patent Law Department
20080107727 - Multiple unit oral sustained release preparation and production method thereof: Specifically, granules or powders comprising imidafenacin dispersed in a water-insoluble polymer or a higher alcohol are used in the preparation. These preparations achieve sustained release of imidafenacin since the molecular network structure that the water-insoluble polymer or the higher alcohol forms during the preparation of the granules or powders serves... Agent: Wenderoth, Lind & Ponack, L.l.p.
20080107728 - Formula and method for making relief lozenges and method by which ingredients in lozenges are delivered to user: A lozenge or tablet which has a lozenge or tablet base, eleuthero, St. John's Wort, Valerian, and Passion flower.... Agent: Barnes & Thornburg LLP
20080107729 - Orally disintegrating compositions: This invention provides a solid pharmaceutical composition comprising an active ingredient (e.g., rasagiline) or a pharmaceutically acceptable salt thereof, and particles having a non-filamentous microstructure of at least two sugar alcohols. This invention also provides a solid pharmaceutical composition comprising an active ingredient (e.g., rasagiline) or a pharmaceutically acceptable salt... Agent: Morgan, Lewis & Bockius LLP
20080107730 - Sustained release pharmaceutical preparations and methods for producing the same: An extended release tablet comprising a core including albuterol sulfate and extended release agent; and an extended release coating on the core to provide for sustained release of the albuterol sulfate.... Agent: Foley And Lardner LLP Suite 500
20080107731 - Dpp iv inhibitor formulations: The present invention relates to pharmaceutical compositions of DPP IV inhibitors with an amino group, their preparation and their use to treat diabetes mellitus.... Agent: Michael P. Morris Boehringer Ingelheim Corporation
20080107732 - Gastric retention system: The present invention provides a novel gastric retention system in the form of a tablet or a capsule coated with an expandable coating, more particularly, with an expandable coating comprising a film-forming polymer and an expandable component.... Agent: Sughrue Mion, Pllc
20080107733 - Formulation obtained from a powder mixture comprising an inorganic pigment: A solid dosage form having a matrix with at least one active compound dispersed homogeneously in the matrix, which is obtainable by melting a powder mixture, wherein the powder mixture comprises at least one thermoplastic binder and a combination of highly disperse silica and at least one inorganic pigment, is... Agent: Edwards Angell Palmer & Dodge LLP
20080107734 - Healing powder and method of use thereof: A wound healing powder, comprising a sugar selected from the group consisting of one or more pharmaceutically acceptable monosaccharides and disaccharides, in an amount of at least 25% by weight of the powder mixture; and an absorbent agent which forms a bioabsorbable biocompatible matrix with wound secretions, comprising a polymer... Agent: Milde & Hoffberg, LLP
20080107735 - Macrocyclic formulations for transmembrane drug delivery: Topically applied pharmaceutical products comprising (a) an active ingredient, (b) an organogel, and (c) a non-irritating permeation enhancer, are disclosed, along with and methods of use and formulations thereof. The topically applied products and methods are intended to be used to enhance any of the transdermal, subdermal, transmembrane, musculoskeletal, transungual,... Agent: Raymond E. Stauffer, Esq. C/o Carella, Byrne, Bain, Gilfillan,
20080107743 - Composition and method for enhancing skin cell growth, proliferation and repair: A skin treatment composition is provided which contains calcium glycerophosphate and a fatty acid source derived from an animal or a vegetable. The composition enhances skin cell proliferation and growth and repair of damage to skin cells. Methods for enhancing skin cell repair, proliferation, and growth and for enhancing ceramide... Agent: Panitch Schwarze Belisario & Nadel LLP
20080107737 - Crosslinked amine polymers: The present invention provides methods and compositions for the treatment of ion imbalances. In particular, the invention provides polymeric and pharmaceutical compositions comprising crosslinked amine polymers. Methods of use of the polymeric and pharmaceutical compositions for therapeutic and/or prophylactic benefits are disclosed herein. Examples of these methods include the treatment... Agent: Senniger Powers LLP (ilps)
20080107744 - Injectable hollow tissue filler: The present invention comprises a plurality of injectable hollow particulate fillers suspended in a biocompatible fluid carrier to significantly improve the clumping resistance and injectability of the composition. The hollow particulate fillers have a lower effective density and are able to suspend in the carrier without precipitation. The loss of... Agent: Jack Chu
20080107739 - Medical nanobody: A particle-sized nanobody that can be inserted into at least one major physiological system of a mammal's body such as the blood stream or the gastro-intestinal track or other system. The nanobody of the present invention can remain in the system for a predetermined time to perform a predetermined task.... Agent: Clifford Kraft
20080107738 - Ophthalmic emulsions containing prostaglandins: Cationic ophthalmic oil-in-water type emulsions, include colloid particles having an oily core surrounded by an interfacial film, the emulsion including at least one cationic agent and at least one non ionic surfactant, the oily core including a prostaglandin selected from the group comprising in particular latanoprost, unoprostone isopropyl, travoprost, bimatoprost,... Agent: Young & Thompson
20080107736 - Pharmaceutically active nanosuspensions: The present disclosure is directed at a pharmaceutically active nanoparticle suspension that may be optically clear. Such suspensions may be formed by selective dissolution of a pharmaceutically active compound in a first solvent followed by introduction into a second solvent, such as an aqueous medium, without substantial use of surfactants... Agent: Grossman, Tucker, Perreault & Pfleger, Pllc
20080107746 - Anti-inflamatory inhalation pharmaceutical composition: The present invention is directed to the discovery of the anti-inflammatory properties of basic amino salts of acetylcysteine when administered directly to the lungs and/or the nose. This observed inflammation reduction in the lungs and/or the nasal cavity is confirmed by the diminution of at least one of the following... Agent: Lowe Hauptman Ham & Berner, LLP
20080107742 - Compositions and methods for removing urushiol and treating the resulting skin condition: The present application is directed to various compositions to treat the itching and conditions that result from contracting poison ivy, poison oak, and poison sumac, as well as other plant and substances that contain substances that lead to a skin reaction but that upon removal alleviate the symptoms of the... Agent: William Douglas Hare
20080107745 - Controlled release sterile injectable aripiprazole formulation and method: A controlled release sterile freeze-dried aripiprazole formulation is provided which is formed of aripiprazole of a desired mean particle size and a vehicle therefor, which upon constitution with water and intramuscular injection releases aripiprazole over a period of at least about one week and up to about eight weeks. A... Agent: Sughrue Mion, Pllc
20080107741 - Nanoparticulate compositions of angiogenesis inhibitors: Nanoparticulate compositions comprising at least one poorly soluble angiogenesis inhibitor and at least one surface stabilizer are described. The nanoparticulate compositions have an average particle size of less than about 2000 nm. The invention also describes methods of making and using such compositions.... Agent: Foley & Lardner LLP
20080107740 - Pharmaceutical composition comprising salmeterol and budesonide for the treatment of respiratory disorders: Pharmaceutical composition for inhalation, containing as active ingredient effective amounts of salmeterol or a physiologically salt of salmeterol or a solvate thereof, and budesonide or a therapeutically salt of budesonide or a solvate thereof, wherein the molecular ratio of salmeterol component to budesonide component is in the range 1:2 to... Agent: Dickinson Wright Pllc
20080107747 - Pain relief composition: Disclosed is a pain relief composition comprising an effective amount of a nerve inhibiting component, including capsaicin, a capsaicinoid or a capsaicin analogue, which numbs or inhibits the nerve endings that signal pain, in combination with at least one of the following: an effective amount of an inflammation control component... Agent: Cislo & Thomas LLP
20080107748 - Microcapsules for removing and absorbing a chemical from a mixture: A microcapsule comprising a chemical skeleton with at least one ligand attached to the chemical skeleton. The chemical skeleton is placed within a capsule. The capsule can then separate a substance from a mixture. The capsule is placed within the mixture and the substance is allowed to enter the capsule.... Agent: Nathaniel Gordon-clark
20080107749 - Water-dispersible oral, parenteral, and topical formulations for poorly water soluble drugs using smart polymeric nanoparticles: Polymeric nanoparticles with a hydrophobic core and a hydrophilic shell are formed from: 1) N-isopropyl acrylamide (NIPAAM), at a molar ratio of about 50% to about 90%, and preferably 60% for specific delivery routes such as oral or parenteral; either water-soluble vinyl derivatives like vinylpyrolidone (VP) or vinyl acetate (VA),... Agent: Whitham, Curtis & Christofferson & Cook, P.c.
20080107750 - Graft materials containing ecm components, and methods for their manufacture: Described are packaged, sterile medical graft products containing controlled levels of a growth factor such as Fibroblast Growth Factor-2 (FGF-2). Also described are methods of manufacturing medical graft products wherein processing, including sterilization, is controlled and monitored to provide medical graft products having modulated, known levels of a extracellular matrix... Agent: Woodard, Emhardt, Moriarty, Mcnett & Henry LLP
20080107751 - Antimicrobial wax composition for wax therapy: A wax composition comprises a wax and an antimicrobial agent in an amount effective to inhibit the growth of micro-organisms in the wax in both solid and liquid states. According to the preferred embodiment of the present invention, the wax composition comprises a wax that is solid at room temperature,... Agent: Storm LLP
20080107752 - Modified elapid venoms as stimulators of the immune reaction: Detoxified cobra venom and its constituent neurotoxins have been reported to have potent antiviral activity. Others have reported that snake venoms were generally immune stimulants. Recent research has revealed more specific details on the effects of detoxified venoms and isolated alpha-neurotoxins on cells of the immune system. Exposure of the... Agent: Robert J. Van Der Wall Gables One Tower
20080107753 - Compositions to alleviate menopausal symptoms: Compositions and methods of preparing and using such compositions to treat the symptoms of perimenopause and menopause.... Agent: Cr Miles, P.c. Craig R. Miles
20080107754 - Dietary supplement and a method to enhance sleep and lucid dreaming: A nutritional supplement for enhancing sleep and lucid dreaming in humans. It contains a combination of ingredients in proportions calculated to enhance lucid dreaming. The primary ingredients are Calea zacatechichi, L-5-Hydroxytryptophan (L-5-HTP), and Vinpocetine. In addition, the nutritional supplement may include the secondary ingredient Melatonin and the tertiary ingredients Wild... Agent: Brown & Michaels, Pc 400 M & T Bank Building
20080107755 - Methods and compositions for altering cell function: The present invention relates to compositions and methods for altering cell function. In particular, the present invention provides compositions comprising selenium (e.g., SEL-PLEX) and methods of using the same (e.g., as a therapeutic and/or prophylactic treatment). Additionally, the present invention demonstrates that specific forms of selenium (e.g., SEL-PLEX), when administered... Agent: Casimir Jones, S.c.
20080107756 - Lithium combinations, and uses related thereto: The present invention relates to combinatorial therapies for treating anxiety, depression or psychotic conditions using a lithium salt and a psychoactive drug selected from the group consisting of serotonin reuptake inhibitor, a 5HT2 receptor antagonist, an anticonvulsant, a norepinephrine reuptake inhibitor, an α-adrenoreceptor antagonist, an NK-3 antagonist, an NK-1 receptor... Agent: Irving M. Fishman C/o Cohen, Tauber, Spievack, And Wagner
20080107757 - Sophorae subprostratae radix extract for prevention and treatment of respiratory diseases: The present invention relates to an extract isolated from Sophorae Radix useful for prevention and treatment of respiratory diseases. More specifically, the present invention relates to a pharmaceutical drug comprising the Sophorae Radix extract having excellent effects of inhibiting airway contraction, respiratory infections, 5-lipoxygenase activity, phosphodiesterase 4 activity, airway hyper-responsiveness... Agent: Frommer Lawrence & Haug
20080107758 - Topical steroid spray with botanic seed oils: A pharmaceutical topical spray composition of corticosteroid, an alcohol, a propellant, and botanic seed oils having a blend of black raspberry seed oil, black cumin seed oil, and red raspberry seed oil prepared according to a cold press method. A method for treating an inflammatory skin condition using the administration... Agent: Briggs And Morgan P.a.
20080107760 - Beverage and medicament containing bamboo extract as a main ingredient: The present invention relates to a beverage containing bamboo extract as a main ingredient, for details, a beverage containing bamboo extract as the main ingredient, which is useful for amelioration of diabetes, cancer, life-style related diseases or the like. A beverage characterized in containing, as the main ingredient, bamboo extract... Agent: Ladas & Parry
20080107759 - Composition comprising bamboo extract and the compounds isolated therefrom showing treating and preventing activity for inflammatory and blood circulation disease: The present invention relates to a composition comprising a bamboo plant extract for the prevention and treatment of inflammatory or blood circulation disease. The extracts of bamboo plant has potent anti-inflammatory activity by inhibiting NO production and blood circulation-improving activity by inhibiting elastase activity and healing the wound of vascular... Agent: Swanson & Bratschun, L.l.c.
20080107761 - Composition and method for promoting the production of and/or enhancing the activity of fibulin-5: There is provided a composition for promoting the production of and/or enhancing the activity of fibulin-5, said composition comprising as an active ingredient one or a plurality of pharmaceutical agents selected from the group consisting of extracts of Caesalpinia crista, extracts of Psophocarpus tetragonolobus, phytic acid and a pharmaceutically acceptable... Agent: Snider & Associates
20080107762 - Neurotoxin component treatment for spasticity: A method and composition for treating a patient suffering from a disease, disorder or condition and associated pain include the administration to the patient of a therapeutically effective amount of a neurotoxin selected from a group consisting of Botulinum toxin types A, B, C, D, E, F and G.... Agent: Allergan, Inc.
20080107763 - Use of the neurotoxic component of a botulinum toxin for treating a spastic muscle: A method and composition for treating a patient suffering from a disease, disorder or condition and associated pain include the administration to the patient of a therapeutically effective amount of a neurotoxin selected from a group consisting of Botulinum toxin types A, B, C, D, E, F and G.... Agent: Allergan, Inc.05/01/2008 > patent applications in patent subcategories. archived by USPTO category
20080102026 - Hypoxia-selective, weakly basic 2-nitroimidazole delivery agents and methods of use thereof: The invention features a class of 2-nitroimidazole compounds with a secondary basic nitrogen atom and a linker bearing one or more therapeutic agents, cytotoxic agents, detectable labels, or chelating groups. In particular, the invention provides 2-nitroimidazole compounds containing a cluster of boron atoms for use in boron neutron capture therapy... Agent: Clark & Elbing LLP
20080102027 - Targer for b-cell disorders: The present invention relates to the diagnosis and treatment of B-cell disorders such as multiple myeloma (MM). In particular, the present invention relates to the treatment of B-cell disorders using ligands which bind to free lambda light chains expressed on the surface of lymphoid cancer cells.... Agent: Marshall, Gerstein & Borun LLP
20080102028 - Methods for preparing 2-methoxyisobutylisonitrile and tetrakis(2-methoxyisobutylisonitrile)copper(i) tetrafluoroborate: The present invention relates to new synthetic methods for preparing 2-methoxyisobutylisonitrile and metal isonitrile complexes, such as tetrakis(2-methoxyisobutylisonitrile)copper(I) tetrafluroroborate, which are used in the preparation of technetium (99mTc) Sestamibi, and novel intermediate compounds useful in such methods.... Agent: Darby & Darby P.C.
20080102033 - Preparation for the prophylaxis of restenosis: The invention relates to a preparation for restenosis prevention. The preparations for restenosis prevention known as yet do not reach sufficient active agent concentrations in the affected sections of the vascular walls as higher doses cause undesirable side effects. The present invention is a preparation to which at least one... Agent: Millen, White, Zelano & Branigan, P.C.
20080102034 - Preparation for the prophylaxis of restenosis: The invention relates to a preparation for restenosis prevention. The preparations for restenosis prevention known as yet do not reach sufficient active agent concentrations in the affected sections of the vascular walls as higher doses cause undesirable side effects. The present invention is a preparation to which at least one... Agent: Millen, White, Zelano & Branigan, P.C.
20080102035 - Medical device having discrete regions: An apparatus prepares a medical device from a polymeric composition having properties such as increased visibility of the device and the ability to deliver therapeutic and other agents. The device is constructed with additives incorporated into the polymeric structure, such as a material that increases visibility of the device, while... Agent: Philip S. Johnson Johnson & Johnson
20080102036 - Biocompatible fluorescent silicon nanoparticles: The invention features biocompatible fluorescent nanoparticle and their use in in vivo imaging methods.... Agent: Goodwin Proctor
20080102039 - Betamethasone spray: A spray foaming dosage form comprising betamethasone valerate, dimethyl isosorbide, propylene glycol, non ionic surfactant, sodium dodecyl sulphate, a buffer, optional preservative, optional further excipients, and water.... Agent: Daniel B. Schein, Ph.d., Esq., Inc.
20080102038 - Clobetasol spray: A spray foaming dosage form comprising clobetasol propionate, dimethyl isosorbide, propylene glycol, polysorbate, sodium dodecyl sulphate, buffer, optional preservative, optional further excipients, and water.... Agent: Daniel B. Schein, Ph.d., Esq., Inc.
20080102042 - Oral composition: The present invention provides an oral composition which is effective for the prevention or treatment of periodontal disease such as gingivitis, periodontitis and alveolar pyorrhea. According to the present invention, there can be provided an oral composition such as a dentifrice, a mouthwash or a gingival massage cream which is... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP
20080102041 - Teeth stain inhibitor composition and methods of use thereof: The invention provides ingestible compositions for reducing or inhibiting teeth stain, and methods for using the same.... Agent: Faegre & Benson LLP Patent Docketing
20080102044 - Raw material for cosmetic preparation containing benzoate and cosmetic preparation containing such raw material: Disclosed is a raw material for cosmetic preparations having excellent gloss imparting properties and oxidation stability. Also disclosed is a cosmetic preparation having excellent gloss and feeling of use. The raw material for cosmetic preparations contains an ester compound of (A) benzoic acid, (B) an alcohol selected from the group... Agent: Mcginn Intellectual Property Law Group, PLLC
20080102048 - Long-wearing cosmetic product system for providing extended shine and gloss: A method of making-up a keratinous substrate involving: (a) providing a keratinous substrate; (b) applying a basecoat composition onto the keratinous substrate, the basecoat composition comprising: (i) at least one silicone- polyamide copolymer; (ii) at least one silicone film former; (iii) at least one volatile oil; and (iv) at least... Agent: L'oreal Usa/ Patent Department
20080102049 - Long-wearing cosmetic product system having high shine and gloss: A method of making-up a keratinous substrate involving: (a) providing a keratinous substrate; (b) applying a basecoat composition onto the keratinous substrate, the basecoat composition comprising: (i) at least one (co)polymer comprising at least one organosiloxane unit and at least two other groups capable of forming hydrogen interactions chosen from... Agent: L'oreal Usa/ Patent Department
20080102050 - Water-based skin care composition with polyalkylsilsesquioxane powder emulsion and method for making the same: A process for making a water-based skin care composition including blending a polyalkylsilsesquioxane powder emulsion and water. A skin care composition made by the process is also presented, which is easy to prepare and do not require additional heating or further emulsification of the skin care formulation.... Agent: General Electric Co. Global Patent Operation
20080102051 - Use of polyols to increase stiffness in low voc hair styling products: Low to no-VOC hair styling compositions are described that comprise at least one synthetic polymer or copolymer, a starch, modified starch or other cellulosic material and a polyol. Due to the presence of at least one polyol, the compositions of the present invention provide hard-hold to hair with great durability,... Agent: The Dial Corporation
20080102052 - Aldehyde conjugated flavonoid preparations: There is provided a method of conjugating a polymer containing a free aldehyde group with a flavonoid in the presence of an acid catalyst, such that the polymer is conjugated to the C6 or C8 position of the flavonoid A ring. The resulting conjugates may be used to form delivery... Agent: Klarquist Sparkman, LLP
20080102054 - Compositions containing agm cells and methods of use thereof: The invention features a therapeutic composition containing mammalian, preferably human, post-fetal, AGM cells in a pharmaceutically acceptable carrier. The compositions of the invention can be administered to treat patients suffering from autoimmune diseases, to treat patients in need of organ or cell regeneration, and to treat patients in need of... Agent: Clark & Elbing LLP
20080102056 - Marketing system for improving patient compliance and methods and devices relating to same: The present invention provides a marketing system and methods for marketing a dosage form comprising interferon gamma (IFN-γ) to a patient in need thereof, for the treatment of idiopathic pulmonary fibrosis (IPF). The present invention further provides a method for increasing patient compliance. The present invention further provides methods of... Agent: Marshall, Gerstein & Borun LLP
20080102062 - Novel bacillus amyloliquefaciens ktgb0202 and control method of plant pathogenic fungi using that: The present invention relates to a novel microorganism Bacillus amyloliquefaciens KTGB0202 and a method for controlling plant pathogens using the same. More particularly, the present invention relates to a novel microorganism Bacillus amyloliquefaciens KTGB0202 (accession number: KCTC 10564BP) bacterium which has an excellent control effect against crop powdery mildew and... Agent: Park Law Firm
20080102058 - Stromal cell use: The invention relates to the use of marrow stromal cells to enhance hematopoiesis in a mammal.... Agent: Seed Intellectual Property Law Group PLLC
20080102063 - Methods and compositions for stem cell therapies: The present invention includes methods and compositions for the differentiation of stem cells and enhancement of stem cell therapies. In certain embodiments, the present invention includes methods and compositions of autoimmune T-cells reactive to the desired cell type or types cultured with stem cells to induce differentiation of the stem... Agent: Morrison & Foerster LLP
20080102029 - Loadable polymeric particles for enhanced imaging in clinical applications and methods of preparing and using the same: Particles are provided for use in therapeutic and/or diagnostic procedures. The particles include poly[bis(trifluoroethoxy)phosphazene] and/or a derivatives thereof which may be present throughout the particles or within an outer coating of the particles. The particles can also include a core having a hydrogel formed from an acrylic-based polymer. Such particles... Agent: Sutherland Asbill & Brennan LLP
20080102030 - Particles for cell targeting: Provided is a composition that includes oblate spheroidal particles comprising an active agent, such as a therapeutic or imaging agent, and a method for treating or monitoring a physiological condition, such as a disease, by administering the composition to a subject in need thereof. Also provided are methods for making... Agent: Conley Rose, P.C. David A. Rose
20080102031 - Spirocyclic heterocyclic derivatives and methods of their use: Spirocyclic heterocyclic derivatives, pharmaceutical compositions containing these compounds, and methods for their pharmaceutical use are disclosed. In certain embodiments, the spirocyclic heterocyclic derivatives are ligands of the δ opioid receptor and may be useful, inter alia, for treating and/or preventing pain, anxiety, gastrointestinal disorders, and other δ opioid receptor-mediated conditions.... Agent: Woodcock Washburn LLP
20080102032 - Methods of treating diabetes using inhibitors of arnt2: The invention provides methods of screening for compounds that decrease ARNT2 expression, levels or activity, for the treatment and prevention of diabetes-related disorders, including type 1 and type 2 diabetes mellitus, impaired glucose tolerance, insulin resistance and beta cell dysfunction; compounds identified by said screening methods; and methods of using... Agent: Fish & Richardson PC
20080102037 - Stable pharmaceutical budesonide preparation for producing propellant-free aerosols: The invention relates to ethanol-containing pharmaceutical preparations for the production of propellant-free aerosols.... Agent: Michael P. Morris Boehringer Ingelheim Corporation
20080102040 - Inhibition of factor b, the alternative complement pathway and methods related thereto: Disclosed are novel inhibitors of the alternative complement pathway and particularly, novel anti-factor B antibodies. Also disclosed is the use of such inhibitors to reduce or prevent airway hyperresponsiveness and/or airway inflammation by selectively inhibiting the alternative complement pathway, thereby treating diseases in which such conditions play a role. Also... Agent: Morrison & Foerster LLP
20080102043 - Antimicrobial flavor and oral care compositon containing the same: The present invention provides antimicrobial flavors and flavor compositions which are of high safety and little influential on intestinal bacteria, as well as oral care compositions and foods containing the same. The flavor is selected from dihydrofarnesol, isocamphylcyclohexanol, levosandol, bacdanol, Santalinol, methyl atrarate, 10-undecen-1-ol, 2-methyl undecanal, sandalol, dodecanal, brahmanol, neroridol,... Agent: Sughrue Mion, PLLC
20080102045 - Topical preparations containing antioxidant extracts of broccoli, green tea, and red tea: A topical preparation, which includes sunscreens, UV protective lotions and cosmetics is described which includes, at least one physical agent compound, at least one natural or chemically-derived extract, and at least one additional compound. In addition, methods for preparing these topical preparations are disclosed which include: providing at least one... Agent: Buchalter Nemer
20080102046 - Cosmetic composition: at least one interference pigment dispersed in this aqueous phase, capable of generating, when the composition is applied to a support, overbrightness points with an intensity of greater than or equal to 3500 cd·m−2 and with a dominant wavelength of between 580 and 650 nm.... Agent: Oliff & Berridge, PLC
20080102047 - Cosmetic preparation for coloring the eyelids and eyebrows: An aqueous cosmetic preparation for coloring the eyelids and eyebrows contains 0.1% by weight to 5% by weight of polyvinyl pyrrolidone; 4% by weight to 25% by weight of an alcohol from the group of ethanol and propanol; 2% by weight to 15% by weight of a dampening agent; 0.1%... Agent: Lerner Greenberg Stemer LLP
20080102053 - Enhanced antimicrobial skin preparation: An antimicrobial skin composition comprised of an antimicrobial agent, an alcohol, one or more pH sensitive viscosity builders, a plasticizer and water. Preferably, the viscosity builders of the present invention are comprised of pH sensitive methacrylic polymers which are alcohol compatible and have pH controlled water solubility. The composition combines... Agent: Dinsmore & Shohl LLP
20080102055 - Method for detecting alzheimer's disease: The present invention provides a method for detecting or diagnosing in vitro Alzheimer's disease, or memory and/or cognitive disorders, using a human biological sample and the inactivation of STAT3 protein as an indication, and a method for screening for a therapeutic drug for Alzheimer's disease or memory and/or cognitive disorders,... Agent: Birch Stewart Kolasch & Birch
20080102057 - Bipotential liver cell lines from wild-type mammalian liver tissue: The present invention relates to a hepatic cell line derived from wild-type mammalian liver tissue by culture methodology, the cells of the cell line being capable of differentiating into hepatocytes and bile duct cells. The present invention also relates to methods of producing such cells as well as to their... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.
20080102060 - Methods of using bcl-2 for the therapeutic treatment and prevention of diseases: The invention provides a method of treating a disease or pathological condition resulting in apoptotic cell death. The method includes increasing the activity of Bcl-2 in cells affected by the disease or pathological condition. Diseases or pathological conditions can include, for example, neurodegenerative diseases, cancer and viral infections. Also provided... Agent: Mcdermott, Will & Emery
20080102061 - Use hydrolyzed medium containing microorganisms medicinally: A method for treating a vaginal disease by applying a hydrolyzed product in a variety of ways including preferably intravaginal, as well as oral, rectal, or transcutaneous administration, inhalation, intravenous or intraperitoneal injection. The product is produced by providing at least one solid plant product reduced to small pieces and... Agent: Boris Leschinsky
20080102059 - Treatment for arthritis: The insertion of a growth factor in the body of a human patient is used to treat arthritis. A reduction of inflammation occurs; and in the avascular necrosis type of arthritis, blood vessels and/or bone are grown at the joint to provide correction thereof.... Agent: Gerald K. White, Esq. Gerald K. White & Associates, P.C.
20080102064 - Pharmaceutical composition comprising factor vii polypeptides and protein c inhibitors: The present invention relates to a composition comprising factor VII or a factor VII-related polypeptide and a protein C inhibitor, and the use thereof for treating bleeding episodes.... Agent: Novo Nordisk, Inc. Patent Department
20080102065 - Erythropoietin receptor extended duration limited agonists: A genus of erythropoietin (Epo) receptor agonists having unique structural, biochemical, and physiological characteristics has been discovered and is referred to herein as Erythropoietin Receptor extended Duration Limited Agonist (EREDLA).... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP
20080102066 - Ultrapure transferrin for pharmaceutical compositions: The present invention relates to an ultrapure human transferrin, and to methods for manufacturing the ultrapure transferrin. The transferrin may be holo-, apo- or at any desired degree of iron saturation. The invention further relates to the use of ultrapure transferrin as the protein moiety of conjugates, and to pharmaceutical... Agent: Winston & Strawn LLP Patent Department
20080102067 - Immunogenic composition: Methods and compositions for increasing antibody titer in egg yolks and for using the antibodies are disclosed.... Agent: Quarles & Brady LLP
20080102068 - Mitotic kinesin inhibitors: The present invention relates to fluorinated 2-aminomethylthienopyrimidinone compounds that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.... Agent: Merck And Co., Inc
20080102069 - Tumor therapy with a combination of anti-her2 antibodies: The present invention provides a method for treating HER2 positive cancer or metastasis of HER2 positive cancer in a patient, who does not respond to a monotherapy with trastuzumab or a monotherapy with pertuzumab or to successive monotherapies with trastuzumab and pertuzumab, comprising co-administering to said patient a therapeutically-effective amount... Agent: Hoffmann-la Roche Inc. Patent Law Department
20080102070 - Scds as modifiers of the p53 pathway and methods of use: Human SCD genes are identified as modulators of the p53 pathway, and thus are therapeutic targets for disorders associated with defective p53 function. Methods for identifying modulators of p53, comprising screening for agents that modulate the activity of SCD are provided.... Agent: Mcdonnell Boehnen Hulbert @ Berghoff LLP
20080102071 - T cell inhibitory receptor compositions and uses thereof: The invention relates to compositions which bind T cell inhibitory receptor molecules and modulate T cell activity, and methods of using such compositions. Such compositions include biliary glycoprotein binding agents. Methods for modulating killer T cell activities, including cytotoxicity and proliferation also are provided.... Agent: Wolf Greenfield & Sacks, P.C.
20080102072 - Monoclonal antibodies to type i interferon receptor: Anti-IFNAR1 monoclonal antibodies with neutralizing activities against the anti-viral cytopathic effects of various type I interferons are provided.... Agent: Genentech, Inc.
20080102073 - Antigen-antibody complexes as hiv-1 vaccines: The present relation relates to antigen-antibody complexes for use as prophylactic and therapeutic vaccines for infectious diseases of AIDS. The present invention encompasses the preparation and purification of immunogenic antibody-antigen complexes which formulated into the vaccines of the present invention.... Agent: Frommer Lawrence & Haug
20080102074 - Trace elements: The invention discloses a trace element solution, which comprises at least one metal selected from the group comprising selenium, copper, zinc, manganese and chromium; and at least one component selected from the group comprising a vitamin, a vaccine, a growth stimulant, a dewormer, iron dextran, an antibiotic and a synchronisation... Agent: Stites & Harbison PLLC
20080102075 - Pharmaceutical compositions for treating arthritis and inflammatory disease: The biological effects of the cytokine TNF are mediated by binding to receptors on the surface of cells. This disclosure describes new proteins and polynucleotides that promote enzymatic cleavage and release of TNF receptors. Also provided are methods for identifying additional compounds that influence TNF receptor shedding. As the active... Agent: Bozicevic, Field & Francis LLP
20080102076 - Immunostimulatory compositions and uses thereof: The present invention provides novel immuno-stimulatory polypeptides, and methods for their use and identification.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP
20080102077 - Nucleic and protein sequences from the hxhv virus and uses thereof: The disclosure relates to isolated nucleic acid sequences obtainable from the genome of the HXHV virus, specifically, nucleic acid sequences comprising the sequence identified by SEQ ID NO: 4 or the complementary sequence to SEQ ID NO: 4, and to polypeptides coded by the nucleic acid sequences and uses thereof.... Agent: Oliff & Berridge, PLC
20080102078 - Mutated e. coli heat-labile enterotoxin: This invention relates to a mutant E. coli heat-labile enterotoxin (LT) subunit A that can be used as an adjuvant. This subunit A mutant contains an amino acid substitution at a position corresponding to position 61 of a wild-type LT. An LT containing this mutated subunit A exhibits reduced toxicity... Agent: Occhiuti Rohlicek & Tsao, LLP
20080102079 - Poultry vaccine, for necrotic enteritis, comprising a mutated clostridium perfringens alpha toxin antigen, and methods of producing the vaccine: This invention pertains in part to the development of a vaccine for poultry against necrotic enteritis (NE). The vaccine utilizes a protective antigen that is a mutated, full-length, non-toxic Clostridium perfringens (Cp) α-toxin protein (Mcpa). Utility of this vaccine was demonstrated by reduction of lesion severity in NE challenge trails,... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association
20080102080 - Fusion proteins comprising hiv-1 tat and/or nef proteins: The invention provides (a) an HIV Tat protein or derivative thereof linked to either (i) a fusion partner or (ii) an HIV Nef protein or derivative thereof; or (b) an HIV Nef protein or derivative thereof linked to either (i) a fusion partner or (ii) an HIV Tat protein or... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220
20080102082 - Formulation for oral administration having a health-promoting effect on the cardiovascular system: Composition for oral administration, having a health-promoting effect on the cardiovascular system, comprising as active principles a policosanol or a mixture of policosanols, red yeast and an agent selected from astaxanthin and folic acid, preferably in combination with coenzyme Q10. The composition can be used in particular for the preparation... Agent: Roylance, Abrams, Berdo & Goodman, L.L.P.
20080102081 - Preparations and applications for treatment of high cholesterol levels: A novel composition of modified strains of Monascus spp. which produce biologically active products useful as therapeutic treatments is disclosed. The novel composition of modified Monascus strains disclosed has a high level of total antioxidant activity and is useful as therapeutic composition, such as for lowering serum cholesterol and triglycerides... Agent: Cislo & Thomas LLP
20080102083 - Compositions and methods for the preparation of human growth hormone glycosylation mutants: The present invention relates to mutants of human growth hormone, which contain newly introduced N-linked or O-linked glycosylation site(s), such that these recombinantly produced polypeptides have glycosylation patterns distinctly different from that of the naturally occurring human growth hormone. The polynucleotide coding sequences for the mutants, expression cassettes comprising the... Agent: Morgan, Lewis & Bockius LLP (sf)
20080102084 - Anti-cancer dna vaccine employing plasmids encoding mutant oncoprotein antigen and calreticulin: Novel nucleic acid vectors comprising sequences encoding (a) calreticulin or a domain thereof, and (b) an antigen, such as human papillomavirus oncoproteins E7 or E6 in detoxified form, are disclosed, as are methods for using such vectors to induce antigen-specific immune responses and to treat or prevent development of tumors.... Agent: Foley Hoag, LLP (w/jhv)
20080102085 - Vaccine comprising gp120 and nef and/or tat for the immunization against hiv: Use of a) an HIV Tat protein or polynucleotide; or b) an HIV Nef protein or polynucleotide; or c) an HIV Tat protein or polynucleotide linked to an HIV Nef protein or polynucleotide; and an HIV gp120 protein or polynucleotide in the manufacture of a vaccine suitable for a prime-boost... Agent: Glaxosmithkline Corporate Intellectual Property - Uw2220
20080102086 - Feline influenza vaccine and method of use: This invention is directed to a vaccine and a method for using the vaccine to protect a feline from influenza virus infection. The vaccine comprises one or more antigens from one or more H3, N8, H7 or N7-type influenza viruses.... Agent: Intervet Inc. Patent Department
20080102087 - Compositions and methods for vaccinating against hsv-2: This invention relates to a method for systemic immune activation which is effective for eliciting both a systemic, non-antigen specific immune response and a strong antigen-specific immune response in a mammal. The method is particularly effective for protecting a mammal from herpes simplex virus. Also disclosed are therapeutic compositions useful... Agent: Townsend And Townsend And Crew, LLP
20080102088 - Use of cross-protection to identify novel vaccine candidates for infectious agents: This invention discloses methods for identifying Francisella tularensis vaccine candidates. It enables identification of novel vaccine candidates and quality assurance for vaccine batches, assessment of protection in vaccinates and identification of the infecting agent in vaccinates. Mice were first vaccinated with Brucella abortus O-polysaccharide (OPS) vaccine. These animals were then... Agent: Nixon & Vanderhye, PC
20080102090 - Pharmaceutical compositon containing botulinum neurotoxin a2: i
20080102089 - Topical and transdermal treatments using urea formulations: Various medical conditions previously treated by injection or surgery are effectively treated by a topical application of a composition of urea and a chemotherapeutic agent. Such agents include sclerosing agents, varodilators and botulinum toxin. Conditions as diverse as spider veins, erectile dysfunction and facial wrinkles can be effectively treated with... Agent: Lawrence J. Shurupoff
20080102091 - Vaccines: The present invention relates to a novel use of a malaria antigen to immunise against malarial disease. The invention relates in particular to the use of sporozoite antigens, in particular circumsporozoite (CS) protein or fragments thereof, to immunise against severe malarial disease.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220
20080102092 - Anti-trichophyton film forming agent and remedies for dermatophytosis: An anti-Trichophyton film containing calcium hydrogen carbonate and an anti-Trichophyton forming agent enable easy formation, on a human skin, of an antibacterial film containing calcium hydrogen carbonate while assigning antibacterial effect possessed by a natural material thereto by using scallop shell as a raw material, and form an antibacterial film... Agent: J.c. Patents
20080102093 - Appliance for delivering a composition, the appliance having an elastic layer and a shielding layer: Disclosed is an appliance adapted to transfer to, or associate with, the skin or tissue of a user, a composition, e.g., a moisturizing formulation. Because of possible interactions between the formulation and/or formulation ingredients and elastomeric polymers that may be employed to help give the appliance elastomeric qualities, the appliance... Agent: Kimberly-clark Worldwide, Inc. Catherine E. Wolf
20080102094 - Microbicidal compositions including a cyanodithiocarbimate and a second microbicide, and methods of using the same: Microbicidal compositions including (a) cyanodithiocarbimate and (b) an N-alkyl heterocyclic compound; a triazole compound or salt thereof or metal complex thereof; a microbicide with an activated halogen atom or a formaldehyde releasing compound; 1,4-bis(bromoacetoxy)-2-butene; 2-(thiocyanomethylthio)benzothiazole; a methylene-bis(thiocyanate); a halogenated acetophenone; a halopropynl compound; an iodosulfone; a phenol; a halocyanoacetamide compound... Agent: Kilyk & Bowersox, P.l.l.c.
20080102095 - Acidic processes to prepare antimicrobial contact lenses: This invention relates to antimicrobial lenses containing metals and methods for their production.... Agent: Philip S. Johnson Johnson & Johnson
20080102096 - Implantable biocompatible component integrating an active sensor for measurement of a physiological parameter, a micro-electromechanical system or an integrated circuit: An implantable biocompatible component (10) integrating an active element of the type of a sensor for the measurement of a physiologic parameter, a micro-electromechanical system and an integrated electronic circuit. This component (10) has a substrate (12) and a lid (22) in silicon or quartz. The substrate (12) integrates the... Agent: Orrick, Herrington & Sutcliffe, LLPIPProsecution Department
20080102097 - Device and method for treating osteolysis using a drug depot to deliver an anti-inflammatory agent: The present invention relates to a device and method of treating an osteo-degenerative disease followed by an optional procedure using an osteoconductive material to accelerate healing of bone tissue damaged by the disease. The device for treating the bone degenerative disease comprises an in situ drug depot that time releases... Agent: Fox Rothschild, LLP
20080102098 - Method for making a device having discrete regions: A medical device is constructed from a polymeric composition having properties such as increased visibility of the device and the ability to deliver therapeutic and other agents. The device is constructed with additives incorporated into the polymeric structure, such as a material that increases visibility of the device, while still... Agent: Philip S. Johnson Johnson & Johnson
20080102099 - Implants and microspheres for the sustained release of drugs for ophthalmic use and preparation methods thereof: The invention relates to a novel solid complex, which is insoluble in an aqueous environment and which, in dry form thereof, can be used to develop novel systems for the sustained release of drugs for ophthalmic use. The invention also relates to a method of preparing said complex. The complex... Agent: Knobbe Martens Olson & Bear LLP
20080102101 - Enhanced recovery following ocular surgery: An ocular method comprising localized ocular administration of a pharmaceutically acceptable formulation and effective concentration of at least one neuro-stimulatory agent, which may include a macrolide, for a duration sufficient to at least partially restore corneal sensation, or at least one macrolide to reduce scarring after ocular surgery. The neuro-stimulatory... Agent: Thompson Hine L.L.P. Intellectual Property Group
20080102100 - Processes to prepare antimicrobial contact lenses: This invention relates to antimicrobial lenses containing metals and methods for their production.... Agent: Philip S. Johnson Johnson & Johnson
20080102102 - Methods and compositions for decreasing saliva production: The invention provides methods and compositions comprising an anti-cholinergic agent for decreasing saliva production and treating sialorrhea.... Agent: Leon R Yankwich Yankwich & Associates
20080102104 - Suture-specific coatings for modulated release of bioactive agents: Suture-specific coatings having a number average molecular weight not exceeding 20 kDa, a melting temperature above 37° C., and heat of fusion exceeding 20 J/g, are formed of copolyesters of polycaprolactone or of ε-caprolactone and at least one cyclic monomer forming a segmented polyester chain initiated by a polyaxial crystalline... Agent: Leigh P. Gregory
20080102103 - Dissolvable film composition: A system, a kit and methods for delivering an effective amount of a labile active to the skin, comprising a composition comprising an effective amount of a labile active agent incorporated into a water-soluble polymeric film and an additive composition capable of dissolving the water-soluble polymeric film.... Agent: The Estee Lauder Cos, Inc
20080102105 - Method of producing an absorbent article and an absorbent article produced according to the method: A method for applying lotion to a surface of an absorbent article. The method includes the steps of: placing the surface of the absorbent article in the proximity of a spraying apparatus having a spray head with an orifice; pushing the lotion through the spray head orifice; and propelling the... Agent: Buchanan, Ingersoll & Rooney PC
20080102106 - Wound healing composition comprising substances from diptera larvae: Disclosed is a wound healing composition comprising a mixture of substances that are obtained from diptera larvae, are heat-resistant at 100° C., and have molecular weights ranging from 500 to 10,000 Dalton. Also, disclosed are the use of said composition as well as a method for the production thereof.... Agent: Rankin, Hill & Clark LLP
20080102107 - Compositions and methods for transdermal joint pain therapy: Compositions suitable for use in treating pain and increasing range of motion of an affected joint of an animal, particularly a human. The compositions contain a transdermal delivery formulation for delivering effective amounts of glutamine, hyaluronic acid, methysulfonylmethane, and glucosamine to the affected joint. The compositions are applied topically to... Agent: Patton Boggs, LLP
20080102108 - Therapeutic film forming composition and treatment system therefor: By providing a film forming composition incorporating one or more therapeutic substances for application to nails and/or skin surfaces which can be employed independently or, if desired, in combination with an easily employed holding or support member for delivering heat directly to the application site an easily employed, convenient, consumer-oriented... Agent: Melvin I. Stoltz, Esq.
20080102110 - Method for preparing lipid-spacer-reactive functional group-peptide: which is characterized in that the reaction is carried out in a liquid phase and comprises the following steps of (a) firstly protecting Lys amino acid residue in the peptide through a protection group; (b) subsequently reacting the peptide with the lipid-spacer-reactive functional group; and (c) finally removing the protection... Agent: Wpat, PC
20080102109 - Methods of enhancing solubility of agents: This invention concerns novel methods of enhancing the solubility of a compound. Compositions prepared using such methods are also disclosed. Compositions prepared using the methods have various advantages over conventionally known compositions.... Agent: Jones Day
20080102111 - Anticancer composition for oral use comprising liposome containing phytosterols and prevention or treatment for cancer using the liposome: A novel use is disclosed of liposomes that contain phytosterol (e.g., β-sitosterol, campesterol, stigmasterol, brassicasterol, ergosterol, and ergostadienol, and so forth). It has been newly discovered that liposomes that contain phytosterol have a cancer metastasis inhibiting activity. Cancer metastasis is inhibited by the oral administration of liposomes that contain phytosterol... Agent: Posz Law Group, PLC
20080102112 - Chlamydia vaccines: Vaccine preparations are provided for the prevention of Chlamydia infections comprising a major outer membrane protein from chlamydia and a mucosal adjuvant such as a combination of QS21 and 3D-MPL, or chlorea Toxin or Heat labile enterotoxin. Such preparations provide protection from Chlamydia induced fertility.... Agent: Glaxosmithkline Corporate Intellectual Property - Uw2220
20080102113 - Emetic embedded capsule: This invention provides capsules containing an emetic, which capsules can encapsulate a drug, wherein the amount of emetic and the amount of drug is such that the number of capsules needed to be ingested to cause emesis is fewer than the number of capsules needed to be ingested to cause... Agent: Hoxie & Associates LLC
20080102114 - Microparticles and nanoparticles for the transmucosal delivery of therapeutic and diagnostic agents: The invention relates to compositions and methods for the administration of therapeutic and/or diagnostic agents such as polypeptides to a mammal, and in particular, compositions suitable for oral administration. The invention provides polymeric particles, and in particular, nano/microparticles such as, but not limited to, microspheres and nanospheres, as well as... Agent: Ropes & Gray LLP
20080102115 - Modified coagulation factor ix polypeptides and use thereof for treatment: Provided are modified factor IX (FIX) polypeptides and methods of generating modified FIX polypeptides. Also provided are pharmaceutical compositions, including compositions formulation for oral administration, that contain the modified FIX polypeptides, and methods of treatment using modified FIX polypeptides.... Agent: Fish & Richardson, PC
20080102116 - Quick dissolve medicament and method of manufacturing: A medicament core which contains a super disintegrant or an effervescent couple including a foaming agent and a pharmaceutically acceptable acid activator, which core is partially covered by preformed shell coverings shaped to expose at least a part of the core for activation upon exposure to bodily fluids.... Agent: Price Heneveld Cooper Dewitt & Litton, LLP
20080102117 - Base material for dry direct tableting comprising low-substituted hydroxypropyl cellulose: It is an object of the present invention to modify low-substituted hydroxypropyl cellulose added as a binder and disintegrator in the formation of tablets, so as to serve as a base material for dry direct tableting having high binding power and good flowability. This object is accomplished by providing a... Agent: Myers Bigel Sibley & Sajovec
20080102118 - Glipizide controlled-release composition and method of preparation: A glipizide controlled release composition is provided comprising a drug-layer and a push-layer at a ratio of 1:0.5˜3 by weight. The drug-layer contains glipizide and 40˜99 percent by weight of the drug-layer of hydrophilic polyvinylpyrrolidone homopolymer and/or copolymer carrier. The push-layer comprises about 10 to 80 percent by weight of... Agent: Beyer Weaver LLP
20080102119 - Osmotic pump apparatus and associated methods: Apparatuses and methods for pumping fluids such as fluid medications are disclosed. Embodiments of the invention provide an osmotic pump fluid delivery apparatus including elements designed to control the fluid delivery rate. Typical embodiments of the invention include an arrangement of elements such as solute reservoirs that can manipulate the... Agent: Gates & Cooper LLP Howard Hughes Center
20080102120 - Solid pharmaceutical composition comprising valsartan: This invention relates to a solid pharmaceutical composition containing valsartan particles characterized in that the D50 of said valsartan particles is 150 μm or below and that the valsartan particles have a maximum diameter of no more than 1100 μm, as determined by electron microscopy.... Agent: Nath & Associates
20080102122 - Antimicrobial polymeric articles, processes to prepare them and methods of their use: This invention relates to antimicrobial polymeric articles containing metal salt particles having a particle size of less than about 200 nm dispersed throughout the polymer and methods for their production.... Agent: Philip S. Johnson Johnson & Johnson
20080102121 - Compositions comprising nanoparticulate meloxicam and controlled release hydrocodone: The invention relates to a compositions comprising a nanoparticulate meloxicam composition in combination with a multiparticulate modified release hydrocodone composition that, upon administration to a patient, delivers a hydrocodone in a bimodal or multimodal manner. The multiparticulate modified release composition comprises a first component and at least one subsequent component;... Agent: Maryilou E. Watson Synnestvedt & Lechner LLP
20080102126 - Novel hydrogels based on aliphatic nco prepolymers: The invention concerns novel hydrogels, a process for the preparation of these hydrogels and would contact materials comprising these hydrogels. These polyurethane hydrogels are obtained by the reaction of aliphatic isocyanate prepolymers with polyols comprising tertiary nitrogen in water.... Agent: Bayer Material Science LLC
20080102123 - Self-gelling tunable drug delivery system: A self-gelling tunable drug delivery system is disclosed. The self-gelling tunable drug delivery system is comprised of a hydrophilic matrix and a hydrophobic matrix.... Agent: Philip S. Johnson Johnson & Johnson
20080102124 - Modified human growth hormone: Modified growth hormone polypeptide and uses thereof are provided.... Agent: Attn: John W. Wallen, Iii Ambrx, Inc.
20080102125 - Modified human growth hormone: Modified growth hormone polypeptide and uses thereof are provided.... Agent: Attn: John W. Wallen, Iii Ambrx, Inc.
20080102130 - Dry granulated pharmaceutical compositions and methods for producing same: Method are provided for dry granulation processing of a pharmaceutical composition to provide granulated pharmaceutical compositions with improved flow characteristics and reduced amounts of fine particles.... Agent: Woodcock Washburn LLP
20080102127 - Hybrid lipid-polymer nanoparticulate delivery composition: The invention relates to a nanoparticulate colloidal delivery vehicle comprising a biodegradable polymer in combination with a hydrophobic lipid component. Variation of the lipid and polymer types and variation in the ratio between the polymer and lipid components allows regulation of drug loading and release rate.... Agent: Alpharx Inc.
20080102129 - Method of use of monomeric insulin as a means for improving the reproducibility of inhaled insulin: The need for the delivery of insulin by injection can be reduced or eliminated by delivering an aerosolized monomeric insulin formulation. Repeatability of dosing and more particularly the repeatability of the blood concentration versus time profile is improved relative to regular insulin. The blood concentration versus time profile is substantially... Agent: Bozicevic, Field & Francis LLP
20080102128 - Modified-release microparticles based on amphiphilic copolymer and on active principles(s) and pharmaceutical formulations comprising them: The present invention relates to novel microparticles formed of amphiphilic polyamino acids which transport active principle(s), AP(s), in particular protein and peptide active principle(s), and to novel modified-release pharmaceutical formulations comprising said AP microparticles. The aim of the invention is to develop novel microparticles, charged with AP, obtained by aggregation... Agent: Patton Boggs LLP
20080102131 - Particulate composition comprising bioactive substance and method of producing the same: The present invention provides a particulate composition wherein an oil component (A) comprising a water-insoluble bioactive substance is poly-dispersed while forming a domain in a matrix comprising of a water-soluble excipient based on a water-soluble polymer, and wherein the sphericity of the particulate composition is not less than 0.9 and... Agent: Sughrue Mion, PLLC
20080102133 - Oral pharmaceutical preparation for proton pump antagonists: The invention relates to novel dosage forms for proton pump antagonists.... Agent: Nath & Associates PLLC
20080102132 - Continuous multi-microencapsulation process for improving the stability and storage life of biologically active ingredients: The invention relates to microcapsules, and a continuous micro-encapsulation water-in-oil-in-water microencapsulation process through in situ and interfacial polymerization of the emulsion. The formulation comprises a continuous water phase having a dispersion of microcapsules which contain oil drops and wherein the inside of each oil phase drop—containing optionally oil-soluble materials—there is... Agent: Vedder Price Kaufman & Kammholz
20080102134 - Controlled release color stable pharmaceutical dosage form of hmg-coa reductase inhibitors, free of alkalizing or buffering agents: A color stable controlled release pharmaceutical dosage form comprising HMG CoA reductase inhibitor, rate controlling polymers and one or more pharmaceutical excipients wherein the granules are independent of particle size the pharmaceutical dosage form is free of alkalizing/buffering agents. A color stable controlled release pharmaceutical dosage form comprising Fluvastatin Sodium,... Agent: Akerman Senterfitt
20080102135 - Use of equine amniotic membrane in ophthalmic surgeries in veterinary medicine: A method for making, storing and using a surgical graft from equine amniotic membrane in veterinary ophthalmology. The amniotic membrane is obtained from equine placenta, from which the chorion has been separated. Sheets of the amniotic membrane are cut to size and mounted on filter paper. The cells of the... Agent: Franck Ollivier
20080102136 - Reactive nanoparticles as destructive adsorbents for biological and chemical contamination: Compositions and methods for destroying biological agents such as toxins and bacteria are provided wherein the substance to be destroyed is contacted with finely divided metal oxide or hydroxide nanocrystals. In various embodiments, the metal oxide or metal hydroxide nanocrystals have reactive atoms stabilized on their surfaces, species adsorbed on... Agent: Hovey Williams LLP
20080102137 - Composition and method for etiological treatment and prevention of diseases and/or complications associated with chronic glucose metabolism destabilization: A natural composition formulated to modulate multiple pathophysiological processes in order to facilitate homeostatic glucose metabolism in a patient, and more particularly to increase insulin sensitivity in the same. The natural composition is a safe and effective formulation for the etiological prevention and treatment of diseases, complications, conditions, or disorders... Agent: P. Jeff Martin The Mcgougan Law Firm, LLC
20080102138 - Replacement of vitamins, minerals and neurotransmitter losses from tobacco smoking: A compound for the simultaneous treatment of nicotine addiction, the side effects of nicotine withdrawal, such as excessive appetite, and detrimental health effects caused by loss of vital body substances such as vitamins, minerals, amino acids, co-factors and neurotransmitters which result from tobacco smoking. The first component is a bivalent... Agent: John C. Smith, Esq.
20080102139 - Pharmaceutical formulation for treatment of acquired immune deficiency syndrome (aids).: Present invention is related to pharmaceutical branch and in particular to an extract obtained from a purple maguey (Tradescantia Spathacea) plant be used in the elaboration of pharmaceutical formulations applied to immune deficiency syndrome (AIDS) treatment. Extract obtaining procedure is also illustrated.... Agent: Furr Law Firm
20080102140 - Use of solidago virgaurea in the treatment and prevention of viral infections: This invention teaches the use of Solidago virgaurea for treating and preventing H5N1 avian influenza, influenza virus, and HIV/AIDS. An herbal stock solution was extracted from the natural plant Solidago virgaurea. The herbal extract had anti-H5N1 avian influenza, anti-influenza, and anti-HIV/AIDS properties. Pharmaceutical compositions of Solidago virgaurea were prepared by... Agent: Matthias Scholl
20080102141 - Use as a means to improve fertility of a phytotherapeutic composition and method for improving and/or promoting fertility health: Use as a means to improve fertility of a phytotherapeutic composition and method for improving and/or promoting fertility health. The phytotherapeutic composition comprising at least 6 volume % Allium Sativum extract, 17 volume % Eleutherococcus Senticosus extract, 11 volume % Juglans Regia extract, 17 volume % Echinacea Purpurea extract, 17... Agent: Law Offices Of Eric Karich
20080102142 - Method of using ajoene as alcohol dehydrogenase inhibitor, composition for removing hangover comprising ajoene and method of preparing the same: The present invention provides a composition for removing a hangover. In particular, the present invention discloses a method of using ajoene as an alcohol dehydrogenase inhibitor based on the fact that ajoene strongly inhibits alcohol dehydrogenase (ADH) activity. A composition for removing a hangover comprising ajoene suppresses the over-production of... Agent: Cantor Colburn, LLP
20080102143 - Uses for the extract of a plant of the family asclepiadaceae: The present invention is concerned with an extract of a plant, whereby the plant belongs to the family Asclepiadaceae for use as a medicament. One embodiment of the present invention is an extract of the plant Gymnema sylvestre for use as a medicament. Said medicaments are inter alia useful for... Agent: Cognis Corporation Patent Department
20080102144 - Fat beta-oxidation enhancing and carbohydrate absorption inhibition supplement: The present invention relates to a method for increasing the β-oxidation of fatty acids while substantially simultaneously maintaining blood glucose concentration through the inhibition of carbohydrate absorption. Furthermore, the present invention additionally provides a composition for increasing the β-oxidation of fatty acids while substantially simultaneously maintaining blood glucose concentration through... Agent: Torys LLPPrevious industry: Chemistry of inorganic compounds
Next industry: Plastic article or earthenware shaping or treating: apparatus
RSS FEED for 20130613:
Integrate FreshPatents.com into your RSS reader/aggregator or website to track weekly updates.
For more info, read this article.
Thank you for viewing Drug, bio-affecting and body treating compositions patents on the FreshPatents.com website. These are patent applications which have been filed in the United States. There are a variety ways to browse Drug, bio-affecting and body treating compositions patent applications on our website including browsing by date, agent, inventor, and industry. If you are interested in receiving occasional emails regarding Drug, bio-affecting and body treating compositions patents we recommend signing up for free keyword monitoring by email.
FreshPatents.com Support - Terms & Conditions
Results in 3.94658 seconds
- - - - - - - - - - - - - - - - - - - - - -
Other Companies and Websites related to this category:
National Enzyme Company
Neurotech Co., Ltd.
Next Generation Clinical Research Consulting
NigerianGerman Chemicals PLC